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SUMMARY
mTORCI functions as a nutrient sensor within the cell. It integrates signalling inputs 
from growth factors, nutrients and amino acids to regulate key cellular processes 
involving growth, proliferation and development. Perturbed mTORCI signalling is a 
feature of a variety of diseases including the hamartoma syndromes, various cancer 
types as well as both autoimmune and neurological diseases; yet many downstream 
signalling effects remain uncharacterised.
The central aim of this study was to characterise mTORCI as a regulator of 
transcription. This has been carried out focusing upon the regulation of two 
transcription factors which are fundamental to the pathophysiology of the hamartoma 
disorders and many types of cancer; HIF-1a and STAT3.
I have shown evidence that m TORCI is able to regulate HIF-1a on a 
translational level through phosphorylation of 4E-BP1. 1 have also shown that 
mTORCI is able to regulate the synthesis of HIF-1a mRNA to further augment its 
activity.
I present evidence that HIF-1a is subject to mTORCI independent regulation 
from the upstream regulator TSC2. Significantly, mTORCI inhibitors were able to 
normalise HIF-1a elevation through TSC1/2 loss in the absence of TSC1 but not 
TSC2 in a cell line model for the disease Tuberous Sclerosis.
Furthermore I have shown that m TORCI can directly phosphorylate STAT3 at 
Ser727, promoting its transcriptional activity. I have also shown direct functional link 
between STAT3 and HIF-1a.
This study includes an analysis of the current knowledge regarding these two 
transcription factors and highlights the possibilities for targeting this signalling 
pathway in the treatment of disease.
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Rb Retinoblastoma gene product
REDD1/2 Also known as DNA-damage-inducible transcript 4 (DDIT4)
REPO Recruitment of polvcomb domain
Rheb Ras homolog enriched in brain
Rictor Raptor independent companion of mTORC2
RNC Raptor N-terminal conserved domain
ROS Reactive oxygen species
rpS6 Ribsomal protein S6
RTKs Receptor tyrosine kinases
S1p Sphingosine-l-phosphate
S6Ks rpS6 kinases
SCAP Sterol regulatory element-binding proteins-cleavage-activating protein
s c f Ptrcp Skp1, Cdc53, and the F-box protein Cdc4 - p-transducin repeat-containing protein
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SH2 Src-homology-2 domain
shRNA Small hairpin ribonucleic acid
SIFT Sorting intolerant from tolerant
Sin-1 Stress-activated protein kinase-interacting protein-1
siRNA Small interfering ribonucleic acid
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ABBREVIATIONS
SKAR S6K1 Aly/REF-like substrate
SLE Systemic lupus erythematosus
SOCS Suppressor of cytokine signalling
SREBP1 Sterol regulatory element-binding protein-1
STATs Signal transducer and activator of transcription transcription factors
TAD Transcriptional activation domain
TBS(T) Tris buffered saline (plus tween)
TCTP Translationally controlled tumour protein
TIP41 TAP42-interacting protein of 41 kDa
TM Transmembrane domain
Tor1/2 Target of rapamycin (yeast homolog)
TOS mTOR signalling motif
TPR Tetratricopeptide repeat
tRNA Transfer ribonucleic acid
TSC(1/2) Tuberous sclerosis complex (1/2 - also known as tuberin and hamartin)
UBR1/2 Ubiquitin protein ligase E3 component n-recognin-1/2
ULK-1/2/3/4 UNC-51 like kinase-1/2/3/4
VEGF-A Vascular endothelial growth factor-A
VHL Von hippeMindau tumour suppressor
Vps34/15 Vacuolar protein sortina 34/15
YY1 Yin-yang-1
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CODON TABLE
Second position of codon
T c A G
First T TTT F TCT S TAT Y TGT C T Third
position TTC F TCC S TAC Y TGC C C position
TTA L TCA S TAA Stop TGA Stop A
TTG L TCG S TAG Stop TGG W G
C CTT L CCT P CAT H CGT R T
CTC L CCC P CAC H CGC R C
CTA L CCA P CAA Q CGA R A
CTG L CCG P CAG Q CGG R G
A ATT 1 ACT T AAT N AGT S T
ATC 1 ACC T AAC N AGC S C
ATA 1 ACA T AAA K AGA R A
ATG M ACG T AAG K AGG R G
G GTT V GCT A GAT D GGT G T
GTC V GCC A GAC D GGC G C
GTA V GCA A GAA E GGA G A
GTC V GCG A GAG E GGG G G
Key:
G -  Glycine (Gly) W  -  Tryptophan (Trp)
P -  Proline (Pro) H -  Histidine (His)
A -  Alanine (Ala) K -  Lysine (Lys)
V -  Valine (Val) R -  Arginine (Arg)
L -  Leucine (Leu) Q -  Glutamine (Gin)
I -  Isoleucine (lie) N -  Asparagine (Asn)
M -  Methionine (Met) E -  Glutamic Acid (Glu) 
C -  Cysteine (Cys) D -  Aspartic Acid (Asp)
F -  Phenylalanine (Phe) S -  Serine (Ser)
Y -  Tyrosine (Tyr) T -  Threonine (Thr)
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CHAPTER 1: INTRODUCTION
1.1 OXYGEN
Throughout evolution, the earth’s atmospheric oxygen levels have fluctuated. The 
arrival of photosynthetic organisms initiated a gradual rise in atmospheric oxygen, 
which increased exponentially as plant life flourished [1, 2]. This rise facilitated the 
evolution of eukaryotic organisms with cellular mitochondria. Complex organisms 
are dependent upon the mitochondrial process of oxidative phosphorylation, which 
produces significant levels of ATP from molecular glucose; this process is critically 
dependent upon oxygen. It is this process which facilitated the evolution of complex, 
multicellular organisms, including the evolution of man. These variations in 
atmospheric oxygen levels have therefore been one of most significant driving forces 
behind the evolution of our species.
A vast network of blood vessels distributes nutrients and oxygen around the 
human body. Oxygen diffuses through the tissue and into the cell where it reaches 
the mitochondria. In the mitochondria, an electrochemical gradient is formed as 
electrons are passed from electron donors such as NADH (nicotinamide adenine 
dinucleotide).. Oxygen is the final electron acceptor, and is ultimately reduced to H20  
[1, 3]. The electrochemical gradient produced from these reactions drives the 
synthesis of ATP by ATPases, producing significant levels of cellular energy [4].
This process is not without its drawbacks, molecular oxygen can be released 
before it is fully reduced to H2O, one-electron reduction of 0 2 results in the formation 
of reactive oxygen species (ROS) [2, 4]. This process, referred to as oxidative stress, 
has been linked to the aging process [5], as well as the pathology of a number of 
neurodegenerative diseases [6]. For these reasons, the maintenance of oxygen 
homeostasis is a critical process.
The human body is therefore highly sensitive to fluctuations in oxygen on both 
a systemic and a cellular level, oxygen levels must be maintained within strict 
parameters. Critical components in cellular oxygen sensing are the evolutionary 
conserved HIF proteins (hypoxia inducible factors). HIFs are transcription factors 
which, as indicated by the name, become activated under conditions of hypoxia. 
HIFs can alter gene expression in order to promote glucose uptake, increase 
anaerobic respiration and promote new blood vessel formation, increasing blood flow 
to the hypoxic tissue. This promotes cells survival during hypoxia and also facilitates
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growth [7]. The involvement of HIFs in these processes makes them an interesting 
potential therapeutic target in the pathology of cancer. One unifying feature of all 
cancers is uncontrolled cellular growth and proliferation. As a tumour expands, the 
core becomes hypoxic; it therefore relies upon the activation of HIFs to facilitate new 
blood vessel formation, promoting survival and expansion of the tumour. 
Understanding how HIFs are regulated on a cellular level is therefore paramount to 
developing potential therapeutics in this field.
HIFs are continuously synthesised within the cell however the protein itself is highly 
unstable in the presence of oxygen (discussed in detail later) so is therefore only 
active when oxygen levels are low. Interestingly HIFs can be transactivated by 
various cellular signalling pathways. The molecular mechanisms governing this 
regulation are only just becoming apparent. This project is primarily focused upon 
elucidating links between an evolutionary conserved master of protein synthesis, 
referred to as mechanistic target of rapamycin complex-1 (m TORCI) and the cellular 
response to hypoxia. m TORCI is regulated by nutrients, growth factors, hormones, 
mechanical stimulus, stress and hypoxia. It responds to fluctuations in the cellular 
environment to control a myriad of cellular processes. It is best characterised as a 
key mediator of protein synthesis, this process and the role mTORCI plays in the 
cell are described in detail in the next section.
1.2 PROTEIN SYNTHESIS
Protein synthesis is a pivotal cell process whereby our genetic code is translated into 
physical characteristics. The physical characteristics of proteins are determined by 
the 20 different amino acids which make them. Cells translate a diverse array of 
proteins with different properties to fulfil specific cellular tasks. In order to efficiently 
translate genetic code, regulation of protein synthesis is subject to a massively 
diverse array of inputs and feedback mechanisms. Synthesis begins with the 
process of ‘transcription’ which is described below.
1.2.1 Transcription
Before protein synthesis, a copy of the DNA has to be made (or transcribed) this is 
messenger RNA (mRNA) and is synthesised using a single strand of the DNA as a 
template.
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Transcription involves the copying of the nucleotide sequence from the gene 
into a single stranded polymer of nucleotides. The initiation of transcription is a major 
point of control for the regulation of gene expression and is primarily controlled by 
RNA polymerases. One of these polymerases in particular, RNA polymerase II (Pol 
II) regulates the transcription of all protein encoding genes. Pol II is subject to strict 
modulation from transcription factors, which have a substantial role to play in the 
regulation of gene expression, recent advances in biochemical and molecular 
techniques have identified thousands of factors which regulate transcription [8], thus 
furthering our understanding of this highly conserved process.
The rate of transcription can be also determined by gene-specific transcription 
factors, these bind to specific response elements contained within promoter or 
enhancer regions of the DNA to accelerate the rate of transcription. There are a 
large number of different transcription factors and the number and position of binding 
response elements differs between genes.
Differing combinations of transcription factors are produced depending upon 
cell type; this is thought to be how particular cell types are able to control specific 
gene expression [9]. The transcription cycle is outlined in figure 1.1 below.
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Figure 1.1: The Transcription cycle: A: Once transcription has been activated, RSC functions to remodel the nucleosome; 
facilitating chromatin removal in order to expose the DNA sequence[10], The TATA-binding protein contained within the TFIID 
binds directly to the TATA-box motif within the promoter region, this forms a platform for the assembly of the initiation complex 
containing the regulatory polymerase; Pol II in association with general transcription factors [11,12]. B: TFIIH and TFIIE function 
to unzip the DNA, the CTD of Pol II is phosphorylated by CdK7 contained within TFIIH, and TFIIH is also required to re-organise 
the GTFs in order to form the elongation complex [13-15]. Pol II in association with GTFs facilitates the addition of the first 
corresponding NTP, this continues until the promoter is cleared when the complex becomes more stable [15]. C: GTFs mediate 
further phosphorylation of the CTD of Pol II enabling it to activate mRNA processing by activation of splicing factors and capping 
enzymes [14]. The cap binding complex recognises the cap structure and facilitates mRNA splicing and poly(A) tail synthesis. Pol II 
facilitates the addition of NTPs and translocation of the elongation complex along the DNA until a stop codon is reached [16], D: 
Pol II facilitates the endonucleolytic cleavage followed by synthesis of the poly-(A) tail at the 3'end, this recruits termination 
factors and the transcript is cleaved downstream of the poly (A) tail. The mRNA transcript is released and TAP proteins facilitate 
it's transport out of the nucleus to the ribosomes, Pol II dissociates from the DNA for recycling and the RSC restructures the DNA 
into chromatin [10].
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1.2.2 Translation
Once the mRNA has been transcribed, it can be translated into protein. The majority 
of eukaryotic translation (cap-dependent) occurs when the 5’-cap end of the mRNA 
transcript is recognised and bound by elF4E. Like the transcriptional process, 
translation can be divided into three phases, initiation, elongation and termination. 
These are described below.
1.2.2.1 Initiation of cap-dependent translation
The m7-5'-cap structure at the 5’end of the mRNA transcript is essential for 
translation. The cap is recognised by elF4E which is part of a heterotrimeric elF4F 
initiation complex. The elF4F complex consists of an adaptor protein elF4G, this 
forms the backbone between elF4E (associated with the m7GpppN cap structure) 
and elF4A, an RNA helicase [17-20]. The elF4Gs then associate with elF3, which is 
complexed with the 40S ribosomal subunit.
Association of elF4F to the 40S forms a tertiary complex (referred to as the 
43S initiation complex) which also comprises of GTP-bound elF2 and initiator 
methionine transfer RNA (tRNA). The assembly of the 43S initiation complex allows 
the unwinding of the mRNA’s 5’ terminal secondary structure, mediated by elF4A, 
however elF4A alone has limited helicase activity and requires accessory proteins, 
elF4G and elF4H (or it’s homolog elF4B) to stimulate it’s intrinsic helicase activity 
[21].
The 43S complex then migrates along the 5’-UTR of the mRNA transcript in 
the 5’-3’ direction until an initiation codon is located (AUG) [22]. After recognition of 
the AUG start codon, elF5 and elF5B facilitate the addition of the 60S subunit [22]. 
elF4Gs also interact with poly-A binding proteins (PABP) bridging the 5’- to the 3’- 
end causing mRNA circularisation, this aids recycling of the 40S ribosomal subunit 
[19], causes synergistic enhancement of translation [23] and may play a role in 
translational silencing of various genes [24].
The initiation step is characterised by the bringing together of the ribosome, 
mRNA and initiator tRNA, this comprises the elongation-competent ribosome and 
allows progression to the elongation phase of translation. This initiation step is a 
rate-limiting step in translation, primarily due to the activity of elF4E inhibitory 
proteins. These inhibitory binding proteins often associate with elF4E to inhibit the
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translational complex, or they may also be found tethered to specific mRNA subsets 
for more specific and targeted inhibition [19]. (See A & B of figure 1.2).
12.2.2 Elongation
Elongation is the process of assembling the polypeptide and therefore has high 
metabolic energy requirements. Initially, the ribosome is in association with the newly 
transcribed mRNA as well as initiator tRNA (see above), this allows incorporation of 
the first amino acid into the ribosome. Amino acids are complexed with tRNA and 
GTP-bound elF2. When the corresponding amino acid finds a matching codon, elF5 
promotes GTP hydrolysis of GTP-elF2 and subsequently GDP-elF2 dissociates from 
the ribosome, this is referred to as decoding[25, 26]. The dissociation of elF2 allows 
the 3’arm of tRNA to move into the peptidyl transfer centre of the large ribosomal 
subunit which facilitates the formation of peptide bonds.
After peptide bond formation, the mRNA translocates through the ribosome by 
an exact distance of one codon, as catalysed by the GTPase eEF2, the ribosome 
also undergoes a conformational change to facilitate the addition of the next amino 
acid. This is a cyclic process which continues until the entire mRNA transcript has 
been read [25, 27, 28] (See ‘C’ of figure 1.2).
12.2.3 Termination
The third and final stage is known as ‘termination’ and is triggered by the recognition 
of the stop codon within the mRNA transcript. Stop codon recognition stimulates the 
release of the protein by catalysing the hydrolysis of the peptidyl-tRNA ester bond 
between the complete peptide chain and the tRNA. This process is modulated via 
various release factors and signifies the end of protein synthesis [28] (See ‘D’ of 
figure 1.2).
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F ig u re  1 .2 :  T h e  T ra n s la tio n  c yc le : A : T h e  tra n s la tio n  cyc le  beg ins  w ith  re c o g n itio n  o f  th e  cap  m o ie ty  b y  e lF4E  w h ic h  is c o n ta in e d  w ith in  th e  e lF 4 F  c o m p le x  
a lo n g s id e  e lF 4 G  an d  th e  h e licase  e lF 4 A . C ap  re c o g n itio n  in it ia te s  th e  a ssem b ly  o f  th e  4 3 s  in it ia t io n  c o m p le x  w h e re b y  e lF 3  in  asso c ia tio n  a m in o -a c id  b o u n d  tR N A  
a n d  th e  4 0 s  r ib o s o m a l s u b u n it b inds  to  e lF 4 G  o f  th e  e lF 4F  c o m p le x . e lF 4 B /H  can  th e n  c a ta lys e  th e  he licase  a c tiv ity  o f  e lF 4 A  to  u n w in d  th e  m R N A , th e  c o m p le x  
m oves  a lo n g  th e  tra n s c r ip t u n til a s ta r t  c o d o n  is rea c h e d  [3 2 ] . B: S ta rt c o d o n  re c o g n itio n  resu lts  in  re c ru itm e n t o f th e  6 0 s  r ib o s o m a l s u b u n it b y  e lF 5 /e lF 5 b  
w h ils t th e  elFG s asso c ia te  w ith  th e  p o ly (A ) ta il o f  th e  m R N A  to  fa c ilita te  m R N A  c irc u la r iz a tio n . C: e lF 5 /b  fa c ilita te  th e  re m o v a l o f  in it ia t io n  fa c to rs  as e lo n g a tio n  
begins. T h e  firs t c o rre s p o n d in g  a m in o  acid  is a d d e d , th is  tr ig g ers  GTP hydro lys is  o f e lF 2  p ro m o tin g  its re lease  an d  a llo w in g  th e  3 'a rm  o f  tR N A  to  fa c ilita te  
p e p tid e  b o n d  fo rm a tio n . G TP -eE F2 fa c ilita te s  th e  tra n s lo c a tio n  o f  m R N A  th ro u g h  th e  r ib o s o m e  o n e  c o d o n  a t a  t im e . D : R elease fa c to rs  recog n ise  th e  s to p  
c o d o n  c o n ta in e d  w ith in  th e  m R N A  a llo w in g  re le as e  o f th e  p ro te in  by  c a ta ly z in g  th e  hydro lys is  o f th e  p e p tid y l-tR N A  e s te r  b o n d  b e tw e e n  th e  c o m p le te  p e p tid e  
ch a in  a n d  th e  tR N A . R ib o so m a l s u b u n its  s e p a ra te  fo r  recyc lin g  (fo r  re v ie w  see [3 3 ]) .
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1.2.3 Alternatives to cap-dependent translation
Approximately 3-5% of mRNAs are transcribed independently of cap-dependent 
translation, however the mechanism behind this has not been fully elucidated. It is 
thought that this occurs through internal ribosome entry sites (IRES) found within the 
5’UTRs of a subset of mRNAs encoding proteins associated with cell growth, 
proliferation or survival [29]. These IRES-containing mRNAs carry a translational 
advantage under conditions of cellular stress, with increased stress coupled with a 
repression of cap-dependent but not IRES mediated translation. IRESs are typically 
found in the 5’-UTR of the mRNA transcript and are usually several hundred 
nucleotides long, so consequently have a substantial secondary structure and 
increased GC content [29].
IRESs recruit the 40S ribosomal subunit directly to the 5’-UTR and thus bi­
pass assembly of the initiation complex. This allows translation to occur 
independently of the 5’cap and is facilitated by a set of factors referred to as ITAFs 
(IRES trans-acting factors) which may be generally acting or specific to the mRNA 
which is being translated [29, 30].
1.2.4 Significance
This section has provided a general overview of the mechanisms which regulate the 
translation of the genetic code into protein, this is a fundamental cellular process 
which explains how genes and traits are translated into physical characteristics. The 
central facet of this study is to identify and characterise downstream substrates of 
mTOR, mTOR is a key mediator of protein synthesis and exerts many of its cellular 
effects through regulation of this process. The mTOR signalling pathway, including 
downstream substrates, cellular inputs and negative feedback mechanisms are 
described in detail in the next section.
1.3 mTOR STRUCTURE AND RELATED COMPLEXES
Mechanistic or mammalian target of rapamycin (mTOR) is a serine/threonine kinase 
that was first identified after the discovery of the immunosuppressant drug, 
rapamycin. Rapamycin is a product of the bacterium Streptomyces hygroscopicus 
which was found in soil samples taken from Easter Island (Rapa Nui). Rapamycin is 
a macrolide which exerts immunosuppressive effects by limiting the growth cycle of 
T-lymphocytes and is currently approved for treatment of transplant patients to
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prevent graft rejection. Yet perhaps more importantly, rapamycin lead to the 
discovery of its drug target, mTOR. Rapamycin exerts its effects by binding within 
the cell to FKBP12, this complex inhibits the functions of mTORCI. mTOR functions 
as two distinct protein kinase complexes, mTORCI consisting of mTOR/Raptor and 
ml_ST8 and mTORC2 consisting of mTOR bound to Rictor, mLST8, Sin-1 and 
Protor-1/2 [31-33] see figure 1.3. The two distinct complexes have different 
downstream targets and regulate distinct pathways, this study aims to identify and 
characterise downstream substrates of m TORCI.
mTORCI acts as an energy sensor within the cell and co-ordinates a wide 
range of cellular processes in response to growth factors and nutrient availability [34, 
35]. mTORCI is a key modulator of cell growth and proliferation, it also regulates 
metabolic processes via transcriptional regulation including ribosomal biogenesis, 
autophagy, glucose transport and angiogenesis (discussed later) [36]. mTORCI is 
subject to tight regulation from feedback loops, upstream components and nutrient 
availability and integrates a number of upstream signalling inputs. Instances where 
mTORCI signalling is improperly regulated invariably result in pathogenesis, 
consequently, mTOR inhibitors are currently being utilised in a number of clinical 
trials.
1.3.1 mTORC2
As stated earlier, mTOR can also form a rapamycin insensitive complex, mTORC2. 
mTORC2 consists of mTOR, Rictor, mLST8 and Sin 1 [37-39] and, like mTORCI is 
negatively regulated by DEPTOR (see section 1.3.7). A new component of the 
mTORC2 complex was recently identified, Protor1/2, protein observed with rictor-1. 
which as the name indicates, is a Rictor binding protein. It was demonstrated that 
both Protor 1 and 2 isoforms bind directly to Rictor and that knockdown of Rictor 
could reduce the expression levels of Protori/2 and Sin-1 [39]. The role of Protori/2 
within mTORC2 has yet to be determined (for comparison of mTORCI and 
mTORC2 complexes see figure 1.3).
Little is known regarding the regulation of mTORC2, it was previously shown 
that insulin stimulation could induce Ser473 phosphorylation of Akt however it wasn’t 
until 2005 that mTORC2 was identified as the kinase responsible for this [40, 41]. Akt 
is involved in regulation of the cell-cycle, cell survival, glucose uptake, 
gluconeogenesis regulation and maintaining neuronal synapse activity through
phosphorylation of ion-channels (see review [42]). Importantly it also plays a role in 
the activation of m TO R C I.
Akt activation occurs in response to insulin or growth factor stimulation 
through phosphorylation at two sites, Ser473 within the hydrophobic motif is 
mediated by mTORC2 and appears to act as a priming site for phosphoinositide- 
dependent kinase 1 (PDK1) to bind and phosphorylate Thr308 causing full Akt 
activation [40, 41].
Studies utilising Rictor knockout mice have indicated that Ser473 
phosphorylation of Akt is essential for embryonic development [43] whilst other 
studies have demonstrated that mTORC2 plays a role in maintaining the actin 
cytoskeleton of the cell [44].
Our knowledge of mTORC2 mediated substrate inhibition is behind that of 
mTORCI, primarily due to the fact that rapamycin can be utilised to investigate 
mTORCI but not mTORC2 signalling. There are multiple studies indicating that the 
rapamycin/FKBP12 complex cannot inhibit mTORC2 [40, 44, 45]. More recently 
however, it has been demonstrated that prolonged rapamycin treatment does infact 
perturb mTORC2 signalling by binding to ‘free mTOR’ thus limiting mTORC2 
complex assembly. Prolonged (24 hour) rapamycin treatment results in saturation of 
newly synthesised mTOR with the rapamycin/FKBP12 complex, causing a 
suppression of Akt signalling. This effect appears to be variable between cell types 
with some being more sensitive to inhibition of mTORC2 assembly with rapamycin 
than others [46]. This could suggest that there are multiple mechanisms of mTORC2 
complex assembly.
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Figure  1 .3 :  A c tiv a tio n  o f  m TO R  c o m p le x e s . 
1. In a c tiv e  c o m p le x e s , l a .  In th e  abs e n c e  o f  
n u tr ie n ts  o r  g ro w th  fa c to rs  th e  in ac tiv e  
m T O R C I c o m p le x  consists o f m TO R , R a p to r  
a n d  m LS T8 as w e ll as in h ib ito ry  p ro te in s :  
P R A S 40, F K B P 3 8 a n d  DEPTOR. l b .  In a c tiv e  
m TO R C 2 c o m p le x  consists  o f m TO R , R ic to r, 
m LS T8, S in -1  a n d  PROTO R as w e ll as th e  
in h ib ito ry  b in d in g  p ro te in  DEPTOR. 2. 
G ro w th  fa c to r  a c tiv a tio n  o f  c o m p le x e s . 2 a . 
G ro w th  fa c to r / in s u lin  cause in cre a se  in 
ra t io  o f  G T P -R h eb  p ro m o tin g  m T O R C I 
a c tiv a tio n  (p e rm iss ive  a m in o  a c id  in p u t  
re q u ire d ). G T P -R h eb  a c tiv a te s  m T O R C I as 
w e ll as d isp la c in g  FK B P 38, ac tiv e  m T O R C I 
p h o s p h o ry la te s  DEPTOR a nd  P R A S 40 to  
s t im u la te  th e ir  re m o v a l, P R A S 40 is 
seq u e s te re d  by  1 4 -3 -3  p ro te in s . 2 b . 
M e c h a n is m s  re g a rd in g  m TO R C 2 a c tiv a tio n  
are  la rg e ly  u n k n o w n  h o w e v e r  it  is lik e ly  to  
also  be  a c tiv a te d  in  response  to  g ro w th  
fa c to rs  s ince m TO R C 2 reg u la te s  g ro w th  
fa c to r  d e p e n d e n t A k t p h o s p h o ry la tio n  (see  
3 b ). 3 . A c tive  c o m p le x e s  m e d ia te  
p h o s p h o ry la tio n  o f  d o w n s tre a m  su b s tra tes . 
3 a . m T O R C I m e d ia te s  p h o s p h o ry la tio n  o f  
m u lt ip le  ta rg e ts , m o s t w id e ly  c h a ra c te ris e d  
b e in g  S 6K 1 a n d  4E -B P 1 . S 6K1 m e d ia te s  
d e g ra d a tio n  o f  IRS-1 a n d  r ic to r  
p h o s p h o ry la tio n  to  re d u c e  A k t in d u c e d  
a c t iv a tio n  o f  m T O R C I 3 b . m TO R C 2  
p h o s p h o ry la te s  A k t  w h ic h  d ire c tly  
p h o s p h o ry la te s  th e  m T O R C I in h ib ito r  
P R A S 40 t o  in crease  m T O R C I a c tiv a tio n . A k t  
also  in d ire c tly  increases  th e  ra t io  o f  G TP- 
R heb to  fu r th e r  p ro m o te  m T O R C I 
s ig n a llin g . Fo r re fe re n c es  see te x t ,  fo r  
re v ie w  see [5 0 ].
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The aim of this study is to characterise signalling downstream of mTORCI, however 
crosstalk between the signalling pathways must be considered. The next section 
goes on to describe the structure and function of mTORCI signalling components.
1.3.2 Rheb
Loss of heterozygosity of either the TSC1 or TSC2 genes leads to the disease 
Tuberous Sclerosis Complex (TSC). TSC is characterised by the development of 
benign hamartomas in multiple organ systems and is a result of upregulation of the 
mTORCI signalling pathway. It wasn’t until 2003 that the link between TSC1, TSC2 
and the mTOR signalling pathway was established.
The pivotal point in this research was the discovery of the small G-protein, 
Rheb as an activator of m TO RCI. Ras-homologue enriched in brain is a novel 
member of the Ras family of small GTP-binding proteins. As the name suggests, 
high levels are found in the brain and its sequence is highly homologous to Ras. As 
with all of the Ras family of proteins, Rheb activity is determined by its nucleotide 
bound status. This is determined by the activity of their corresponding GAPs and 
GEFs (GTPase Activating Proteins and Guanine Exchange Factors). With GAPs 
function to negatively regulate small G-proteins, GEFs perform the opposing function 
and increase GTP-loading to positively regulate them.
It was discovered in 2003 that Rheb was an activator of mTOR and that the 
TSC1 and TSC2 proteins suppressed mTORCI signalling by acting as a GAP 
towards Rheb when complexed together [47-51]. The TS complex binds to GTP- 
Rheb stimulating GTP-hydrolysis.
There is some speculation regarding the GEF which regulates Rheb. It was 
recently demonstrated that the translationally controlled tumour protein (TCTP) could 
act as a GEF towards Rheb in Drosophila [52], However, several subsequent studies 
have found that this is unlikely to be the case is mammalian cells [53, 54].
There is evidence of cross-talk between sphingosine-1-phosphate (S1P) 
signalling and the m TORCI pathway. Similarly to mTOR, S1P regulates cellular 
growth, mitogenesis and apoptosis. It has been demonstrated that S1P can activate 
mTORCI in certain cell types [55, 56], a mechanism has been proposed whereby E3 
ubiquitin ligase Protein Associated with Myc (PAM) (downstream of S1P) acts as a 
GEF to directly activate Rheb, however this has yet to be substantiated [57].
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The precise mechanism by which Rheb functions to activate mTORCI is yet 
to be fully elucidated. mTORCI cannot be activated by other G-proteins, KRas, 
RalA/B or Cdc42 but is activated by Rhebl and Rheb-Like-1 (also known as Rheb 
2). It has been demonstrated that Rheb can activate mTORCI but not mTORC2 [38, 
58, 59] suggesting that Rheb is a highly specific activator of mTORCI. Although 
Huang et al. recently reported that the TS complex interacts directly with mTORC2 
and was required for mTORC2 kinase activity but this occurs independently of Rheb 
[38].
Expression of Rheb induces mTORCI activity under conditions of nutrient 
withdrawal [47] suggesting that Rheb is proximal to mTOR in the signalling pathway. 
Its association with mTOR appears to be fragile and may involve a direct interaction 
with the catalytic domain of mTOR that is independent from Rhebs association with 
TSC2 [60]. It does not however appear to be dependent upon the nucleotide bound 
status of Rheb, as truncated mutants of Rheb which are nucleotide deficient are still 
able to bind to m TORCI but do not confer kinase activity [60]. A mechanism of Rheb 
activation of m TORCI involving FKBP38 has been proposed (described below in 
section 1.3.8), however current thinking suggests that this is not the primary 
mechanism for Rheb activation of m T O R C I Recent studies have suggested that 
Rheb increases the substrate binding capability of mTORCI causing more efficient 
phospho-transfer, rather than just enhancing the kinase activity directly [59]. 
However other studies have seen increases in phosphorylation of mTORCI 
substrates by addition of Rheb and hypothesised an increase in kinase activity [60].
Rheb contains a C-terminal CaaX motif whereby the ‘a’s represent aliphatic 
amino acids and X represents the C-terminal amino acid, usually serine, alanine, 
glutamine, cysteine or methionine. The CaaX motif becomes post-translationally 
farnesylated and many studies have indicated that this is required for Rheb 
activation of m TORCI. This is supported by use of farnesyltransferase inhibitors 
which downregulate mTORCI signalling [47, 61]. It has also been shown that 
unfarnesylated Rheb can activate mTORCI in vitro [59] but not in vivo [47]. It is 
therefore likely that the farnesylation of Rheb is required for its localisation to allow 
its interaction with mTOR at the membrane. Further research investigating the 
structure of Rheb by Tee et al. revealed that the Thr38 and Asp41 residues 
contained within the switch 1 region of Rheb are required for maximal interaction 
with mTOR [62].
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Whilst comparisons between Ras and Rheb revealed that the effector region 
is highly homologous, Rheb contains an arginine at position 12 rather than a glycine 
residue. This confers intrinsically low GTPase activity as it allows for a 
conformational change in the switch I region during GTP/GDP cycling. This causes 
displacement of the Gln64 residue making it incapable of participating in GTP 
hydrolysis [63]. Further research is required to determine how these functional 
domains interact with m TORCI and the exact mechanism behind mTORCI 
activation.
1.3.3 mTOR
mTOR belongs to a family of phosphoinositide kinase-related kinase (PIKK) protein 
kinases. mTOR contains a serine/threonine kinase domain in the C-terminal which is 
structurally similar to the catalytic domain found in the lipid kinase, phosphoinositide 
kinase (PI3K) (see figure 1.4). However, mTOR only functions as a ser/thr kinase 
[35, 64]. Structurally, the N-terminal half is made up of 20 tandem HEAT repeats 
(see figure 1.4 ‘A’ for schematic) consisting of two a-helices of approximately 40 
amino acids arranged in terms of their hydrophilic and hydrophobic residues [65]. 
HEAT repeats are thought to coordinate protein to protein interactions so it is likely 
that this region of mTOR provides docking sites for other protein interactions [66]. 
Adjacent to the HEAT repeats is the FRB (FKBP12/rapamycin binding) domain. This 
is the region that the FKBP12/rapamycin heterodimer binds to [67]. The FRB domain 
is essential for mTOR kinase activity since mTOR mutants lacking the FRB domain 
are unable to promote cell cycle progression into the Gi phase [68]. Within the FRB 
domain is a Ser2035 residue which appears to be necessary for interactions with 
FKBP12/rapamycin. Ser2035 substitution to any amino acid structurally larger than 
an alanine reduces the binding affinity of FKBP12/rapamycin and also affects mTOR 
kinase activity indicating that Ser2035 may be a regulatory site [24].
Oshiro et al. demonstrated that rapamycin treatment disrupted mTOR binding 
to Raptor independently of mTOR kinase activity [69] however, it is still thought that 
there is a functional relationship between the FRB domain and the kinase domain 
[68]. In addition to the HEAT repeats and FRB domain, there are two conserved FAT 
domains (see figure 1.4), one being substantially smaller and situated at the C- 
terminus, termed FATC. This is also seen in PIKK’s and is adjacent to the kinase 
domain. The FATC domain is crucial for mTOR kinase activity, where single point
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amino acid substitutions cannot be tolerated in vivo or in vitro [70], FATC contains a 
structural motif entailing an a-helix and a di-sulphide bonded loop situated between 
two cysteines. Reduction of the di-sulphide bond results in a conformational change 
increasing flexibility of the carboxyl-terminal loop region, potentially revealing 
hydrophobic regions of the domain. This may impact binding partners and 
interactions with other domains of mTOR [71].
Altering the redox status of mTOR by introducing mutations to this FATC 
domain causes in a reduction in mTOR protein levels, suggesting that the redox 
status of the FATC domain is involved in protein stability [71]. The larger 550 amino 
acid length FAT domain is composed of a-helices structures, similarly to the HEAT 
repeats suggesting that the FAT domain also plays a role in protein-protein 
interactions [72]. Since FAT domains are usually found in conjunction with FATC 
domains [73], it is likely that these domains interact with one another upon mTOR 
activation, causing a conformational change and exposing the protein kinase domain 
to induce activity [65, 70].
The actions of mTOR are determined by what proteins it is complexed with. 
The rapamycin sensitive m TORCI complex is responsive to growth factors, 
hormones and nutrients. The mTORC2 complex is less well described and is known 
to regulate the actin cytoskeleton and moderate Akt phosphorylation and therefore 
may also play a role in m TORCI regulation. The mTORCI complex consists of 
mTOR, Raptor, ml_ST8, PRAS40, Deptor, FKBP38 and Protor-1/2 (as shown in 
figure 1.3), and it is directly activated by GTP-Rheb. The structure and function of 
each of the proteins within the mTORCI complex are described below.
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1.3.4 Raptor
Raptor was first identified in 2002 by Hara et al. and Kim et al. Both groups identified 
Raptor as a 150kDa mTOR binding protein which was also able to interact with 4E- 
BP1 and S6K1. [74, 75]. It is thought that Raptor is the substrate recognition 
component of the complex and is therefore indispensible in mTORCI signalling.
Raptor is an evolutionary conserved protein containing a highly conserved N- 
terminal domain named the RNC (Raptor N-terminal conserved) domain followed by 
three HEAT repeats and then seven W D40 repeats (see figure 1.4 ‘B’). The RNC 
domain is made up of three blocks with around 67-79% sequence homology [74]. 
This region has a tendency to form a-helices and work by Dunlop et al. identified that 
this region is also required for mTOR/Raptor interaction with substrates [76]. Thus 
identifying that Raptor mutant 4, containing a mutation to the RNC domain, was able 
to interact with mTOR but not facilitate substrate phosphorylation. Raptor mutant 4 
therefore acts as a dominant inhibitor of mTORCI signalling and has been utilised 
within these studies.
mTORCI substrate phosphorylation has been found to be dependent upon a 
conserved regulatory motif which is found in the N-terminal of all known S6K’s and 
the C-terminal of the 4E-BPs, which is referred to as the mTOR signalling (TOS) 
motif [77-79]. The TOS motif acts as a docking site for mTORCI interaction and 
Raptor acts as the recognition component to facilitate this. A fully intact TOS motif is 
required for both interaction with Raptor and mTORCI mediated substrate 
phosphorylation. It has therefore been proposed that the TOS motif mediates 
substrate binding to Raptor, recruiting mTOR to the substrate/Raptor complex so 
that phosphorylation can occur [78]. More recently, putative TOS motifs have been 
found in a range of potential or candidate mTORCI substrates, described in table 
1.1. The TOS motif consists of a five amino acid sequence with a phenylalanine at 
position one which is indispensible for Raptor binding. It has been suggested that an 
aliphatic uncharged residue is also preferred at position three [80] however elF3F 
has more recently been demonstrated to contain a potential TOS motif with a 
Threonine residue at the third position, suggesting that this is not necessary [81]. It 
has also been suggested that the remaining amino acids consist of alternating acidic 
and hydrophobic residues [82]. However, there are some discrepancies with this 
notion, for instance the TOS motif found in HIF-1a is made up entirely of hydrophobic
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residues (see table 1.1) and the Threonine residue in elF3F is polar and hence 
hydrophilic.
More recently it has been shown that Raptor is phosphorylated by mTOR at 
Ser863 in response to insulin and other mTOR stimuli. This appears to trigger 
phosphorylation of Raptor at five other sites: Ser696/Thr706/Ser855/Ser859/Ser877.
Mutation of the mTOR directed phosphorylation site (Ser863) renders mTOR 
unresponsive to Rheb induced activation. This indicates that Raptor not only 
functions in the recognition of substrates but also plays a role in modulating mTOR 
kinase activity [83, 84].
Table 1.1: Substrates containing potential TOS motifs
S6K1 FDIDL 5-9
S6K2 FDLDL 5-9
4EBP1 FEMDI 114-118
4EBP2 FEMDI 116-120
4EBP3 FEMDI 86-90
H IF -la FVMVL 99-103
PLD2 FEVQV 264-269
PRAS40 FVMDE 129-133
PKC6 FVMEF 425-429
PKCe FVMEY 484-488
STAT3 FPMEL/FDMDL 26-30/756-760
elF3f FETML 323-327
GTF3C FEVDR 90-94
*Table adapted from [83].
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1.3.5 mLST8
mLST8 is a widely expressed 36 kDa protein which consists mainly of seven WD40 
repeats (see figure 1.4 ‘C ’). It was first identified in 2003 and was thought to bind 
directly to the kinase domain of mTOR increasing the stability of mTOR/Raptor 
interactions and promoting m TORCI kinase activity. The interaction between mTOR 
and mLST8 was reported to be stable, independent of Raptor and unaffected by 
nutrient status [85]. It was later found to also be a component of the mTORC2 
complex [45]. More recent work suggests that although it does form part of the 
mTORCI complex, it is more contributory to mTORC2 mediated signalling. As 
demonstrated by studies of mLST8-/- MEFs which exhibit impaired mTORC2 
signalling whilst m TORCI signalling remains intact [86]. Additionally, knockout of 
mLST8 disturbs mTOR/Rictor association but not mTOR/Raptor association, 
producing a phenotype similar to Rictor knockouts [86, 87]. ml_ST8 is therefore 
indispensible in mTORC2 complex formation but not mTORCI.
1.3.6 PRAS40
PRAS40 is a 40 kDa proline enriched Akt substrate. It was identified in 2007 by 
several research groups. PRAS40 was demonstrated to interact with mTORCI but 
not mTORC2 via Raptor recognition of a TOS motif identified in the C-terminal (see 
schematic, figure 1.4 ‘D’).
PRAS40 acts as a negative regulator of mTORCI activity under conditions of 
insulin-deprivation. It is thought to bind to the C-terminal kinase domain of mTOR 
[88] inhibiting its activation by Rheb [82, 88-91]. Insulin stimulation causes Akt and 
mTORCI to directly phosphorylate PRAS40 causing it’s dissociation from the 
complex. This promotes m TORCI interaction with substrates via their TOS motifs. 
Phosphorylated PRAS40 then binds to 14-3-3 chaperone proteins, fully alleviating 
the suppression of m TORCI [92].
1.3.7 DEPTOR
Research into inhibitory components of the mTOR complexes revealed a 48kDa 
protein referred to as DEPTOR. Unlike PRAS40 it is present in both mTORCI and 
mTORC2 complexes and is only conserved among invertebrates. It has been shown 
to bind directly to mTOR regardless of mLST8 expression. Its interaction is 
modulated by the PDZ domain located in the C-terminus of DEPTOR (see figure 1.4
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‘E’). It binds to a region of mTOR in the C-terminus adjacent to the kinase domain. 
DEPTOR depleted cells exhibit increased kinase activity towards mTORCI 
substrates 4E-BP1 and S6K1 as well as the mTORC2 substrate Akt. Serum- 
starvation causes a rise in DEPTOR expression and re-stimulation with serum 
causes a reduction in its expression. mTORCI and mTORC2 both negatively 
regulate the expression of DEPTOR when activated by phosphorylating it at one of 
the thirteen potential serine/threonine phosphorylation sites located between the C- 
terminal DEP domain and the PDZ domain. This appears to induce its removal from 
the complex in a manner similar to that of PRAS40 [93].
1.3.8 FKBP38
FKBP38 belongs to the peptidyl prolyl cis/trans isomerase (PPIase) family of FK506- 
binding proteins (FKBP). Also included in this family is the rapamycin binding partner 
FKBP12. This PPIases act as chaperones to modulate protein folding, biogenesis, 
assembly and trafficking [94]. They are characterised by a PPIase or PPIase-like 
domain referred to as the FKBP-C domain (see figure 1.4 ‘F’). The PPIase family 
catalyse the cis/trans isomerisation between native-state prolyl bond isomers of 
different biological activity via FKBP-C domains [94].
The FKBP-C domain of FKBP38 is situated in the N-terminus (see figure 1.4 
‘F’). It also contains a tetratricopeptide repeat (TPR domain) involved in protein- 
protein interactions, a binding site for calcium induced calmodulin, and finally a TM 
(transmembrane) domain. The TM domain allows FKBP38 to anchor itself to 
mitochondrial membranes and is unique to FKBP38 [95]. FKBP38’s PPIase domain 
becomes active in response to calcium influx and can then bind to Bcl-2 to regulate 
apoptosis [94].
There are several reports indicating that FKBP38 may form part of the 
mTORCI complex functioning as an endogenous inhibitor [76, 96, 97]. Studies have 
also demonstrated that like rapamycin, FKBP38 binds to the FRB region of mTOR, 
suggesting a similar mechanism of inhibition as with rapamycin [95]. A mechanism 
has been suggested whereby GTP-Rheb interacts with the inactive mTORCI 
complex in order to displace FKBP38. Consistent with this theory, mTORCI has 
been demonstrated to localise to the mitochondrial membrane [98, 99].
Work by Ma et al. has implicated the switch I region of Rheb as necessary for 
displacing FKBP38 interactions [96]. Tee et al. had also previously demonstrated
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that mutations to this switch 1 region prevent Rheb induced activation of mTOR [62]. 
This is consistent with research on other small G-proteins such as Ras, which in its 
GTP bound state can interact with its effectors via its switch I region [96]. Both Rheb 
and mTORCI have been demonstrated to localise to the mitochondria where 
FKBP38 is tethered [96]. This is consistent with the role of mTORCI as an energy 
and oxygen sensor. Studies have shown that Rheb interaction with FKBP38 is 
dependent upon the presence of amino acids and growth factors [97], indicating that 
interactions are determined by its guanine nucleotide status. Increases in Rheb 
binding to FKBP38 appear to be coupled with decreases in the amount of FKBP38 
bound to mTOR, supporting the notion of Rheb modulated displacement [97]. It has 
been suggested that this may be the mechanism by which Rheb activates mTOR, 
however this remains controversial. Some studies have been unable to demonstrate 
any inhibition of m TORCI through FKBP38 expression but show direct interaction 
[54, 59, 100]. Dunlop et al. demonstrated that FKBP38 induced a modest inhibition of 
mTORCI kinase activity in vivo and in vitro that was not as potent as PRAS40 [76]. 
This may explain why some groups did not see inhibition. It also makes it unlikely 
that the sole mechanism for Rheb induced activation of mTORCI is via removal of 
FKBP38 as Rheb is a potent activator of m T O R C I It is likely that Rheb modulates 
mTORCI through FKBP38 dependent and independent mechanisms.
1.4 ACTIVATION OF mTORCI
mTORCI is activated by a number of different mechanisms, this is unsurprising 
given the diverse and complex nature of the cellular processes moderated by 
mTORCI. mTORCI is regulated by nutrient status, growth factors, insulin and other 
mitogens. The known mechanisms resulting in mTORCI activation are described in 
detail below and summarised in figure 1.5.
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1.4.1 Insulin and Growth Factors
PI3Ks are a family of lipid kinases which play regulatory roles within the cell. They 
are classified by their structure and their ability to recognise substrates. Of particular 
interest in this project is the Class 1a PI3Ks which are heterodimers consisting of a 
p85 regulatory subunit coupled to a p110 catalytic subunit. The 1a class of PI3Ks are 
activated via cell surface receptors and are switched on with insulin and growth 
factor stimulation. The insulin receptor substrates (IRS 1-4) are potent activators of 
PI3Ks when phosphorylated. PI3Ks also demonstrate an affinity for the 
phosphorylated tyrosine residues found in activated growth factor RTKS. 
Phosphorylation of these tyrosine residues facilitates the recruitment of PI3Ks to the 
membrane where the p85 regulatory subunit directly binds to the receptors (see 
figure 1.5). The p110 catalytic subunit then converts phosphatidylinositol-4,5- 
bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3) [101]. It is 
significant to note that PI3K is negatively regulated by phosphatase and tensin 
homolog (PTEN), which reverses the conversion of PIP2 to PIP3 and thus functions 
as a tumour suppressor [102]. Importantly, the conversion of PIP2 to PIP3 provides a 
docking site for Akt (also known as Protein Kinase B (PKB)). This ‘docking’ of Akt, 
causes a conformational change exposing two phosphorylation sites within Akt. The 
first, Ser473 is phosphorylated by mTORC2, this allows PDK1 to phosphorylate the 
second Thr308 site. Akt/PKB also up-regulates mTORCI signalling by 
phosphorylation of PRAS40 and TSC2 [101].
Phosphorylation of PRAS40 by Akt triggers its removal from mTORCI by 14- 
3-3 chaperone proteins (see section 1.3.6) while phosphorylation of TSC2 at Ser939 
and Thr1462 by Akt causes disruption of the TSC1/TSC2 heterodimer. Tuberin and 
Hamartin (TSC1 and 2) form a heterodimer in response to mitogenic withdrawal. 
When complexed together, TSC1 and TSC2 are able to confer GAP activity towards 
the small G-protein Rheb to suppress m TORCI. Activation of the TSC complex, 
therefore, results in the conversion of Rheb to the inactive GDP-bound state and 
suppression of m TORCI signalling (as shown in figure 1.5).
Other mitogenic signalling pathways activate mTORCI signalling through 
disruption of the TSC 1/2 complex. Growth factor binding to membrane receptors 
activates Ras, which in turn activates PI3K, inducing Akt mediated phosphorylation 
of TSC2 (as described above). It also activates a Raf/Mek1 signalling cascade which 
stimulates the phosphorylation of TSC2 at Ser664 (and possibly to a lesser extent
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Ser540) by ERK1/2, disrupting the TSC tumour suppressor complex [103]. ERK1/2 is 
also able to phosphorylate and subsequently activate p90-RSK1 [104] which 
phosphorylates TSC2 at Ser1798 [105], p90-RSK1 also phosphorylates Raptor to 
increase mTORCI kinase activity directly [106]. TSC2 is therefore the axis at which 
Raf/Mek and PI3K signalling cascades meet, convergence of the two pathways to 
mediate mTORCI signal transduction indicates the significance of mTOR in the 
regulation of cellular growth and metabolism.
1.4.2 Phospholipase-D
Phospholipase-D (PLD) is a widely expressed enzyme which is activated in 
response to a wealth of hormones, growth factors, cytokines and neurotransmitters 
(see review [107]). PLD1 hydrolyses phosphatidycholine, producing phosphatidic 
acid (PA) and choline [107]. Phosphatidic acid (PA) is a positive regulator of 
mTORCI. It was demonstrated in vitro that PA bound directly to the FRB domain 
within mTOR (FKBP12/rapamycin binding domain -  see figure 1.4 ‘A’) and as 
expected was displaced by the rapamycin/FKBP12 complex. Elevation of 
intracellular PA renders cells less sensitive to rapamycin treatment indicating a 
competitive relationship between PA and rapamycin, with PA binding causing 
activation and rapamycin binding causing inhibition [108].
Interestingly, not all production of PA results in mTORCI activation, for 
instance RhoA activates PLD1 but not mTORCI [109]. This suggests that the 
cellular localisation of PA production is significant in the regulation of m TO R C I In 
addition to the direct binding of PA to m TORCI, there is evidence that PLD1 itself is 
a direct effector of Rheb [110]. Sun et al. demonstrated that Rheb knockdown 
impaired serum-induced activation of PLD1 whilst over-expression of Rheb resulted 
in PLD1 activation in the absence of mitogenic stimulation. They were able to 
demonstrate that Rheb bound directly to PLD1 in a GTP dependent manner in vitro 
and have therefore proposed a mechanism by which Rheb signals to PLD1 in order 
to stimulate PA production, resulting in mTORCI activation [110]. A more recent 
study however provided evidence disputing the direct effect of PA upon mTORCI, 
suggesting that PA must first be metabolised to LPA (lysophosphatidic acid) to 
permit activation of m TO RCI, furthermore they suggested that neither PA nor LPA 
bound directly to mTORCI and that activation is a result of upregulation of the ERK
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pathway [111]. The reason for these discrepancies is unclear within the literature and 
further studies are required to determine the correct mechanism.
1.4.3 AMPK
A mechanism has been described whereby AMPK activation results in the 
phosphorylation of TSC2 (see figure 1.5). AMP levels are inversely proportionate to 
ATP levels, therefore when ATP becomes depleted, AMP levels rise and AMPK is 
activated. When ATP levels are depleted, homeostatic mechanisms are induced to 
switch off energy consuming cellular processes such as protein synthesis and cell 
growth. Therefore AMPK acts to switch off mTORCI signalling via phosphorylation 
of TSC2 [112]. Although phosphorylation of TSC2 by RSK, Akt and ERK results in 
disruption of TSC1/TSC2 causing its inhibition, phosphorylation at a different site, 
Ser1345 by AMPK results in TSC2 activation and subsequent inhibition of mTORCI 
[112].
It was later established that GSK3P also phosphorylates TSC2 at Ser1341 as 
well as Ser1337 to mediate its activation and subsequent inhibition of mTORCI 
[113]. AMPK mediated Ser1345 phosphorylation of TSC2 is required for this to occur 
so it is likely that AMPK and GSK3p act in synergy to promote the GAP activity of 
TSC towards Rheb. Thus indicating crosstalk between the Wnt signalling pathway 
which negatively regulates GSK3P and mTORCI [114].
Studies have also identified a TSC2 independent mechanism of AMPK 
mediated inhibition of m TORCI whereby AMPK directly phosphorylates Raptor. This 
results in the recruitment of inhibitory 14-3-3 proteins to the mTORCI complex and 
subsequent inhibition of signal transduction [115].
1.4.4 Nutrient Regulation
As mTORCI regulates a significant range of energy costly processes, it is 
paramount that mTORCI activity is appropriate for the nutrient status of the cell. It is 
not fully understood how mTORCI is regulated by nutrients, with amino acid 
regulation being the best characterised. In addition to this, several other mediators 
have also been identified which contribute to nutrient mediation of mTORCI and are 
described below.
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1.4.4.1 Amino Acid Regulation
A permissive amino acid input is required for Rheb to activate mTORCI in response 
to growth factors however it is unknown how amino acids signal to mTORCI. 
Recently, details of this mechanism have been uncovered, implicating a series of 
proteins referred to as the Rag GTPases. A model has been described whereby 
amino acids stimulate the GTP loading of Rag proteins. Once this occurs, they are 
able to bind to the Raptor component within mTORCI and trigger re-localisation of 
the complex to membrane surfaces where farnesylated Rheb is also situated. This 
translocation occurs independently of mTORCI kinase activity and is therefore 
insensitive to rapamycin inhibition. It is thought that for the above described 
activation of m TORCI, this amino acid induced localisation of mTORCI must first 
occur [116, 117]. More recent work by Sancak et ai. identified that amino acids 
induce the translocation of m TORCI to the lysosomal membrane where it interacts 
with the aptly named ‘Ragulator complex’ consisting of MP1, p14 and p18. The 
Ragulator complex functions to recruit Rag GTPases to the lysosomal membranes 
where they function to activate m TO RCI. It has been demonstrated that constitutive 
targeting of mTOR to the lysosomal surface is sufficient to render it unresponsive to 
amino acids [118].
1.4.4.2 Vps34
Vacuolar protein sorting 34 (Vps34) was recently identified as a positive regulator of 
mTORCI signalling. Vps34 is involved in vesicular trafficking processes and 
autophagy [119]. It was shown that over expression of Vps34 causes upregulation of 
mTORCI signalling to its downstream substrates. In addition to this, Vps34 was 
inhibited by amino acid/glucose withdrawal but not rapamycin, indicating that it lies 
upstream of mTORCI [120, 121].
Vps34 binds to Vps15 to form an active complex, then uses Ptdlns 
(phosphoinositides) as a substrate to produce Ptdlns(3)Pi [122], this results in the 
recruitment of various proteins to the early endosome where it may provide a 
platform for mTORCI signalling [120, 121].
It was later established that amino acid stimulation causes an influx of 
calcium, Vps34 contains a calmodulin binding domain and has been postulated that 
binding of calcium/calmodulin to Vps34 increases lipid kinase activity and increases 
mTORCI signalling, suggesting in fact that Vps34 senses calcium rather than amino
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acids [123]. However Yan et al. in 2009 indicated that Vps34 activity was unaffected 
by calcium chelators or calmodulin inhibitors disputing this argument [124]. In 
addition, a recent study implementing Drosophila containing loss-of-function 
mutations to the Vps34 ortholog demonstrated that TOR signalling was unaffected 
while autophagy and endocytosis were disrupted [119]. This may indicate that Vps34 
signalling is only conserved among invertebrates. Alternatively it may be possible 
that Vps34 activates m TORCI when amino acids are present in order to repress 
autophagy (see figure 1.6) since it has a well characterised role as an activator of 
autophagy under appropriate nutrient conditions.
Further research is required to determine whether amino acids signal to 
Vps34 within the cell.
1.4.4.3 MAP4K3
MAP4K3 is an Ste20 related kinase which was identified in 2007 as a regulator of 
mTORCI in response to amino acids [125]. Findlay et al. established that over­
expression of MAP4K3 could propagate mTORCI signalling as determined by 
increased phosphorylation of S6K1 and 4E-BP1 (see section 1.5). This was subject 
to inhibition by rapamycin but not the PI3K inhibitor wortmannin. MAP4K3 activity 
was shown to be regulated by amino acids but not insulin or rapamycin. 
Furthermore, knockdown of MAP4K3 prevented amino acid induced S6K1 
phosphorylation. This suggests that MAP4K3 lies upstream of mTORCI and may 
function to regulate m TORCI in response to amino acids [125]. Later work in 2010 
utilised Drosophila MAP4K3 mutants to investigate this further. Interestingly, the 
mutant flies were viable indicating that TOR signalling could still occur. The mutants 
however displayed reduced TOR signalling which may suggest that MAP4K3 
functions to modulate mTOR but is not required for its activation. Interestingly, 
differences between the mutant flies and wild-type could be diminished if the flies 
were raised under low-nutrient conditions. This suggests that MAP4K3 plays an 
important role in modulation of TOR signalling when nutrients are plentiful. Yan et al. 
observed that suppression of the Rag proteins reduced the ability of MAP4K3 to 
propagate mTORCI signalling but concluded that it was unlikely that RagGTPases 
were directly modulated by MAP4K3. Further work is required to determine how the 
two pathways are related.
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Yan et al. also used mass spectrometry phosphopeptide analysis to identify a 
phosphorylation site, Ser170 within the kinase activation domain of MAP4K3. 
Phosphorylation at this site is thought to be required for amino acid modulation of 
MAP4K3 activity and for MAP4K3 activation of m TORCI. Phosphorylation at Ser170 
was eliminated by amino acid withdrawal but unaffected by insulin treatment. 
Interestingly, they showed that amino acid withdrawal caused an acute drop in 
Ser170 phosphorylation within 5 minutes and postulated that this rapid 
dephosphorylation was likely to be the action of a phosphatase. Further studies 
revealed that MAP4K dephosphorylation could be inhibited by incubation with the 
specific PP2A inhibitor okadaic acid [126]. PP2A is a multiprotein serine/threonine 
phosphatase which functions to reverse the action of many kinases in many major 
signalling pathways. Consisting of a structural A-subunit, a regulatory B-subunit and 
a catalytic C-subunit, the regulatory B-subunit is thought to determine substrate 
specificity [127]. Yan et al. revealed that MAP4K3 could bind to the B-subunit of 
PP2A, PR61e. It was demonstrated that ectopic expression of PR61e could abolish 
Ser170 phosphorylation of MAP4K and hence mTORCI signalling even in the 
presence of amino acids. Furthermore, amino acid deprivation lead to an increase in 
the binding of PP2A to MAP4K3 [126]. This may suggest a model of competitive 
inhibition between PP2AT61e (PP2A in complex with the B-subunit) and amino acids 
(more likely a factor regulated by both) but further work is required to fully elucidate 
how amino acids regulate MAP4K3 (see figure 1.5).
1.4.4.4 RalA
RalA is a member of the Ras superfamily of GTPases involved in modulation of 
protein transcription, cellular membranes and cell migration. It has also been 
implicated in cellular proliferation and participates in Ras-induced oncogenic 
transformation of cells. More recently however it has been implicated in nutrient 
regulation of m TORCI. Maehema et al. demonstrated that amino acid and glucose 
induced S6K1 phosphorylation could be inhibited by knockdown of RalA or its 
activator Ral-GDS. It was reported that amino acids increased the levels of GTP- 
bound RalA but not RalB, concluding that amino acids were able to regulate RalA to 
activate m TORCI. Furthermore, RalA knockdown was sufficient to suppress 
mTORCI signalling in cells overexpressing a hyperactive mutant of Rheb and that 
RalA knockdown did not affect Rheb’s nucleotide bound status, thus placing RalA
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downstream of Rheb. However they were not able to show direct interaction of RalA 
with mTORCI or with FKBP38 indicating that RalA is not able to activate mTORCI 
alone. From this, they hypothesised that nutrients may be able to activate mTORCI 
independently or downstream from Rheb [100], however the mechanism is yet to be 
uncovered.
1.4.4.5 UBR1 and UBR2
The branched chain amino acids, in particular leucine, elicit a much stronger impact 
upon mTORCI signalling than other amino acids [128, 129]. Leucine withdrawal 
alone is as effective as complete amino acid starvation at suppressing mTORCI 
signalling and stimulation with leucine is sufficient to promote mTORCI signal 
transduction [128]. It has been speculated that leucine may be more frequently 
utilised in protein synthesis and therefore mTORCI is more responsive to their 
depletion [128].
A recent study has however shed light on how leucine in particular is able to 
modulate mTORCI by identifying UBR1 and UBR2 as both leucine binding proteins 
and negative regulators of m TO R C I. UBR1 and UBR2 are E3 ubiquitin ligases 
which specifically recognise ‘N-degrons’ which are destabilising N-terminal basic or 
bulky hydrophobic residues of protein substrates. UBR1 and 2 function as ‘N- 
recognins’ which identify N-degrons and target these specific proteins for 
ubiquitination and subsequent degradation at the 26S proteasome (N-end rule 
pathway) [130]. A study by Kume et al. demonstrated that over-expression of UBR1 
and UBR2 causes a suppression of m TORCI signal transduction which can be 
rescued by stimulating with high concentrations of leucine. They demonstrated that 
leucine directly binds to the substrate recognition domain of UBR2 preventing 
degradation via the N-end rule pathway, this promotes signalling via mTORCI [131]. 
It is unclear how they function to inhibit mTORCI signalling and whether this is 
related to their roles as ubiquitin ligases, leucine may also be able to exert a more 
direct effect but this has yet to be discovered.
1.4.4.6 NPR2 and NPR3
Within yeast, conditions of rapamycin treatment or amino acid withdrawal result in 
the nuclear translocation of transcription factors Gln3 and Gat1 causing expression 
of Dal80 and suppression of Tor. When nutrients are plentiful, Gln3 and Gat1 remain
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cytoplasmic and hence inactive. Neklesa et al. developed a flow-cytometry based 
genetic screen to discover regulators of TOR1 in yeast. They identified a highly 
conserved complex consisting of NPR2 and NPR3 which responds specifically to 
amino acid deprivation in yeast to inactivate TOR1 [132]. Unfortunately they were 
unable to identify the mechanistic action of NPR2 and NPR3, nor whether this 
activity was conserved among higher eukaryotes.
NPR2 and 3 are nitrogen permease regulators, the human analogues of 
which are NPRL2 and NPRL3 which are now known to function as tumour 
suppressors [133] so it may be likely that the human analogues of NPRL2/3 perform 
similar functions in mammalian cells. A recent study by Kuruta et al. also 
demonstrated that NPRL2 interacts with and inhibits PDK1 [134]. PDK1 
phosphorylates Akt to promote activation of mTORCI (see section 1.4.1). It was 
demonstrated that active NPRL2 functions to inhibit PDK1 and subsequently 
decrease phosphorylation of the inhibitory mTORCI regulators PRAS40 and TSC2, 
suppressing m TORCI. Unfortunately Kurata et al. did not investigate NPRL2 activity 
under the context of nutrient deprivation. Since a similar mechanism occurs in 
eukaryotes as yeast and NPRL2 can inhibit m TORCI, it is possible that NPRL2 may 
also be subject to amino acid regulation and may present one of the mechanisms by 
which amino acids signal to m TO RCI.
1.4.5 Hypoxic Regulation
The cell is continuously orchestrating a fine balance between ensuring sufficient 
oxygen concentration for metabolic processes without allowing it to reach toxic 
levels. During O2 deprivation, the cell rapidly adapts to compensate for the lack of 
0 2, this is regulated in part by increased production of HIFs (see section 1.1 
Oxygen),but also by suppression of energy demanding process such as protein 
translation. This is modulated in part by a hypoxia induced suppression of mTORCI 
signalling. Hypoxia induces suppression of mTORCI by several distinct 
mechanisms, all of which are dispensable. HIF-1a has been identified as a potential 
target of m TORCI signalling and is a focus of this study [135]. There are multiple 
mechanisms of hypoxia mediated m TORCI suppression, both HIF-1a dependent 
and independent mechanisms are described. See figure 1.6 for overview.
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1.4.5.1 AMPK
As described above, induction of AMPK as a result of energy stress results in 
mTORCI suppression. AMPK phosphorylates TSC2 at Ser1345 to induce formation 
of the inhibitory TSC [112] (see figure 1.6). In addition to this, AMPK can also directly 
phosphorylate Raptor to reduce m TORCI activity [115]. Both these events play a 
role in hypoxia induced m TORCI suppression.
1.4.5.2 REDD1 and REDD2
REDD1/2 expression is upregulated in response to hypoxia, cell stress and DNA 
damage and it is thought to be a direct target for the transcription factor HIF-1a [136]. 
When mTORCI is active, inhibitory 14-3-3 proteins bind to TSC2 to disrupt TSC- 
mediated inhibition of mTOR [137-140]. Under hypoxia, REDD1/2 binds to and 
sequesters 14-3-3 proteins, thus releasing TSC2 and thereby rescuing TSC Rheb- 
GAP activity to inhibit m TORCI [35, 141, 142].
1.4.5.3 PML (Promyelocytic leukaemia tumour suppressor)
PML induces growth arrest, cellular senescence and apoptosis. In 2006, Bernardi et 
al. identified PML as a key regulator of angiogenesis, demonstrating that PML could 
be induced by hypoxia and that it led to a down-regulation of HIF-1a. They identified 
a novel mechanism by which PML functions to sequester mTOR to the nucleus, 
away from its activator Rheb. This results in suppression of mTORCI signalling and 
therefore down-regulation of HIF-1a [143].
1.4.5.4 BNIP3 (Bcl-2/adenovirus E1B 19-kDa interacting protein 3)
BNIP3 is a member of the of the Bcl-2 family of apoptosis regulating proteins [144]. It 
is also a target for HIF-1a and it is thought to play a role in hypoxic-induced cell 
death [144, 145]. More recently it has been identified as one of the mediators of 
hypoxia-induced mTOR suppression. BNIP3 has been shown to bind directly to 
Rheb where it appears to reduce the GTP-level, thus preventing its activation of 
mTORCI [146].
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1.4.5.5 Hypoxia and m TO R C I
The relationship between 0 2 homeostasis is complex, mTORCI appears to regulate 
the activity of HIF-1a which is an essential mediator of the hypoxic response, 
paradoxically however m TORCI itself is suppressed during hypoxia but HIF-1a is 
not. This suggests that m TORCI is able to upregulate HIF-1a specifically whilst 
mediating suppression of other cellular processes; however this has yet to be 
demonstrated. One of the primary aims of this study is to characterise how mTORCI 
regulates HIF-1a. In order to understand how mTORCI can regulate HIF-1a it is 
important to dissect what we already know about mTORCI and its downstream 
substrates.
1.4.6 Feedback Loops
There are many positive and negative feedback loops in place which fine tune signal 
transduction through mTOR. Several mechanisms have been described involving 
S6K1 which is a direct substrate for m TORCI. For instance, S6K1 phosphorylates 
Ser/Thr residues in IRS proteins inhibiting tyrosine phosphorylation and thus 
preventing PI3Kinase activation, this renders cells resistant to insulin [147, 148]. 
Active S6K1 also reduces the expression of both a and (3 isoforms of the platelet 
derived growth factor receptor (PDGFR), causing insensitivity to serum and platelet 
derived growth factor when m TORCI is active. TSC 1/2 deficient cells lines thus 
exhibit reduced expression of PDGFR isoforms in comparison to their wild-types 
[149]. Finally, S6K1 is also reported to phosphorylate Rictor in order to downregulate 
mTORC2 mediated phosphorylation of Akt [150, 151].
Recent reports suggest inhibition of mTORCI by rapamycin causes 
upregulation of ERK1/2 signalling to TSC2, disrupting the TSC1/2 tumour suppressor 
complex (see section 1.4.1). It is thought that active S6K1 functions to suppress 
activation of the Ras/Raf signalling cascade, therefore mTORCI inhibition with 
rapamycin alleviates the S6K1 mediated repression of Ras/Raf signalling [152]. This 
may lead to activation of other pathways downstream of Raf and Ras which may be 
inappropriately upregulated. Feedback mechanisms have direct implications for the 
therapeutic use of m TORCI inhibitors since they too become dysregulated when 
signalling pathways are manipulated. Identifying these feedback loops is paramount 
to understanding how diseases manifest through perturbed signalling, and also for 
successful therapeutic intervention.
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1.5 DOWNSTREAM SUBSTRATES OF mTORCI
mTORCI regulates multiple processes, including cell growth and proliferation, 
cell cycle progression, angiogenesis, erythropoiesis, glucose transport and 
mitochondrial biogenesis (see figure 1.7). It exerts many effects through regulation of 
protein synthesis at a translational and transcriptional level, mediating 
phosphorylation of multiple downstream substrates. Our knowledge base is rapidly 
expanding in the field with identification of several new mTORCI substrates in recent 
years and many still yet to be uncovered.
Below is a review of the current knowledge of signalling downstream of 
mTORCI. See figure 1.7 for an overview of mTORCI downstream signalling effects.
1.5.1 The ribosomal protein S6-kinases
The S6-kinases are a subset of the AGC family of protein kinases, several other 
AGC kinases are also involved in mTOR signal transduction including Akt and p90- 
RSK. S6K1 and S6K2, like mTOR, are serine/threonine kinases and are known 
regulators of protein synthesis. In addition to this role, they have been implicated in 
the regulation of mRNA processing, cell growth and survival as well as glucose 
homeostasis (see review [153]). The S6-kinases exert many of their effects through 
phosphorylation of ribosomal protein S6 (rpS6) however a full list of the known S6 
kinase substrates is shown in table 1.2.
The family of AGC protein kinases share an analogous mechanism for 
activation, for maximal induction they require phosphorylation at two conserved 
Ser/Thr residues. One of which is situated in the T-loop domain (or activation-loop) 
and one is contained within a hydrophobic motif found in the C-terminal catalytic 
domain. PDK1 is thought to be the major T-loop kinase for the S6 kinases and many 
other AGC kinases downstream of PI3K. It is thought that phosphorylation of the 
Thr389 site (Thr388 in S6K2) contained within the hydrophobic motif, creates a 
docking site for PDK1 which promotes its phosphorylation at the T-loop domain and 
hence its full activation [154].
It was demonstrated in 2002 that mTORCI specifically interacts with S6K1 via 
an mTORCI signalling motif to mediate its phosphorylation and subsequent 
activation in a rapamycin sensitive manner. The TOS motif is found in the N-terminus 
of both S6K1 and S6K2, mutation to this motif was found to mimic the effects of 
rapamycin [77]. Rapamycin treatment is thought to repress S6K1 activation not only
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through down regulation of m TORCI, but also through increased activity of the 
phosphatase PP2A towards S6K1 [155].
Studies utilising Drosophila have revealed the importance of the S6K’s in 
modulating cell growth and development. Disruption to the singular S6K gene found 
in Drosophila (dS6K1) resulted in lethality for the majority of flies at the larval stage. 
Those that did survive presented with a significantly smaller phenotype than the wild- 
type as a result of a reduction in cell size not proliferation [156].
The S6Ks exert the majority of their effects through phosphorylation of rpS6, 
rpS6 becomes activated after sequential phosphorylation at 5 different Serine sites 
within its C-terminus: Ser236 > Ser235 > Ser240 > Ser244 > Ser247, the S6Ks are 
able to mediate phosphorylation of Ser240/244 [157]. Mice studies demonstrated 
that rpS6-/- mice share a similar phenotype to S6K1-/- mice and both exhibit defects 
in cell growth. Interestingly, S6K1-/- mice show minimal changes to rpS6 
phosphorylation whereas S6K2-/- mice show significantly reduced levels of 
phosphorylated rpS6 but normal growth [158]. This would indicate that S6K2 is the 
primary kinase for rpS6 but does not explain the discrepancies in the cell growth 
phenotype. It may indicate that rpS6 is only able to effect cell growth when 
phosphorylated by S6K1, and could be explained by differential localisation of S6K1 
and S6K2. S6K2 contains an additional C-terminal nuclear localisation sequence 
whilst S6K1 contains an additional PDZ domain associated with recruitment to the 
cytoskeleton [153] in support of this.
S6K1 also has multiple roles in protein translation (see figure 1.8). Introns 
within a gene promote splicing which enhances gene expression via recruitment of 
the exon junction complex (EJC) [159, 160]. In 2004, Richardson et al. identified 
SKAR to be a specific target of S6K1 [161]. Ma et al. later demonstrated that S6K1 
was recruited to the EJC via binding to SKAR where it functions to enhance 
translational efficiency mediated via increased splicing [162].
Furthermore, a recent a study by Yamnik et al. demonstrated that S6K1 directly 
phosphorylates the oestrogen receptor (ERa) at Ser167 promoting its transcriptional 
activity in a rapamycin sensitive manner [163]. Increased transcriptional activity of 
ERa promotes cell proliferation and is thought to confer enhanced proliferation in 
breast cancer cell lines, implicating mTORCI dysregulation in the manifestation of 
breast cancer. See figure 1.8 for an overview of the effects of S6 kinases upon 
protein synthesis.
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Table 1.2: Substrates of the S6 kinases
rpS6 Component of the ribosomal 40s subunit, required for translation.
elF4b Assists elF4A in unwinding of mRNA for translation.
eEF2k
Inhibits eEF2 required for elongation (protein translation), also 
activates autophagy. Inactivated by S6 kinase mediated 
phosphorylation.
MAD1
Also inactivated by the S6 kinases, MAD1 is an inhibitor of myc- 
directed transcription which upregulates genes involved in cell 
proliferation and apoptosis, it is also associated with oncogenic 
transformation. MAD1 has also been shown to regulate UBF which 
is a transcription factor required for ribosomal biogenesis.
CBP80
80 kDa subunit of the nuclear cap binding complex. Activated by S6 
kinases and facilitates pre-mRNA splicing and synthesis of poly (A) 
tail (see figure 1.1 The  Transcription Cycle').
Pdcd4
Pdcd4 is a tumour suppressor which inhibits protein translation by 
blocking elF4A. S6 kinases mediate its degradation to enhance 
protein translation.
SKAR
Activated by S6K1 but not S6K2. Interacts with the DNA polymerase 
delta p50 subunit and appears to play a role in cell growth 
regulation.
IRS-1
S6 kinases phosphorylate IRS-1 to facilitate its degradation 
preventing further insulin induced S6 Kinase activity as a means of 
negative feedback.
mTOR
S6 kinase mediate phosphorylation of mTOR directly at Thr- 
2446/Ser-2448, the function of this is unclear but may be a positive 
feedback loop.
BAD
BAD is a pro-apoptotic protein which can dimerise with BCl-2to  
promote cell death. Phosphorylation of BAD by S6 kinases prevents 
BCL-2 binding.
MDM2
M DM 2 functions as an E3 ligaseto p53 and is regulated by S6 
kinases. p53 is involved in a plethora of cellular processes including 
cell cycle arrest, apoptosis and senescence. S6 kinase represses 
these processes via MDM2.
CREM
cAMP-responsive modulator (CREMt) regulates the transcription of 
cAMP-responsive genes and plays a role in spermatogenesis.
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1 .5 .1 )  w h ic h  r e g u la t e  t h e  c e l l  c y c le  r e p r e s s o r  R b . m T O R C ls  r o le  a s  a  t r a n s c r ip t io n a l  r e g u la t o r  h a s  y e t  t o  b e  f u l ly  e lu c id a t e d ,  m T O R C I  h a s  
b e e n  r e p o r t e d  t o  r e g u la t e  S T A T 3 , H IF - 1 ,  Y Y 1 , S R E B P 1 , P P A R y , M a f - 1  a n d  p 2 7  ( in d i r e c t l y )  w h ic h  in  t u r n  r e g u la t e  g e n e  e x p r e s s io n  r e la t in g  t o  
a  d iv e r s e  r a n g e  o f  f u n c t io n s  ( h ig h l ig h t e d ) .  I t  is  u n k n o w n  i f  t h is  r e g u la t io n  is d i r e c t  o r  m e d ia t e d  b y  a n  m T O R C I  e f f e c t o r s  s u c h  a s  S 6 K 1 .
1.5.2 4E-BPS
As described in section 1.2.2.1, elF4G interacts directly with the cap-bound protein 
elF4E for the initiation of cap-dependent translation. The 4E-BPs regulate protein 
translation at this rate-limiting stage by disrupting this interaction. Hypo- 
phosphorylated 4E-BPs compete for and bind reversibly to the binding site on elF4E 
also targeted by elF4G, thus preventing its binding and suppressing cap-dependent 
translation [164, 165]. Phosphorylation from mTORCI reduces the affinity of the 4E- 
BPs towards elF4E, triggering removal from the cap-bound elF4E so cap-dependent 
translation can then commence [166].
There are three 4E-BP isoforms, they belong to a poorly understood group of 
largely unstructured proteins which are thought to regulate a diverse range of cellular 
functions. 4E-BP1, 2 and 3 all share the elF4E binding region found in elF4G and 
hence are regulated in the same manner [167]. Binding of the 4E-BPs to elF4E 
causes a change in conformation with the 4E-BPs adopting a more structured state 
consisting of around 50% a-helices, this may aid their inhibitive action [168].
4E-BPs tend to differ primarily in terms of their expression with 4E-BP1 being 
the most widely expressed and best characterised. Phosphorylation of 4E-BP1 is 
thought to be a two-step mechanism. There are six identified mTORCI 
phosphorylation sites contained within the 4E-BPs. mTORCI phosphorylates Thr37 
and Thr46 and this acts as a priming event for phosphorylation at other sites. These 
sites are more readily phosphorylated whilst 4E-BP1 is in complex with elF4E, and 
do not appear to influence the affinity of 4E-BP1 for elF4E. However 4E-BP1 must 
be initially phosphorylated at these residues to allow subsequent phosphorylation of 
Ser65, Thr70, Ser83 and Ser112 (by mTORC1/Akt/PI3Ks) [166]. Phosphorylation at 
Ser65 has the greatest impact upon elF4E binding affinity which is perhaps expected 
as it is the site situated closest to the elF4E binding domain (see figure 1.9 below).
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mTORCI interaction with 4E-BP1 is modulated by two distinct regulatory motifs. The 
mTOR signalling motif or TOS motif and an additional RAIP motif, named after its 
amino acid sequence (see figure 1.9). As with other mTORCI substrates, mutations 
to the TOS motif of 4E-BP1 prevent interaction of m TO R C I The TOS mutant of 4E- 
BP1 therefore acts as a dominant inhibitor of cap-dependent translation [169], still 
able to bind to and inhibit elF4E but not phosphorylated by mTORCI to initiate its 
removal. The RAIP motif was later identified by Tee et al. [169] and appears to 
facilitate maximal phosphorylation of 4E-BP1 although there are discrepancies within 
the literature regarding whether it is involved in Raptor binding [170, 171], further 
characterisation of this motif is carried out as part of these studies.
1.5.3 HIF-1a
HIF-1a is a ubiquitously expressed HIF protein. HIF-1a is primarily responsible for 
the hypoxic response. It can modulate over 100 different target genes and regulates 
processes involved in angiogenesis, erythropoiesis, energy metabolism as well as 
cell cycle progression [135, 172]. It functions as a heterodimer which is comprised of 
a constitutively expressed HIF-(3 subunit and an inducible a sub-unit. The a-subunit 
is present in 3 isoforms, HIF-1a, HIF-2a and HIF-3a. HIF-1a and HIF-2a are similar 
in their structure and function whereas HIF-3a appears to play more of an opposing 
role, functioning to inhibit the expression of hypoxia induced genes [173]. HIF-1a and 
HIF-2a both appear to be activated and regulated in the same oxygen dependent 
manner however HIF-1a is the only form which is expressed ubiquitously. HIF-2a 
expression is restricted to the endothelium of blood vessels and distinct cells of the 
kidney, brain, heart, lung, liver, pancreas, and intestine [174, 175]. It is the 
ubiquitously expressed HIF-1a isoform which is the focus of this study due to its 
widespread expression and the presence of an mTOR signalling motif within the N- 
terminus which is not present in the HIF-2a isoform. Land and Tee (2007) discovered 
the mTOR signalling motif at the 3’-end of the period-ARNT-Sim conserved domain- 
A (PAS-A) of HIF-1a. In their study, the TOS motif, FVMVL, was mutated at the first 
crucial phenylalanine to an inactivating alanine residue (see figure 1.10). This 
produced a dominant negative mutant of HIF-1a and indicated a regulatory input 
from the mTORCI signalling pathway [135].
Many diseases linked with mTOR feature the development of tumours. 
Whether they are benign hamartomas like those seen in TSC patients, or highly
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metastatic cancers like those seen in renal cell carcinoma, activation of HIF-1a is 
required to induce the formation of new blood vessels. The diffusion of O2 through 
tissues is very limited therefore tumours absolutely require activation of HIFs to 
increase O2 and nutrient delivery to all areas of the tissue. The effects of 
inappropriate HIF-1a activation can be seen best in sufferers of Von-Hippel Lindau 
(VHL) syndrome. VHL results from mutations to the Von Hippel-Lindau tumour 
suppressor protein. The disease is characterised by the development of highly 
vascularised, both benign and malignant tumours with increased risk of 
hemangioblastoma and clear-cell renal carcinoma [176, 177]. VHL modulates the 
oxygen dependent degradation of the HIF-1a subunit (see figure 1.11 for an 
overview of this degradation). HIF-1a contains an oxygen dependent degradation 
domain, within this domain are two proline residues of significance, Pro564 and 
Pro402 (see figure 1.10). These proline sites become hydroxylated by any of three 2- 
oxoglutarate and Fe(ll) dependent prolyl hydroxylases (PHDs) in the presence of O2. 
This reaction causes a significant increase in the binding of VHL to HIF-1a, where 
VHL is the recognition component of the E3 ligase for HIF-1a, ubiquitinating it for 
degradation at the proteasome [178, 179]. OS-9 (osteosarcoma amplified 9) 
has also been demonstrated to influence the stability of HIF-1a. OS-9 appears to 
stabilise the interaction between HIF-1a and PHD2/3 to promote HIF-1a 
hydroxylation [180].
In addition to this, there is further hydroxylation of an asparaginyl residue C- 
terminal transcriptional activational domain of HIF-1a, which acts to inhibit 
interactions with the transcriptional co-activator of HIF-1a, p300 [179]. This is 
mediated by factor inhibiting HIF (FIH) [181] Oxygen is required for the hydroxylation 
of the proline and asparagine sites, therefore under hypoxic conditions this does not 
occur. Therefore under hypoxia, HIF-1a remains stable enough to form a 
heterodimer with the p-subunit, it then translocates into the nucleus. This 
heterodimer then binds to HIF response elements located upstream of the promoters 
on target genes (see figure 1.11.)
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HIF-1 a is also subject to other post-translational modications. For instance, it 
is acetylated by an acetyltransferase referred to as ARrest Defective-1 protein 
(ARD1). This interaction promotes VHL interaction with HIF-1 a and therefore 
promotes HIF-1 a proteasomal degradation. ARD1 is thought to be suppressed by 
hypoxic conditions to promote HIF-1 a stability [182].
Conversely, HIF-1 a stability can also be increased through post-translational 
modifications. Recent studies show evidence that HIF-1 a is sumoylated by SUMO-1 
(small ubiquitin-related modifier-1) at Lys391 and Lys477 resulting in an upregulation 
of its transcriptional activity and stability [183]
Nitric oxide has also recently been demonstrated to upregulate HIF-1 a, it is 
thought that all 15 thiol groups found in human HIF-1 a are subjected to S-nitrosation 
which promotes HIF-1 a stabilisation and activation during hypoxia [184].
HIF-1 a transcriptional activity appears to be dependent upon its interaction 
with co-activators p300 and CBP (CREB binding protein). p300/CBP bind to HIF-1 a 
via the C-terminal and N-terminal TAD domains. It is thought that p300/CBP facilitate 
histone acetylation to promote chromatin remodelling, this enhances HIF-1 a DNA- 
binding to HRE on target gene promoters. Interaction with p300 is thought to be a 
critical aspect of HIF-1 a activation. Other acetyl-transferases such as steroid- 
receptor co-activator-1 (SRC-1) and transcription intermediary factor 2 (TIF2) are 
also thought to act in synergy with p300 to activate HIF-1 a and this appears to be 
regulated by the redox regulated protein, Ref-1 [185]. Furthermore s-nitrosation on 
cys800 appears to promote it’s interaction with p300
As indicated above, mTOR has been shown to regulate HIF-1 a and diseases 
associated with m TO RCI, such as TSC, exhibit highly vascularised hamartomas, 
however the mechanism behind this regulation has yet to be determined. One of the 
primary aims of this project is to characterise mTORCI regulation of HIF-1a.
1.5.4 STAT3
1.5.4.1 The STAT family
STAT3 is a member of the STAT protein family. The STATs are a group of latent 
transcription factors which become activated in response to cytokine or growth factor 
interactions with cell membrane receptors [155-157], There are currently seven 
recognised STAT proteins which are subject to similar mechanisms of regulation and 
activation, STAT-1, 2, 3, 4, 5a, 5b and 6.
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Cytokine/growth factor stimulation causes recruitment of STAT proteins to the 
appropriate receptor as mediated by a highly conserved Src-homology-2 (SH2) 
domain found within the STAT family of proteins [186]. In resting cells, STAT 
proteins reside primarily as homodimers in the cytoplasm [187]. Upon ligand receptor 
binding, associated Janus-activated kinase family kinases (JAK kinases) are 
activated to promote phosphorylation of specific tyrosine residues within the STAT 
protein. The phospho-tyrosine residue then interacts directly with the SH2 domains 
within inactive STAT proteins to create protein dimers. The inactive STAT proteins 
are also phosphorylated at their tyrosine residue promoting the release and nuclear 
translocation of the activated dimers to upregulate cytokine mediated gene 
expression [186-188].
1.5.4.2 STAT3 Structure and function
STAT3 is ubiquitously expressed and activated by a number of cytokines, growth 
factors and other stimuli [188]. It is reportedly involved in cellular processes including 
cellular differentiation and survival, wound healing and the acute phase immune 
response. It also facilitates neuronal development in the brain in response to Ciliary 
Neurotrophic Factor (CNTF) [188-190] [191]. More recently, it has been 
demonstrated that STAT3 plays a role in carcinogenesis and tumour formation, in 
part due to the protective effect activated STAT3 can have from apoptosis [192-194]. 
A number of STAT3 target genes are reported to be upregulated during tumour 
formation including Bcl-XL survivin, Hsp70, cyclin-D1 and c-myc which are likely to 
contribute to the pathogenesis [190]. Many genes have been proposed to be 
regulated in a STAT3 dependent manner, microarray analysis has indicated 
hundreds of potential target genes for STAT3 however not all these have been 
shown to be direct targets. A more recent study by Snyder et al. used chromatin 
immunoprecipitation (ChIP) to specifically look at STAT3 DNA binding and cross 
referenced interactors with those previously identified by microarray giving an 
extensive list (see below figure 1.12 for overview of probable STAT3 targets) [195].
Structurally, STAT3 is similar to the other members of the STAT family. It is 
activated by ligand binding to the gp-130 receptor, this receptor is activated by IL-6, 
CNTF, LIF (Leukaemia Inhibitory Factor), IL-11, oncostatin-M and cardiotrophin-1, 
causing dimerisation of the gp-130 receptor subunit. This recruits JAK kinases to
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mediate tyrosine phosphorylation, firstly of the gp-130 receptor, providing a docking 
site for STAT3, then of STAT3 itself for activation [196-198]. STAT3 contains two 
characterised phosphorylation sites, Tyr705 and Ser727 both situated within the 
transcriptional activation domain (TAD) - see figure 1.11. It was initially thought that 
STAT proteins were modulated entirely by phosphorylation at the tyrosine residue 
(this is still thought to be the case for STAT2). However, further studies identified a 
secondary serine phosphorylation site within the TAD of STAT proteins which 
regulate the transcriptional activity. Phosphorylation at Ser727 on STAT1 is required 
for its maximal activation and facilitates the recruitment of its transcriptional 
cofactors, MCM5 and CamKII [199, 200], leading to enhanced activation. In the case 
of STAT3, there is substantial evidence for a similar positive role of Ser727 in STAT3 
activation. STAT3 also contains two putative TOS motifs, FDMDL at amino acids 26- 
30 and FDMDL at amino acids 756-760 [80] (see figure 1.12) although research has 
not been carried out to determine whether they are functional mTORCI signalling 
motifs.
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1.5.4.3 Serine phosphorylation of STAT3
Mice engineered to express a mutant form of STAT3 whereby the Ser727 site is 
substituted with an alanine (S727A) revealed that serine phosphorylation of STAT3 
is required for embryonic growth and development. Many of the S727A mice died 
shortly after birth, those that didn’t were approximately 50% smaller than the wild- 
type at one week old and exhibited altered IGF-1 serum levels and increased 
apoptosis [191]. This indicates that the supplementary signalling via growth factors to 
Ser727 may serve to regulate alternative cellular processes of STAT3. STAT3 is 
often referred to as the acute phase response gene due to its modulation of this 
process, however, S727A mice exhibited a normal STAT3 dependent liver acute 
phase response. This indicates that the acute phase response is modulated mainly 
via Tyr705 phosphorylation [191]. Shen et al suggested a model whereby STAT3 
effects are determined by its phosphorylation status at both sites and suggest a 
more prominent role for Ser727 of STAT3 than was first thought [191].
However, other studies have indicated that Ser727 phosphorylation functions 
to negatively regulate Tyr705 phosphorylation, with cells expressing the S727A 
mutant exhibiting higher levels of tyrosine phosphorylation [201]. This could suggest 
that Ser727 phosphorylation may play a role in the negative feedback loops for 
STAT3. A study by Yokogami et al. demonstrated that in the case of neuroblastoma 
cell lines, CNTF (a neuropoeitic cytokine which stimulates the JAK STAT pathway in 
addition to ERK1/2, PI3K and mTOR signalling) stimulation activated both Tyr705 
phosphorylation and Ser727 phosphorylation of STAT3, and phosphorylation of both 
sites was required for maximal transcriptional activation. Furthermore they showed 
evidence that mTORCI may be the kinase which modulates Ser727 phosphorylation 
and demonstrated m TORCI directed phosphorylation of a C-terminal STAT3 peptide 
in vitro [202].
A more recent study indicated that STAT3 could be activated at Ser727 but 
not Tyr705 phosphorylation by amino acid stimulation in a rapamycin sensitive 
manner [203] adding support for the hypothesis that mTORCI is a regulator of 
STAT3. However, aside from Yokogami et al. studies providing evidence for 
mTORCI mediated regulation of STAT3 are based upon inhibition seen with 
rapamycin treatment. Therefore it is unclear from these whether STAT3 is a direct 
substrate for m TORCI or whether it occurs further downstream. In addition to this, 
more recently it was reported that the phosphatase PP2A could bind to a
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dephosphorylate the Ser727 residue of STAT3 [204], since PP2A is activated by 
rapamycin treatment [205] it is possible that the rapamycin sensitivity demonstrated 
in many studies is a result of PP2A activation as opposed to mTORCI inhibition. 
This study aims to determine whether STAT3 is indeed a direct substrate for 
m TO R C I
1.5.5 STAT3 and HIF-1 a
The first evidence for a link between STAT3 and HIF-1 a was published in 2002. As 
described earlier, VEGF is a gene target of HIF-1 a. Analysis of the promoter region 
of VEGF revealed a putative STAT3 binding site, indicating that VEGF may be 
activated by STAT3 as well as HIF-1 a [206] (it should be noted that there are also 
binding sites within the VEGF promoter for other transcription factors including Sp-1, 
AP-1, AP-2 and Egr-1 etc. [207]).
Nui et al. described how STAT3 and VEGF activity correlated and saw 
upregulation of VEGF with expression of a constitutively active STAT3 mutant [206]. 
This was confirmed by Wei et al. who demonstrated that VEGF was upregulated by 
STAT3 directly in pancreatic cancer cell lines [208].
In 2005, Gray et al. demonstrated that STAT3 and HIF-1 a could bind to the 
VEGF promoter simultaneously in complex with the transcriptional co-activators 
p300 and APE. They postulated that both STAT3 and HIF-1 a were required for 
maximal activation of the VEGF gene [209]. A second group later reported that 
hypoxia could induce STAT3 phosphorylation, promoting recruitment of HIF-1 a and 
p300 as well as inducing histone H3 acetylation to cause transactivation of the VEGF 
promoter [210]. These studies provide clear evidence that STAT3 and HIF-1 a 
function in synergy. The latter study suggests that STAT3 may in fact be a regulator 
of HIF-1 a, this was confirmed shortly afterwards when Xu et al. showed that 
knockdown of STAT3 prevented both basal and growth-factor induced HIF-1 a 
protein expression [211].
In 2008 it was reported that STAT3 is able to interact directly with the C- 
terminal domain of HIF-1 a whereby it functions to directly compete with VHL for 
binding. Jung et al. demonstrated that over expression of constitutively active STAT3 
inhibited the binding of VHL to HIF-1 a in a dose dependent manner. (See figure 1.11 
for VHL mechanistic action) [212]. This therefore represents at least one of the
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mechanisms by which STAT3 is able to modulate HIF-1 a. This study aims to 
investigate this relationship further.
1.5.6 YY1
It was demonstrated in 2006 that rapamycin treatment caused a reduction in 
mitochondrial membrane potential, oxygen consumption and ATP synthesis. Similar 
results were achieved through knockdown of TSC2/Raptor indicating that this is not 
a result of rapamycin induced phosphatase activity [213]. A later publication revealed 
a potential mechanism behind this showing evidence that Yin-Yang-1 may be a 
direct substrate for m TORCI [214]. They established this via studies of the 
transcriptional co-activator, peroxisome proliferator-activated receptor y coactivator- 
1a (PGC-1a). PGC-1a is a regulator of mitochondrial function, it modulates the 
expression of genes related to mitochondrial oxidative function, including the 
oestrogen-related receptor a (ERR-a) and nuclear respiratory factors (NRFs) [215]. 
Rapamycin treatment inhibits PGC-1a, ERR-a and NRF-1 mRNA levels and 
genomic analysis revealed that YY1-binding motifs were highly enriched within these 
rapamycin sensitive genes [214]. Cunningham et al. used shRNA interference to 
knockdown YY1 causing a dramatic decrease in mitochondrial activity. Knockdown 
of YY1 also rendered the cells insensitive to rapamycin inhibition of mitochondrial 
gene expression suggesting that YY1 is the intermediary component linking 
mTORCI to mitochondrial function. They revealed that YY1 and PGC-1a formed a 
transcriptional complex and that this interaction could be disrupted by rapamycin 
treatment, resulting in a reduction in mitochondrial gene expression. YY1 is a zinc- 
finger transcription factor of the Polycomb group protein family. It is a 44kDa protein 
which is 414 amino acids in length. Eight different isoforms of YY1 are generated 
from alternative splicing of the YY1 gene, however the functional significance of this 
remains unknown [216]. It contains several conserved domains relating to its 
function, the N-terminus region appears to function as an activating domain, whereas 
the C-terminus appears to be involved in its repression. The four zinc fingered motifs 
are involved in its repression as well as its interaction with PGC-1a [214, 216]. 
Cunningham et al. demonstrated that mTORCI could bind to the conserved ‘REPO’ 
domain of YY1 (so called because it is thought to mediate recruitment of polycomb 
proteins to their appropriate target genes [217]), however analysis of the sequence 
reveals only one phenylalanine within this domain. Therefore the only potential TOS
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motif within this domain is VTMW S which would be unconventional. Although there 
are several reports implicating m TORCI with mitochondrial biogenesis [213, 218, 
219], little is known about the mechanisms governing this regulation. Further 
research is required to confirm whether YY1 is indeed a direct substrate for 
m TO R C I
1.5.7 GTF3C and Maf-1
Ribosomal synthesis is an expensive and complex process which requires all three 
classes of the RNA polymerases (Pol I, II and III). A proliferating HeLa cell is 
reported to produce approximately 7,500 ribosomes per minute, this requires 
transcription of around 150-200 rRNA genes and synthesis of around 300,000 
ribosomal proteins [220]
It is well established that m TORCI is a key regulator in this process. Studies 
examining the effects of rapamycin upon mammalian cells and yeast have 
demonstrated that mTOR plays a role in modulating transcription, pre-rRNA 
processing, expression of ribosomal proteins and synthesis of 5S rRNA [221-224], 
However the mechanisms behind this regulation are not fully understood.
Recent evidence has demonstrated a direct link between mTORCI and the 
regulation of RNA polymerase III (pol III), identifying GTF3C (general transcription 
factor IIIC or TFIIIC) as a key modulator of this process. Pol III is an RNA 
polymerase required for the production of 5S rRNA and tRNA which is negatively 
regulated by Maf-1. In yeast, Tor interacts with and phosphorylates Maf-1 in vivo. 
Wei et al. demonstrated how Tor translocates to the nucleus, to facilitate the release 
and cytoplasmic export of Maf-1, allowing Pol III mediated transcription to occur 
[225]. More recently it was demonstrated that mTOR is also involved in Maf-1 
phosphorylation in mammalian cells [226].
Kantidakis et al. described a mechanism by which mTOR binds directly to 
GTF3C via an mTOR signalling motif (see table 1.1). GTF3C recognises the 
promoters of the tRNA and 5s rRNA genes and functions to relocate mTOR to the 
target genes (see figure 1.7). Mammalian Maf-1 appears to be is then 
phosphorylated by m TO RCI, alleviating its repressive activity towards Pol III. 
However, Maf-1 remains at the Pol III site rather than translocating to the cytoplasm 
as is seen in yeast [227].
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This case is particularly interesting as the TOS motif has been identified in the 
co-factor not the substrate. It will be of interest to see if the research group takes this 
work further to establish whether GTF3C is also phosphorylated by mTOR or 
whether this is a newly described mechanism.
1.5.8 PRAS40
See section 1.3.6 for details.
1.5.9 PKC5 and e isoforms
Table 1.1 indicates that mTOR signalling motifs have been identified in the the 6 and 
z isoforms of PKC. It was reported in 1999 that these isoforms could in fact be 
regulated and phosphorylated in a rapamycin sensitive manner [228]. However, 
there has been no further evidence to support this. A more recent study investigating 
PKC 6 and z in the context of cardiac hypertrophy has shown evidence that PKC6 
and e isoforms are actually located upstream of mTORCI and required for auto­
phosphorylation of mTOR at Ser2448, as well as Thr389 phosphorylation of S6K1 
during hypertrophy. This may explain the correlation in activity. [229]. Further 
research is required however to determine whether mTORCI can in fact 
phosphorylate PKC6 and z isoforms.
1.6 Cellular processes regulated downstream of mTORCI
1.6.1 Cell cycle progression
The cell cycle is made up of four distinct growth phases, G1, S, G2 and M. Whereby 
‘S’ represents the DNA synthesis phase and ‘M’ represents the mitotic or dividing 
phase. Cells in a quiescent non-dividing state are said to be in Go. For review see 
[230]. Progression through each phase of the cycle is subject to tight regulation from 
various inputs. The first indication that mTORCI may be involved in cell cycle 
progression came from studies of the drug rapamycin. Analysis into the effects of the 
drug revealed its immunosuppressant qualities, with rapamycin treatment inducing 
growth arrest in T-lymhocytes, preventing progression into the S-phase of the cycle.
Although we are yet to discover exactly how mTORCI regulates the cell 
cycle, there have been several recent advancements which are outlined below.
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1.6.1.1 p27
p27 is a cyclin-dependent-kinase inhibitor (CDKI) which as the name indicates has 
inhibitory activity towards cyclin-dependent-kinases (CDKs) [231]. For a cell to 
progress from the G1 phase to the S-phase of the growth cycle, active cyclin 
complexes are formed between cyclins and CDKs. These active complexes 
phosphorylate the retinoblastoma gene product (Rb).
Rb is nuclear protein which is active whilst cells are in the G1 phase of the cell 
cycle, it inhibits the progression into S-phase, primarily through inhibition of the E2F 
family of transcription factors. Once Rb is phosphorylated by the active cyclin 
complexes, its inhibitory activity towards the E2F family is relieved and progression 
to S-phase commences [232].
Whilst the cell is in G1 phase, CDKs are repressed by p27 [231]. Active 
mTORCI reduces expression of p27 to allow active cyclin complexes to form, 
promoting Rb phosphorylation and subsequent activation of E2F target genes. This 
allows progression to the s-phase of the cell cycle [233, 234] (see figure 1.7). When 
p27 is phosphorylated, its nuclear translocation is prevented, and its inhibitory 
activity is lost [235]. A recent publication also indicated a potential involvement of 
Oct1 in the expression of p27. Initial findings indicate that Oct1 mediates the 
transcription of p27 downstream of m TO RCI. Further work is required to confirm this 
and also to confirm whether Oct1 is a direct downstream substrate of mTORCI or 
one of its effectors [236].
1.6.1.2 Cyclin-D1
As outlined above, cyclins are important for the progression from G1 to the S-phase. 
There is growing evidence to suggest that mTORCI may be able to regulate the 
expression of cyclin-D1, this may provide an alternative mechanism of cell cycle 
control. Cyclin-D1 forms an active cyclin complex with Cdk4, this stimulates 
activation of cyclin-E/CdK2 complexes by altering the binding activity of the inhibitory 
p27 [237]. Furthermore the active cyclin-D1 complex mediates phosphorylation of Rb 
on Ser795 [238], hyper-phosphorylation of Rb results in cell cycle progression to the 
S-phase.
The first evidence of m TORCI directed regulation of cyclin-D1 appeared in 
1993, a study by Rosenwald et al. showed that overexpression of elF4E caused an 
increase in the expression of cyclin-D1 protein levels [239]. It was later demonstrated
53
that elevation of cyclin-D1 mRNA did not always lead to increased protein levels 
[240]. This indicates that cyclin-D1 is likely to be subject to post-transcriptional 
modulation and therefore makes elF4E a likely regulator. In 1998 it was reported that 
rapamycin treatment of serum stimulated NIH 3T3 cells suppresses cyclin-D1 mRNA 
accumulation whilst reducing the stability of the transcript, rapamycin was also 
reported to accelerate its degradation at the proteasome [241].
However in 2004, Koziczak and Hynes demonstrated that siRNA mediated 
depletion of S6K1 caused a 20-30% reduction in cyclin-D1 expression which could 
be rescued by expression of an active S6K1 mutant construct in MDA-MB-453 cells. 
They also reported that rapamycin treatment reduced the association of cyclin-D1 
mRNA with the polysome, suggesting that rapamycin can reduce cyclin-D1 levels via 
inhibition of S6K1 and subsequent downregulation of translational efficiency [242] 
rather than targeting the transcription and stability of the mRNA transcript or protein 
as was suggested by Hashemolhosseini et al. The most recently published study in 
this area however shows evidence that knockdown of 4E-BP1 abolishes rapamycin 
induced suppression of cyclin-D1 expression. It was shown that 
4E-BP1 controls the association between cyclin-D1 mRNA and the polysomes, this 
may represent a mechanism by which mTORCI regulates cyclin-D1 expression. It is 
likely that mTORCI regulation of cyclin-D1 can occur by multiple mechanisms 
dependent upon the cell type and stimulus.
It is also notable that cyclin-D1 is a downstream gene target of STAT3 [243] 
which has shown evidence of m TORCI dependent regulation [202]. This will add to 
the suppressive effect of rapamycin upon cyclin-D1 expression and adds to the 
complexity in dissecting the specific mechanisms of cyclin-D1 regulation downstream 
of m TO R C I
1.6.1.3 Other cyclins
It has been demonstrated that rapamycin treatment of T-lymphocytes diminishes the 
formation of active complexes between cyclin-D3 and Cdk4 or Cdk6, repressing the 
phosphorylation of Rb. Furthermore, over-expression of cyclin-D3 can alleviate the 
anti-proliferative effects of rapamycin treatment at low doses [244]. Decker et al. also 
reported that rapamycin treatment prevented upregulation of cyclins E and A, 
resulting in a decrease in CdK2 activity [245].
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It appears from this evidence that cyclins, Cdks and CdK inhibitors are the key 
modulators of the cell cycle across most if not all cell types, many of which are 
subject to regulation from m TO RCI. However difficulty arises given that the 
expression of specific cyclins and CdK inhibitors appears to be cell type and stimulus 
specific. The cell cycle is an appealing potential pharmacological target in the 
development of anti-cancer therapeutics and mTORCI inhibitors may be a viable 
therapeutic tool.
1.6.2 Autophagy
So far this study has highlighted how mTORCI acts as a nutrient sensor within 
eukaryotic cells, fine tuning the intricate balance between the rate of anabolic 
processes and the availability of nutrients. As logic dictates, mTORCI is therefore 
also able to regulate catabolic processes within the cell to counterbalance this 
regulation. It has been known for some time that mTORCI is a regulator of 
autophagy, however the mechanisms behind this have yet to be fully elucidated (see 
review [246]). Autophagy is a homeostatic mechanism induced by serum starvation, 
stress or reduced availability of growth factors. Low nutrient availability leads to 
inhibition of growth and autophagy induction as a mechanism of increasing 
intracellular nutrient levels [247, 248]. Autophagy consists of the breakdown of 
cytoplasmic proteins and organelles and is suppressed by mTORCI signalling when 
nutrients are plentiful [248] [246]. As stated earlier, the mechanism governing 
mTORCI mediated suppression of autophagy is unclear in the case of mammalian 
cells, however studies in yeast have increased our understanding (outlined below). 
Autophagy can be classified into three distinct pathways, microautophagy, 
macroautophagy and chaperone mediated autophagy. Chaperone mediated 
autophagy (CMA), as the name suggests, is a process whereby chaperones 
modulate the translocation of target proteins directly to the lysosome. It is a pathway 
specific to mammalian cells and is involved in the selective breakdown of soluble 
proteins [248] there is no evidence to suggest that it is subject to regulation by 
mTORCI so will not be reviewed here. Macroautophagy (referred to as autophagy 
from here on) is the process involving the breakdown of macromolecules, organelles 
and unwanted structures and is the only autophagy pathway to involve the 
autophagosome.
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When autophagy is induced, a double membrane structure termed the 
‘phagophore’ or ‘isolation membrane’ is formed, this process is referred to as 
nucleation and it is unclear how this occurs. Recent publications have indicated that 
early isolation membrane structures associate with the endoplasmic reticulum and 
that this may provide a source of lipids for the extension of the membrane [249]. It 
has also been suggested that the phagophore is formed in a small omega shaped 
compartment deemed the ‘omegasome’. This is reportedly connected to the 
endoplasmic reticulum and contains high levels of phosphatidylinositol 3-phosphate 
(Ptdlns(3)Pi) [250]. The phagophore envelopes a portion of the cytoplasm or 
targeted organelles, elongates and closes to form the autophagosome. The 
autophagosome membrane then fuses with a lysosome exposing the contents to 
hydrolases which degrade the inner membrane and its targeted contents. This 
produces amino acids which are released back into the cytosol by membrane 
permeases so they can be re-utilised by the cell [246, 247, 251].
Microautophagy is the transfer of cytosolic components directly into the 
lysosome via invagination of the membrane [252] however as with the CMA 
pathway, there is no evidence to suggest that it is regulated by mTORCI and 
therefore will not be considered within this review.
1.6.2.1 Autophagy regulation in yeast
There has been a wealth of investigations regarding the induction of autophagy in 
yeast which has furthered our understanding of autophagy in mammalian cells. The 
process of macrophagy in yeast is very similar to the process of macrophagy in 
mammalian cells, it should be noted that the lysosomes are the equivalent of 
vacuoles in yeast (or can be considered that way for the purpose of this review 
[253]). In 1998, it was reported that rapamycin could induce autophagy in yeast 
grown in nutrient rich medium signifying that suppression of TOR is an initiating 
factor in the induction of autophagy [254]. It was later established that this is 
primarily regulated through the kinase activity of Apg1. A study by Kamada et al. 
demonstrated that rapamycin treatment caused an induction of Apg1 protein 
expression and activation. Furthermore they identified that associated proteins 
Apg13 and Apg17 were required for rapamycin induced Apg1 activation. They 
proposed a mechanism by which Tor phosphorylates Apg13 reducing its affinity for 
Apg1. Inhibition of Tor therefore results in an increase in hypophosphorylated Apg13
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which is able to bind and activate Apg1 initiating autophagy [255]. It was knowledge 
of this pathway which led to several pivotal discoveries regarding the regulation of 
autophagy in mammalian cells which are outlined below.
1.6.2.2 Regulation of autophagy in mammalian cells
It is now known that the mammalian homologue of Apg1 is UNC-51 like kinase or 
ULK1. Since this discovery, three more Apg1 homologues have been identified in 
mammalian cells, namely ULK2, 3 and 4. There is evidence that ULK1, 2 and 3 are 
all involved in the regulation of autophagy within mammalian cells (see review [246]) 
whereas the role of ULK4 remains unknown. Little was understood about how the 
ULKs regulate autophagy in mammalian cells until the discovery of the mammalian 
homologue of Apg13, referred to as Atg13.
Since then, several research groups have demonstrated that Atg13 interacts 
with both ULK1 and ULK2 and that this interaction is required for the formation of the 
autophagosome. A screen for ULK1 binding proteins in mammalian cells identified 
focal adhesion kinase family interacting protein of 200 kD (FIP200) as being an 
interactor of both ULK1 and ULK2. FIP200 had previously been identified as a 
regulator of cell size and proliferation, Hara et al. indicated that under serum 
deprivation FIP200 re-localised from the cytoplasm to the phagophore. Furthermore, 
FIP200 deficient cells failed to induce autophagy after amino acid and serum 
deprivation or rapamycin treatment. FIP200-/- MEFs also exhibited defective ULK 
complex formation and showed a reduction in ULK1 phosphorylation and expression 
in comparison to wild-type confirming that FIP200 is required for autophagy [256]. It 
is now thought that the phosphorylation status of ULK1/2 regulates a complex of 
Atg13 and FIP200 to initiate autophagy. When mTORCI is active, it phosphorylates 
ULK1/2 at Ser757 which inhibits autophagy. Under conditions of cellular stress or 
nutrient depletion, AMPK becomes activated and phosphorylates ULK1/2 at Ser317 
and Ser777 to induce autophagy [257].
1.6.2.3 eEF2k and Autophagy
As shown in table 1.2, eEF2k is a downstream substrate of S6K1. S6K1 mediates 
the phosphorylation of eEF2k causing its inactivation. A recent study reported 
elevated levels of eEF2k during nutrient depletion induced autophagy, which may be 
expected given that m TORCI is suppressed during nutrient deprivation. Interestingly
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though it was demonstrated that knockdown of eEF2k by RNA interference inhibited 
autophagy in glioblastoma cell lines whilst overexpression of eEF2k enhanced it 
[258]. This implicates eEF2k with the regulation of autophagy, this seems plausible 
since ULK1 appears to be regulated in the same fashion. It has also been 
demonstrated that silencing of eEF2k blunted autophagy and relieved the 
suppression of protein synthesis which is usually coupled with autophagy in a breast 
cancer cell line. [259]. It is likely that the suppression is therefore in part mediated 
through disruption to the elongation phase of protein translation, which is regulated 
by eEF2. Since elongation is activated by dephosphorylated eEF2, knockdown of its 
kinase eEF2k will result in an accumulation of dephosphorylated eEF2 increasing 
protein synthesis even under nutrient deprivation. The role eEF2k may play in 
inducing autophagy itself, remains to be seen.
1.6.2.4 STAT3 and autophagy
A recent study of HIV-infected cells has highlighted the possibility of a role for STAT3 
in the inhibition of autophagy. It was recently demonstrated that HIV-1 infected cells 
show defects in the process of autophagy, whereby the HIV-1 viral protein Nef 
functions as an anti-autophagic maturation factor to inhibit interactions with the 
regulator of autophagy, Beclin-1 [260]. One of the defining features in the 
pathogenesis of the HIV-1 virus is its ability to affect cells which are not actually 
infected with the virus. They demonstrated that HIV-1 infected cells exhibited 
defective autophagosome formation in both infected cells and bystander monocytic 
cells when treated with rapamycin. They showed evidence that this was due to the 
release of HIV-1 Tat. Tat is released by HIV-1 infected or dying cells and is known to 
be the primary activator of the virus. Van Grol et al. found that addition of Tat 
reduced autophagy in rapamycin treated MDM cells, importantly they demonstrated 
that this could be reversed by silencing of STAT3 or Akt [261]. As shown in figure 
1.5, Akt inactivates the tumour suppressor TSC complex to activate mTORCI, in 
addition STAT3 is a thought to be active downstream of mTORCI. This evidence 
taken together suggests a role for STAT3 in the suppression of autophagy, it also 
adds support for the hypothesis that STAT3 is activated downstream of m TO R C I 
This was compounded by the finding that Beclin-1 expression was found to correlate 
inversely with phosphorylated STAT3 expression and Akt expression in malignant 
gliomas [262] confirming that STAT3 is a negative regulator of autophagy.
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Furthermore, additional support for this can be found in a study by Aoki et al. Aoki 
investigated the effects of T-oligos on autophagy induction. T-oligos activate DNA 
damage response pathways in the absence of DNA damaging agents. The response 
to DNA damage appears to be cell type specific, in the case of glioma cells, 
treatment with t-oligos lead to the induction of autophagy. Aoki demonstrated that 
this could be enhanced with treatment of the JAK2 inhibitor, Ag490 or by mTORCI 
inhibition with rapamycin [263]. This provides further evidence that STAT3 may play 
a role in the suppression of autophagy, the mechanism behind this however is yet to 
be determined.
1.6.3 Lipid Metabolism
The initial link between lipid biosynthesis and mTORCI was based upon 
observations that m TORCI modulation of sterol and regulatory element binding 
protein-1 (SREBP-1) [264, 265]. SREBP-1 is a member of the basic helix-loop-helix 
leucine zipper transcription factor family [266, 267]. It transduces the insulin signal to 
promote expression of genes regulating the synthesis of cholesterol, phospholipids, 
fatty acids and triglycerides [268] and is therefore a central player in the regulation of 
lipid metabolism (see review [267]). The SREBPs occur in three closely related 
isoforms, SREBPIa, 1c and 2, they are synthesised initially as inactive pre-cursors. 
For activation, SREBPs form a complex with SREBP-cleavage-activating protein 
(SCAP) at the endoplasamic reticulum membrane. This complex is recognised by 
sterol-regulated proteases and is subjected to a two step proteolytic cleavage, 
allowing the release of the mature SREBP form. The mature SREBP then 
translocates the nucleus where it binds to sterol response elements found within the 
promoters of target genes [269]. Porstmann et al. demonstrated that Akt activation 
resulted in SREBP nuclear accumulation in a rapamycin sensitive fashion. 
Furthermore mTOR over-expression activated SREBPs and its target genes whilst 
knockdown of SREBPs caused a significant reduction in cell size [264]. This 
suggests that m TORCI is able to regulate cellular growth not only through protein 
synthesis but also through coordinated lipid metabolism.
Normally, insulin is released in response to elevated glucose levels. It 
functions to increase the synthesis of fats and reduce the synthesis of glucose in 
order to restore a homeostatic balance. However in the case of type II diabetes, 
partial insulin resistance develops whereby gluconeogenesis is not suppressed and
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lipogenesis continues. Li et al. observed the effects of mTOR, Akt and PI3K 
inhibitors on gluconeogenesis and lipogenesis and demonstrated that the insulin 
signal transduction bifuricates upon Akt activation. The activation of Akt not only 
causes activation of m TORCI as previously described, but also mediates the 
phosphorylation of F 0 X 0 1 . FO X01 activates the expression of genes required for 
gluconeogenesis, phosphorylation of FOX01 by Akt results in its expulsion from the 
nucleus and hence repression of gluconeogenesis. We now know that Akt mediated 
activation of mTORCI results in increased activation of SREBPs, promoting 
lipogenesis. This bifurification of the insulin signal transduction may explain how 
insulin resistant cells in type II diabetes are able to promote lipogenesis in response 
to insulin but not inhibit gluconeogenesis. Li’s paper also showed evidence that 
S6K1 inhibition had no effect upon SREBPs activation indicating that it does not lie 
downstream of S6K1 [265] although S6K1 knockout mice do display signs of altered 
lipid metabolism indicating that m TO RCI is able to regulate lipid metabolism via 
several different mechanisms [148].
A recent publication indicated that mTORCI is able to suppress the 
transcription of triacylglycerol hydrolases including ATGL (adipose triglyceride lipase) 
and HSL (hormone sensitive lipase). These enzymes facilitate the metabolism of 
triglycerides into glycerol and free fatty acids which can then be used as an energy 
source [270]. Chakrabarti et al. investigated the impact of activation and inhibition of 
mTORCI upon ATGL and HSL. The study demonstrated that active mTORCI 
represses the transcription of these enzymes. Suppression of ATGL and HSL limited 
the triacylglycerol hydrolase activity within the cell, promoting the accumulation of 
triglycerides.
It is thought that when nutrients are plentiful, active mTORCI suppresses the 
breakdown of fats with the view of building energy stores. When nutrients become 
depleted however, suppression of m TORCI results in a release of inhibitory activity 
towards ATGL (and to a lesser extent HSL) to facilitate the mobilisation of energy 
stores [271]. It is not clear from this study whether mTORCI is able to inhibit the 
transcription of ATGL directly, or via a downstream effector. As stated earlier, S6K1 
knockout mice exhibit altered lipid metabolism by a mechanism unrelated to SREBP 
expression so it is possible that ATGL may be regulated downstream of S6K1, 
although there is no direct evidence for this at present.
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Bacquer et al. investigated the effects of a double knockout (DKO) of 4E-BP1 
and 4E-BP2 on the fat metabolism of mice. In comparison to wild-type, 4E-BP DKO 
mice gained an average 29% more weight when fed on equal amounts of a high 
carbohydrate diet. Interestingly, when fed upon a high fat diet, DKO mice showed 
higher blood insulin levels in comparison to wild-type and although both mice types 
exhibited impaired glucose tolerance, the effects were accentuated in the DKO mice. 
Bacquer et al. saw a suppression of lipolysis in DKO mice, which suggests that 
mTORCI mediated suppression of ATGL does not occur downstream of the 4E-BPs, 
although the levels of ATGL were not examined. Bacquer et al. did however report 
an increase in the expression of peroxisome proliferator-activated receptor gamma 
(PPARy) and its upstream activator C/BP15. PPARy is a key regulator of adipocyte 
differentiation and lipogenesis in adipose tissue [272] so elevated expression would 
explain why the DKO mice accumulated more fat. This may be a direct result of 4E- 
BP1 knockdown, or it may be due to enhanced mTOR/S6K1 signalling which occurs 
when 4E-BP1 is knocked down. It is evident from these reports however that lipid 
metabolism is under multi-faceted control from mTORCI thus potentially implicating 
mTORCI dysregulation with a number of pathologies caused by disrupted lipid 
metabolism [273].
1.6.4 Phosphatase regulation
As outlined earlier, phosphatases oppose the activity of kinases. In yeast, it is 
thought that TAP42, a regulatory subunit of the type 2A phosphatases, is complexed 
with either PP2A or SIT4 to mediate substrate dephosphorylation. It has been 
demonstrated that this complex formation is regulated by Tor within yeast, primarily 
via phosphorylation of a TAP42 binding partner, TIP41 [274].
In mammalian cells, there is limited evidence of phosphatase involvement in 
mTORCI signalling despite the discovery of the mammalian homolog of Tap42, a-4 
in 1998 [275]. One example has already been described, MAP4K3 which transduces 
amino acid input to regulate m TORCI appears to be regulated by PP2A and its 
regulatory subunit PR61s (see section 1.4.4.3). Downstream of mTORCI, it has 
been demonstrated that rapamycin can induce rapid dephosphorylation of S6K1 at 
all sites, despite the fact that only Thr389 phosphorylation is mediated by mTORCI 
[65]. This could suggest that sites are phosphorylated in a sequential manner and 
phosphorylation of Thr389 acts as a priming event, however Thr389 appears to be
61
one of the latter residues to be phosphorylated making this unlikely. It could 
therefore be better explained by phosphatase activation induced by rapamycin 
treatment.
Peterson et al. compared the phosphatase activity in vitro of purified PP2A 
immune complexes from rapamycin treated and untreated cells towards pre- 
phosphorylated purified recombinant 4E-BP1. They revealed that PP2A phosphatase 
activity was elevated in rapamycin treated cells. Indicating that like in yeast, PP2A is 
activated when m TORCI is repressed by rapamycin. An in vitro kinase assay 
indicated that mTORCI could phosphorylate PP2A directly, strikingly, mTORCI 
exhibited a higher level of affinity towards PP2A than to 4E-BP1 in vitro. They were 
also able to show direct PP2A interaction with S6K1 [155]. This study shows 
significant evidence that rapamycin treatment can induce phosphatase activity. A 
mechanism was proposed whereby m TO RCI phosphorylates PP2A to suppress it, 
therefore PP2A becomes active when m TO RCI signalling is inhibited.
Further evidence for rapamycin induced phosphatase activity comes from a 
more recent publication dissecting specific phosphorylation events of rpS6. Moore et 
al. demonstrated that rapamycin suppressed rpS6 phosphorylation at Ser235/236 
and Ser240/244. This was then repeated in the presence of phosphatase inhibitors 
and strikingly rapamycin only caused repression of the Ser240/244 sites, indicating 
phosphatase activity towards the other residues. This type of regulation could extend 
to other substrates which have been linked to m TORCI based upon studies with 
rapamycin, it is therefore no longer appropriate to assume that substrates 
dephosphorylated with rapamycin treatment are indeed downstream substrates for 
mTORCI. [157].
1.6.5 Rapamycin insensitive functions of mTORCI
In addition to this, recently developed inhibitors which specifically disrupt the kinase 
activity of mTOR have revealed some surprising results with kinase inhibitors 
suppressing cellular proliferation much more effectively than rapamycin.
Targeting the mTOR kinase domain also functions to perturb the signalling of 
mTORC2 so it was originally thought that the additional effects of mTOR kinase 
inhibitors compared with rapamycin were a result of simultaneous mTORC2 
inactivation. Intriguingly however, the mTOR kinase inhibitors were still able to 
induce a more complete suppression of cell proliferation in Sin-1-/- MEFs lacking
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mT0RC2 activity. Feldman et al. reported that Sin-1-/- MEFs showed greater 
suppression of 4E-BP1 signalling in response to kinase inhibitors of mTOR than to 
rapamycin, suggesting that rapamycin may in fact be a selective substrate inhibitor 
of mTOR [276]. Rapamycin does not directly target the mTOR kinase domain; it is 
therefore looking increasingly likely that rapamycin only suppresses a subset of 
mTORCI functions. Furthermore, the efficacy of rapamycin may be affected by other 
variables, such as FKBP12 availability, therefore specific kinase inhibitors may 
provide a more complete inhibition of m TORCI (as well as mTORC2). This provides 
a case for utilising kinase inhibitors as a possible alternative to rapamycin derivatives 
for the treatment of TSC patients. The specific manifestations of suppressed 
mTORC2 signalling and potential rapamycin insensitive functions of mTORCI are 
yet to be fully determined but are important considerations in the development of 
therapeutic strategy.
1.7 mTOR DYSREGULATION AND DISEASE
Rapamycin is used to suppress m TO RCI signalling and is already being utilised in a 
number of clinical trials, however the potential rapamycin insensitive functions of 
mTORCI are becoming more apparent thus increasing the emphasis upon 
developing inhibitors which target specific facets of the signalling pathway. Some 
examples of how m TORCI is dysregulated in disease are described below.
1.7.1 Inherited hamartoma disorders
The inherited hamartoma disorders usually arise due to loss of function mutations to 
tumour suppressor genes. Several of these have been linked to aberrant mTORCI 
signalling and are currently undergoing clinical trials to investigate the efficacy of 
mTOR inhibitors as potential treatment. The most well described hamartoma 
disorders are described below.
1.7.1.1 Tuberous Sclerosis Complex
Dysregulation of mTOR signalling is a central facet of the inherited disorder TSC. 
TSC is an autosomal dominant disorder characterised by the formation of benign 
hamartomas primarily in the kidneys, heart, skin, lungs and brain. It affects 
approximately 1/6000 live births and is caused by a mutations to either the TSC1 
gene, located on chromosome 9q34, or the TSC2 gene located on chromosome
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16p13. TSC corresponds to the two-hit model of tumourigenesis, whereby 
hamartomas develop from cells which have suffered a second mutation to either the 
TSC1 or TSC2 gene resulting in a loss of heterozygosity and subsequent loss of 
tumour suppressor function.
As demonstrated in figure 1.5, the TSC1 and TSC2 gene products function 
together as a heterodimer exhibiting GAP activity towards the mTORCI activator 
Rheb. This facilitates the conversion of GTP-Rheb to GDP-Rheb which is unable to 
activate m TORCI. As described in section 1.4, TSC2 is subject to regulation from a 
number of cell signalling pathways and is phosphorylated by multiple kinases in 
response to nutrients and growth factors. Loss of function to either TSC1 or TSC2 
therefore removes the requirement for nutrients in the activation of mTOR. TSC 1/2 
deficient cells find themselves in a state of constitutive upregulation of cellular growth 
and proliferation pathways, resulting in the formation of hamartomas. Furthermore, 
constitutive activation of m TO RCI results in a general suppression of catabolic 
pathways, inhibiting autophagy and apoptosis promoting the survival of these 
mutated cells.
TSC can vary considerable in terms of its presentation and severity, with 
mutations to TSC2 generally corresponding to a more severe phenotype. Several 
functional domains have been characterised within the TSC2 protein however the 
significant variation that is observed in the presentation of the disease makes it 
almost impossible to find correlations between the genetic mutation and the severity 
of the phenotype - the manifestations associated with the disease are described in 
table 1.3 below. Patients may exhibit any number and combination of these 
symptoms, from minor skin involvement to severe mental and behavioural 
impairments, epilepsy and renal failure. In these instances,
TSC is a hugely debilitating disease having major impacts upon the individual 
and their family. The potential severity of the disease is to be expected when you 
consider the extensive signalling network which is governed by the tuberous 
sclerosis complex. Although we still have a long way to come in determining the full 
pathophysiology of TS, sufferers and their families can take solace in just how 
quickly the research has advanced in this field, particularly given the fact that it 
wasn’t until 2003 that it was discovered that TSC1 and TSC2 function together to 
suppress mTORCI signalling.
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H e a r t C a rd ia c  R h a b d o m y o m a R e p o r te d  to  e f fe c t  b e tw e e n  4 7 -6 7 %  o f  p a t ie n ts , c o m m o n  in in fa n c y  b u t  u s u a lly  reg resses  b y  a d u lth o o d . C o u ld  le a d  
t o  a r r h y th m ia  o r  h e a r t  fa ilu re .
B ra in C o ric a l T u b e rs S m a ll a re a s  o f  th e  c o r te x  o f  th e  b ra in  w h ic h  d o  n o t  d e v e lo p  p ro p e r ly , o f te n  re s u lt in g  in  e p ile p s y .
S u b e p e n d y m a l N o d u le s H ig h ly  c a lc if ie d  n o d u le s  w h ic h  a re  p re s e n t a ro u n d  th e  w a ll  o f  c e re b ra l v e n tr ic le s . N o t  th o u g h t  t o  im p a c t  u p o n  b ra in  
fu n c t io n  a t  p re s e n t.
S u b e p e n d y m a l g ia n t  ce ll 
a s tro c y to m a s  (SEGAs)
La rg e r SEGAs c a n  cau s e  b lo c k a g e  o f  c e re b ra l v e n tr ic le s , p re v e n tin g  th e  f lo w  o f  f lu id  in  th e  b ra in  c a u s in g  in c re a s e d  
in t ra c ra n ia l p re ss u re .
D e v e lo p m e n t  d e la y  a n d  
b e h a v io u ra l issues
It  is u n c le a r  w h a t  causes  th is  in  TS h o w e v e r  a p p r o x im a te ly  5 0 -6 0 %  o f  TS p a t ie n ts  e x h ib it  le a rn in g  d if f ic u lt ie s . 
A ro u n d  2 5 %  o f  TS p a t ie n ts  e x h ib it  s o m e  fo r m  o f  a u t is m ; ra n g in g  f ro m  m ild  to  s ev e re .
A t te n t io n  d e f ic it  d is o rd e r  a n d  h y p e ra c t iv i ty  a re  c o m m o n  in c h ild re n . P a ra n o ia , d e p re s s io n  a n d  a n x ie ty  a re  c o m m o n  
in  a d u lts .
Lungs L y m p h a n g io le io m y o m a to s is
(L A M )
L A M  a lm o s t  e x c lu s iv e ly  s ee n  in  fe m a le  s u ffe re rs  w i th  TSC. C h a ra c te r is e d  b y  a b n o rm a l a lv e o la r  s m o o th  m u s c le  
p r o l ife ra t io n  re s u lt in g  in  c ys tic  fo r m a t io n  a n d  p ro g re s s iv e  d e s tru c t io n  o f  th e  lu n g  p a re n c h y m a  u l t im a te ly  le a d in g  to  
re s p ira to ry  fa i lu re  a n d  d e a th .
K id n ey s A n g io m y o lip o m a s  (A M L ) F o u n d  in  a p p r o x im a te ly  8 0 %  o f  TSC p a t ie n ts , a b n o rm a l g ro w th s  c o n s is tin g  o f  s m o o th  m u s c le , fa t  a n d  a b n o rm a l  
v a s c u la r  c o m p o n e n ts . O f te n  a s y m p to m a t ic ;  h o w e v e r  g r o w th  m a y  e ffe c t  re n a l fu n c t io n  d e p e n d in g  u p o n  th e  size  a n d  
lo c a t io n . In c re a s e d  risk  o f  h a e m o rrh a g e  d u e  to  m ic ro  a n d  m a c ro -a n e u ry s m s .
R en a l cysts  a n d  p o ly c y s tic  
k id n e y  d ise a s e  (P K D )
R en a l cysts  in c u r th e  s a m e  risks as w ith  A M L s , cysts  h o w e v e r  a re  m o re  lik e ly  t o  im p a c t u p o n  re n a l fu n c t io n . TSC  
p a t ie n ts  a re  a lso  a t  in c re a s e d  risk o f  d e v e lo p in g  PKD s in c e  th e  PKD g e n e  is a d ja c e n t to  th e  TSC 2 g e n e  (see  s e c tio n  ?? 
P K D ).
R en al ce ll c a rc in o m a TSC p a t ie n ts  e x h ib it  in c re a s e d  risk  o f  d e v e lo p in g  re n a l c e ll c a rc in o m a .
S k in F ac ia l a n g io f ib ro m a s H a m a r to m a to u s  d e v e lo p m e n t  o f d e rm a l c o n n e c tiv e  tis s u e  a n d  v a s c u la r  e le m e n ts  e ffe c t in g  7 0 -8 0 %  o f  TSC s u ffe re rs .
S h a g re e n  p a tc h e s A re a s  o f  d a rk e n e d  th ic k  skin  re s u lt in g  f r o m  an  a c c u m u la t io n  o f  c o lla g e n , d e s c rib e d  as h a v in g  th e  a p p e a ra n c e  o f  
o ra n g e  p e e l.
P e r iu n g u a l a n d  u n g u a l 
f ib ro m a s  (K o e n e n  tu m o rs )
S m o o th  n o d u la r  les ion s  o c c u rr in g  a d ja c e n t to  o r  u n d e rn e a th  th e  n a ils , m o s t c o m m o n  in  a d o le s c e n c e , e ffe c ts  
a p p r o x im a te ly  2 0 %  o f  TSC p a t ie n ts .
H y p o m e la n o t ic  m a c u le s S m a ll h y p o  p ig m e n te d  les io n s  p re s e n t in  a p p r o x im a te ly  9 0 %  o f  TSC p a t ie m ts ;  u s u a lly  p re s e n t f r o m  b ir th .
Table 
1.3: M
anifestations 
of Tuberous 
Sclerosis 
by 
organ 
system
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We now have advanced knowledge of mTORCI signal transduction 
pathways, furthermore, the m TO RCI inhibitor rapamycin had already been clinically 
approved as an immunosuppressant for the use in renal transplant patients. This has 
accelerated it’s progression to the pre-clinical trial phase for the treatment of 
tuberous sclerosis and has already shown some promising results with the reports of 
AML (angiomyolipomas -  see table 1.3) shrinkage of 53.2±26.6% and increased 
lung capacity in LAM sufferers (see table 1.3) after 12 months of rapamycin 
treatment [277].
Our understanding of the signalling pathways downstream of TSC1/2 has 
advanced even during these clinical trials. W e now know that TSC1 and TSC2 can 
also function to activate mTORC2 (see section 1.3.1), and that mTORCI has 
rapamycin insensitive functions (see section 1.6.5). Furthermore there is also 
evidence that Rheb may have m TO R C I independent functions indicated by the 
recent discovery of ‘Notch’ signalling. Notch is a key regulator of cellular 
development and appears to be key in cell-fate selection, Notch signalling was 
recently shown to be dysregulated in TSC lesions [278, 279].
Interestingly, conflicting reports regarding the mechanism of this regulation 
were reported at around the same time, with one group showing evidence that Notch 
was regulated downstream of mTOR (likely via STAT3) [278] and one group arguing 
that Notch is regulated directly by Rheb [279].
At this stage it is unclear which is correct and it may be the case that both 
these mechanisms are contributing to Notch dysregulation, however if the latter is 
proved to be accurate then this reveals a branch of signalling dysregulated in TSC 
patients which would be unaffected by the use of mTOR inhibitors. These 
discoveries mean that we can assess the efficacy of the use of rapamycin or it’s 
analogues for the treatment of TSC in a more enlightened and objective manner. 
Furthermore it may explain in part why although mTOR inhibitors have shown some 
success in clinical trials, the results have been less significant than first hoped. It is 
likely that TSC1, TSC2 and Rheb have functions independent of mTOR regulation 
which would not be targeted with mTOR inhibitors. Elucidating these mechanisms 
could provide new potential therapeutic targets for combinational therapy in 
conjunction with rapamycin.
Furthermore, when m TO RCI signalling is elevated through TSC1/2 loss, 
signalling upstream of mTOR is generally suppressed through compensatory
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mechanisms (see section 1.4.6), treating with rapamycin is likely to therefore 
alleviate this suppression which may cause dysregulation of other signalling 
pathways (discussed further in context of cancer).
It may also be appropriate to utilise specific mTOR kinase inhibitors such as 
the recently described Torin-1, as an alternative which could be used to target 
rapamycin insensitive functions of m TO R C I. All these factors may influence future 
development of treatment strategies for TSC patients, hopefully contributing to a 
brighter future for those sufferers and their families.
11.1.2 Neurofibromatosis type-1 (NF1)
NF1 shares several similarities with TSC, it is also an autosomal dominant disorder 
which affects multiple organ systems. It arises from mutations to the NF1 gene which 
encodes the tumour suppressor neurofibromin-1. The NF1 gene is highly susceptible 
to sporadic mutation and this contributes to a higher incidence rate than is seen with
TSC, with 1 in 3,500 live births affected [280].
Its principal clinical manifestation is the development of benign peripheral 
nerve sheath tumours referred to as neurofibromas. In severe cases, patients can 
present with thousands of neurofibromas which can be painful and disfiguring, 
furthermore, NF1 is associated with cognitive defects as well as an increased risk of 
malignancy [281].
Neurofibromin is a GTPase activating protein expressed in neurons, glial 
cells, schwann cells and early on in melanocyte development. It is a tumour 
suppressor and functions to downregulate signalling downstream of Ras by 
converting active GTP-Ras to inactive GDP-Ras [280, 281]. As described in section 
1.4.1, Ras is normally activated in response to growth factor stimulation and 
functions to activate PI3K signalling, (see figure 1.5) as well as the Raf/Mek1 
signalling cascade disrupting formation of the TSC1/2 complex. NF1 patients exhibit 
constitutive activation of Ras in neuronal cell types, causing inappropriate cellular 
growth and proliferation. At present the only approved clinical treatment is surgical 
removal of neurofibromas, however the rapamycin analogue sirolimus is currently 
undergoing clinical trials as a potential treatment strategy [280]. A recent study 
indicated that mTORCI may play a role in the development of NF1 associated
malignancies [282]. Utilising a genetically engineered murine model, it was
demonstrated that rapamycin could be utilised to suppress tumour growth.
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Intriguingly however it was not via the usual mechanisms of mTORCI mediated 
tumour suppression. Although tumour growth was inhibited, HIF-1a was not 
suppressed and Akt activity was also unaffected, even after long term rapamycin 
treatment. This may suggest that m TO R C I signalling differs in neuronal cells, or this 
may be a result of cross talk between other signalling components downstream of 
Ras. The role mTORCI signalling has upon the pathophysiology of NF1 will become 
more apparent upon the completion of clinical trials using rapamycin and its 
analogues.
1.7.1.3 Peutz-Jeghers Syndrome
Peutz-Jeghers syndrome arises from mutations to the LKB1 tumour suppressor 
gene. LKB1 is a ser/thr kinase which activates AMPK when ATP levels are depleted 
[283]. As described in section 1.4.3, activated AMPK functions to phosphorylate 
TSC2 at the Ser1345 residue. This, in combination with GSK3P mediated 
phosphorylation of TSC2 facilitates the formation of the TSC 1/2 tumour suppressor 
complex, resulting in m TORCI inhibition. AMPK is also thought to inhibit mTORCI 
directly by phosphorylation of Raptor (see section 1.4.3). Therefore mutations to 
LKB1 result in inappropriate activation of m TORCI in the absence of ATP levels. 
This manifests with the formation of intestinal polyps (similar to hamartomas), altered 
pigmentation of the mucas membranes and increased risk of malignancy [284, 285]. 
In addition to peutz-jeghers, LKB1 mutations are also associated with 30% of 
sporadic lung cancer cases, suggesting mTOR inhibitors may also have a role here. 
Mouse models have indicated that rapamycin may be effective at reducing tumour 
burden in peutz-jeghers, specifically through suppression of HIF-1 a and it’s gene 
targets [286].
1.7.1.4 Cowdens Syndrome
For the activation of m TORCI by growth factors or insulin, activated PI3K must first 
catalyse the conversion of PIP2 to PIP3 in order to form a docking site for Akt (see 
figure 1.5). In the absence of such stimulation, PTEN, reverses this conversion, 
promoting the accumulation of PIP2 and preventing Akt activation [283, 287]. 
Therefore mutations to the PTEN gene also result in hyperactive mTOR signalling. 
There are a number of disorders associated with PTEN deficiency including
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Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome and Lhermitte-Duclos 
disease, all of which carry an increased risk of malignancy [288].
Like the other familial-cancer disorders, Cowdens syndrome varies 
considerably in terms of severity and phenotypic presentation, with the most 
commonly associated manifestations being benign skin, uterine, thyroid and breast 
lesions. Cowdens syndrome is also associated with an increased risk of breast and 
thyroid cancer [287]. The use of mTOR inhibitors is currently being trialled for the 
treatment of Cowdens and other PTEN-related hamartomatous tumour syndromes.
1.7.2 Other associated disorders
1.7.2.1 LAM
As described in table 1.3, LAM is one of the complications associated with TSC 
however it does also occur sporadically. It is a progressive and debilitating disease 
characterised by uncontrolled proliferation of abnormal smooth muscle cells in the 
lung. This can cause serious deterioration of lung function, ultimately requiring lung 
transplantation for treatment. Sporadic LAM patients also often develop renal AMLs 
as seen with TSC patients. Although the pathogenesis remains unclear behind this 
disease, LAM cells do exhibit mutations to the TSC1 or TSC2 gene which is likely to 
contribute to the uncontrolled proliferation [289, 290]. In cases of sporadic LAM it is 
likely that the disease develops as a result of somatic mosaicism of TSC1/2 
mutations which is confined to the lungs and kidneys [291]. There are multiple 
clinical trials on-going to establish how this disease could be treated with mTORCI 
inhibitors.
1.7.2.2 Polycystic kidney disease (PKD)
Autosomal dominant PKD is a cystic disease of the kidneys. Multiple cysts form in 
the kidneys as a result of uncontrolled proliferation of renal epithelial cells. These 
highly proliferating cells gradually invade the kidneys over time, impacting upon renal 
function and inevitably resulting in renal failure. The disease occurs through 
mutations to the PDK1/2 gene which encodes for polycystin-1/2, the gene is adjacent 
to the TSC2 gene on chromosome 16p13.3 so PKD can arise as a complication of 
TSC in cases of contiguous gene syndrome [292]. Polycystin 1/2 are integral cilia 
proteins and appear to mediate an influx of calcium in response to fluid flow [293] as 
sensed by primary cilium. Interestingly, loss of polycystin1/2 is also associated with
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hyperactive mTOR signalling which is likely to be contributing heavily to 
cystogenesis in this disease [294]. The mechanisms behind this are not clear 
however the cytoplasmic c-terminal tail of polycystin-1  has been demonstrated to 
regulate the localisation of TSC2 to repress m TORCI [295]. It has also been 
demonstrated that the mechanistic ‘bending’ of the cilia in response to urinary flow 
not only results in a calcium influx but also causes activation of LKB1, thus activating 
AMPK to negatively regulate m TO R C I [296]. Both mechanisms indicate ways in 
which mTORCI signalling can be regulated mechanistically by extracellular cues.
1.7.3 Cancer
The list of publications citing mTOR involvement in the pathology of cancer is 
extensive. Many different cancer types commonly exhibit mutations to genes 
involved in regulating mTOR activity, for example, PTEN, a tumour suppressor which 
functions to dephosphorylate substrates of PI3K (see figure 1.5) is one of the most 
commonly mutated tumour suppressors. The PTEN  gene is located on chromosome 
10q23 and this locus is a hotspot for mutations in primary human cancer [297]. It is 
thought that PTEN is functionally haploinsufficient, therefore mono-allelic mutations 
are sufficient to reduce its expression. Strikingly, PTEN mutations are thought to 
occur in around 50% of endometrial cancer cases [298], approximately 24% of high- 
malignancy-grade gliomas, 1 0 % of prostate carcinoma cases and 26% of 
endometrioid ovarian tumours [299].
It is also thought that mutations to the PIK3CA gene, which encodes the 
catalytic p110 subunit of PI3K, occur in around 15% of all cancer types, making it 
one of the most commonly mutated genes in the entire human genome [300]. mTOR 
also drives the activity of transcription factors HIF-1a and potentially STAT3, the 
gene targets of which are instrumental in the growth and spread of tumours.
Sato et al. recently reported two incidences of direct activating mutations to 
mTOR itself, one was found in a large intestine adenocarcinoma, the other being 
identified in renal cell carcinoma. These mutant forms of mTOR were found to be 
constitutively active regardless of nutrient status which would undoubtedly contribute 
to the cancer phenotype. Sato et al. suggest that mTOR may be directly activated in 
a wide range of cancers and could provide a potential therapeutic target [301].
Surprisingly however, rapamycin and its analogues have not been as 
successful in clinical trials as first hoped. In cell line models exhibiting PI3K
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activating mutations, tumours were demonstrated to be hypersensitive to rapamycin 
inhibition but in patients the anti-tumour activity of rapamycin is much more modest. 
One reason for the limited success in patients was described by O’Reilly et al. who 
demonstrated that rapamycin treatment caused increased expression of IRS-1 and 
induced Akt activation in response to mTOR suppression [302]. Therefore rapamycin 
treated tumour cells would exhibit repression of mTOR signalling components but 
activation of Akt signalling [302]. Evidently TSC2 is not the only downstream 
substrate of Akt, it also suppresses the expression of the pro-apoptotic p53 and 
FOXO transcription factors, promoting cell survival. Akt, like m TORCI, is also 
thought to phosphorylate p27 and p21 to promote cell cycle progression and can 
even initiate the process of angiogenesis via activation of endothelial nitric oxide 
synthase [303]. These are only a few examples of how upregulation of Akt could 
function to counteract the anti-tumour properties of rapamycin and explains at least 
in part the limited efficacy of rapamycin in patients compared with disease models, it 
may therefore be appropriate to utilise Akt inhibitors in conjunction with mTORCI 
inhibitors for maximal anti-tumour activity.
Furthermore, as described in section 1.3.5, rapamycin treatment also initiates 
Ras/raf signalling by alleviating suppression of the pathway from S6K1. Carracedo et 
al. demonstrated that the Mek1/2 inhibitor U 0126  had a synergistic effect upon 
rapamycin mediated growth inhibition, compounding the theory that activation of 
Ras/Raf signalling was instrumental in reducing the anti-tumour effects of rapamycin 
[152].
These studies highlight the significance in determining feedback mechanisms 
which may be initiated or lost when the pathway is manipulated with therapeutics. 
The rapamycin insensitive functions of m TORCI (see section 1.5.5) may also be 
subject to hyper-activation during rapamycin treatment as negative feedback 
mechanisms are initiated to counteract m TO RCI repression. mTOR kinase inhibitors 
may therefore be a more effective therapeutic strategy for diseases involving 
aberrant mTORCI signalling.
1.7.4 Autoimmune diseases
Autoimmune diseases are triggered when T effector cells inappropriately target 
substances and tissues normally present in the body, therefore treatment options 
involve immunosuppression. Rapamycin is an effective immunosuppressant and
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functions to block cytokine mediated proliferation through mTORCI inhibition, it has 
therefore been considered a potential therapeutic in the treatment of several 
autoimmune diseases.
Rapamycin has the advantage over other immunosuppressant drugs such as 
cyclosporine because it allows the thymic generation and peripheral preservation of 
a specific subset of T-cell referred to as CD4+ CD25+ FoxP3+ T cells [304]. It has 
been reported that this particular subset of T-cells suppress autoimmunity and 
promote immune-tolerance [305]. Several autoimmune disease models have shown 
improvement with rapamycin treatment including type 1 diabetes [306], systemic 
lupus erythematosus (SLE) [307], autoimmune lymphoproliferative syndrome (ALPS) 
[308] and autoimmune uveoretinitis [309] indicating the potential applications for 
rapamycin in this field and also implicating mTOR in the development of autoimmune 
diseases.
1.7.5 Lipid signalling in disease
mTORCI promotes lipogenesis by a variety of mechanisms which are described in 
detail in section 1.6.3. Dysregulation of lipid signalling pathways can contribute to the 
progression of a wide number of different diseases types, including, cancer, 
inflammation, autoimmunity, cardiovascular disease, some metabolic disorders and 
a number of degenerative diseases (for review see [310]). Therefore manipulation of 
mTORCI signal transduction could potentially be utilised in the treatment of any of 
these diseases.
mTORCI inhibition could also be used to target obesity where normal 
methods for weight loss have failed. In America, over 60% of the population are 
reported to be overweight or obese and there is a requirement for anti-obesity drugs 
due to the severe health risks which are associated with obesity, mTOR inhibitors 
have the potential to meet this criteria [311].
1.7.6 Diabetes
As described earlier, insulin stimulation in cells causes an initiation of signal 
transduction pathways activating Akt (see figure 1.5). At this point the insulin signal 
bifuricates, whereby Akt causes simultaneous activation of mTORCI to promote 
lipogenesis and fat storage, as well as increasing glucose uptake by phosphorylation
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of GLUT4, and suppressing gluconeogenesis through inhibition of GSK3p and 
F0X01 [303]. This explains how insulin promotes the storage of energy.
Type II diabetes is characterised by partial insulin resistance, whereby insulin 
is still able to activate lipogenesis but cannot suppress gluconeogenesis or increase 
glucose uptake [265]. It is thought that type 2 diabetes develops due to overfeeding. 
Whereby continuous overfeeding increases glucose, insulin and amino acid levels 
causing hyper-activation of Akt and m TORCI [312]. Hyper-activation of S6K1 
downstream of mTORCI induces a negative feedback mechanism to downregulate 
expression of IRS-1 (see section 1.4.6) causing insulin resistance. This is consistent 
with the observation that S6K1-/- mice exhibit enhanced insulin sensitivity even on a 
high fat diet [148]. Suppression of IRS-1 prevents insulin induced Akt activity, 
inhibiting glucose uptake and activating gluconeogenesis [303] aggravating the 
hyperglycaemic condition.
Interestingly in the case of type two diabetes, m TORCI remains activated and 
IRS-1 expression remains repressed. It is unclear how mTORCI remains 
hyperactive in the absence of PI3K/Akt signalling, however it may be a result of 
increased amino acid stimulation of m TO R C I due to overfeeding [312]. A recent 
study indicated that obese individuals had significantly higher levels of amino acids 
in their blood, particularly branched chain amino acids, with obese individuals 
exhibiting 14% higher levels of Leucine than leaner individuals [313]. As described in 
section 1.4.4.5, Leucine alone can induce m TORCI signal transduction [128]. This 
evidence suggests that insulin sensitivity could be reversed with rapamycin 
treatment to alleviate S6K1 dependent suppression of IRS-1, however it may be 
more appropriate to address the problem with dietary improvements and exercise.
1.7.7 Neurological diseases exhibiting aberrant mTOR signalling
Two of the more common manifestations of TSC are epilepsy and impaired cognitive 
abilities, implicating m TORCI signalling in brain and central nervous system 
function. Over the last five years, m TO R C I has been examined in a number of 
neurological disease models including Huntington’s disease, Alzheimer’s disease 
and Parkinson’s disease with particular emphasis upon autophagy dysregulation. 
These links are outlined below.
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1.7.7.1 Huntington’s disease
In the case of Huntington’s disease (HD), symptoms are caused by the accumulation 
of abnormally expanded polyglutamine proteins (in this case the accumulated mutant 
protein is Huntingtin) which form aggregates and impede neurological function, these 
aggregates cannot be degraded via the proteasome due to their long polyglutamine 
tracts. A recent study reported that rapamycin induced autophagy was effective at 
reducing these Huntingtin aggregates in a mouse model, furthermore rapamycin 
treatment caused a reduction in neurological dysfunction in a fly model for HD [314], 
indicating that induction of autophagy by mTOR suppression may be a useful 
therapeutic tool.
1.7.7.2 Parkinson’s disease
Similarly in Parkinson’s disease, the phenotype is associated with increased levels of 
a-synuclein and a mutant form of the protein. Mutant a-synuclein inhibits lysosome- 
mediated autophagy in Parkinson’s sufferers, furthermore the ubiquitin-proteasome 
system for protein degradation is also dysregulated [315], leading to the 
accumulation of protein aggregates.
Rapamycin induced autophagy has been demonstrated to clear all known 
forms of a-synuclein in cell lines suggesting that rapamycin may be useful in the 
treatment of Parkinson’s disease [316].
1.7.7.3 Alzheimer’s disease (AD)
AD patients exhibit inappropriate activation of autophagy through decreased beclin-1 
expression [317], this is coupled with increased synthesis of lysosomal components, 
premature initiation and defects in lysosomal maturation. This causes progressive 
accumulation of autophagic vacuoles and swelling of the neuritis. Importantly, these 
autophagic vacuoles secrete amyloid (3-peptide (Ap) [318]. Ap is a toxic peptide 
which gradually accumulates in the AD brain, increasing oxidative stress ultimately 
inducing apoptosis and causing neurodegeneration [319].
As described in section 1.6.2.4, Beclin-1 expression was found to negatively 
correlate with expression of phosphorylated STAT3 and Akt in malignant gliomas, 
thus downregulation of mTOR and or STAT3 could function to increase Beclin-1 
expression and may be a potential therapeutic target in AD.
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Another hallmark of AD pathology is the accumulation of phosphorylated tau 
protein. It was recently reported that tau suppression could improve memory deficits 
and suppress neuronal death in a mouse model for AD [320]. Furthermore it was 
demonstrated that rapamycin treatment could enhance the clearance of tau and 
decrease it’s toxicity, as well as increasing the lifespan of flies overexpressing tau 
[321]. This adds further support for the use of mTOR inhibitors in the treatment for 
AD.
1.7.8 Other neurological disorders associated with mTOR
A full review of the neurological disorders associated with aberrant mTOR signalling 
is not within the scope of this thesis. However it is pertinent to mention the potential 
associations. For instance cortical dysplasia, a malformation of the neurons in the 
cerebral cortex, is a common cause of intractable epilepsy in children and a recent 
study reported hyper-activation of mTOR within the dysplastic neurons associated 
with the disease [322]. This may suggest that epilepsy associated with TSC is a 
result of altered development of the cerebral cortex.
mTOR has also been associated with the processes of learning and memory 
recall, these processes rely upon long-term synaptic plasticity, whereby neurons 
which are used repeatedly, increase their affinity for each other at the synapse. 
mTOR is thought to control synaptic protein synthesis which is required for learning 
and memory [323]. This is likely to contribute to the cognitive defects common in 
TSC patients [324]. In addition, approximately 8-15% of cases of autism spectrum 
disorder (ASD) can be accounted for by singular genetic mutations, importantly more 
than half of these mutated genes are reported to be involved in the regulation of 
mTOR [324].
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1.8 PROJECT AIMS
In order to understand the pathology governing diseases associated with mTOR, the 
signalling pathway must be further clarified. Research characterising mTORCI as a 
regulator of protein translation has progressed quickly and revealed that mTORCI 
signalling extends to regulate gene expression upon a transcriptional level as well. 
The central objective of this project is to further characterise the mechanisms behind 
the role of mTORCI as a transcriptional regulator. The aims of this project were as 
follows:
1. To characterise m TO RCI dependent regulation of HIF-1a.
2. To examine HIF-1a regulation in the context of the disease Tuberous 
sclerosis.
3. To determine whether STAT3 is regulated by mTOR
4. To determine whether mTOR regulates STAT3 directly or via a 
downstream effector.
5. To investigate the relationship between mTOR, STAT3 and HIF-1a.
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CHAPTER 2: METHODS & MATERIALS
2.1 SUPPLIERS
Materials used within this thesis were purchased from the following companies: 
Abeam, Cambridge, UK 
AbGene Surrey, UK
Amersham Life Sciences Ltd., Buckinghamshire, UK
Applied Biosystems, Cheshire, UK
ATCC, Middlesex, UK
BD Transduction Laboratories, Oxford, UK
Bibby Sterling, Staffordshire, UK
Bio-Rad Laboratories Ltd., Hertfordshire, UK
Calbiochem, Nottingham, UK.
Carl Zeiss Microimaging GmbH, Jena, Germany
Cell Signaling Technologies, Danvers, USA
DAKO, Cambridgeshire, UK
Emscope, Kent, UK
Eurogentec, Hampshire, UK
Eurofins MWG Operon. Ebersberg, Germany
GE Healthcare, Buckinghamshire, UK
GIBCO, Paisley, UK
Helena Biosciences Europe. Gateshead, UK
Hoefer, Holliston, USA
Invitrogen Life Sciences Ltd. Paisley, UK
Millipore, Edinburgh, UK
National Diagnostics, Atlanta, USA
New England Biolabs Ltd., Hertfordshire, UK
Promega, Southampton, UK
Qiagen, West Sussex, UK
Roche Diagnostics, West Sussex, UK.
R & D Systems, Minneapolis, U.S.A.
Santa Cruz Biotechnology Inc., California, UK 
Sigma-Aldrich Company Ltd. Dorset, UK 
Starlabs, Milton Keynes, UK
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Thermo Fisher Scientific, Surrey, UK 
Vector Laboratories, Peterborough, UK 
VWR International. Leicestershire, UK 
Whatman International Ltd., Kent, UK
All standard laboratory chemicals were purchased from Sigma unless otherwise 
stated, tissue culture reagents were purchased from GIBCO, reagents for SDS gel 
electrophoresis and transfections were purchased from Invitrogen and DNA/RNA 
extraction kits were purchased from Qiagen.
2.2 BUFFERS AND SOLUTIONS
Buffers and solutions used in the compilation of this thesis are listed below. MilliQ 
grade water was used to prepare these buffers and solutions unless otherwise 
stated.
Luria Broth
15g Tryptone 
7.5g Yeast Extract 
15g NaCI 
1.5g Glucose 
1.5g Anhydrous MgCI
Combine with 1.51 of dH20 and adjust to pH 7.0 before autoclaving.
Luria Agar
10g Tryptone 
5g Yeast Extract 
10g NaCI 
1g Glucose 
1g Anhydrous MgCI
Add 11 of dH20 and adjust pH to 7.0 before adding:
15 g Agar 
2ml of 1M NaOH
Autoclave for 12 min before pouring.
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TBS-T
Add 2.42g Tris-base and 8 g NaCI to 11 of dH20. Adjust pH to 7.6 and add 1ml 
Tween-20 to give 0.1% (w/v) unless otherwise stated.
TAE Buffer
40 mM Tris acetate 
1 mM EDTA
Blenis Lysis Buffer
1 0 mM K P04 
5mM EGTA pH 7.2 
10mM MgCI2
50mM (3-Glycerophosphate
mTOR/Raptor Lysis Buffer
40mM HEPES pH 7.4 
2mM EDTA
10mM p-Glycerophosphate 
0.3% CHAPs
Rheb Lysis Buffer
40mM HEPES pH 7.4 
10mM P-Glycerophosphate 
5mM MgCI2 
0.3% CHAPs
Low Salt Wash Buffer
40mM HEPES pH 7.4 
2mM EDTA
10mM P-Glycerophosphate 
150mM NaCI 
0.3% CHAPs
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High Salt Wash Buffer
40mM HEPES pH7.4 
2mM EDTA
10mM (3-Glycerophosphate 
400nM NaCI
HEPES/KCL Wash Buffer
25mM HEPES pH 7.4 
20mM KCI
GTP Loading Buffer
25 mM HEPES pH 7.4 
5 mM EDTA 
0.5 mg/ml BSA
MgCI2 Loading Buffer
25 mM HEPES pH. 7.4 
5 mM MgCb
Rheb Storage Buffer
20mM HEPES pH 8.0 
200mM NaCI 
5mM MgCb
3x mTOR Kinase Buffer
75mM HEPES pH 7.4 
60mM KCI 
30mM MgCb
Start Buffer (mTOR kinase assay)
25mM HEPES pH 7.4 
10mM MgCb
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Buffer A -  Hypotonic Buffer (Nuclear and cytoplasmic fractioning)
10mM HEPES pH 7.9 
1.5mM MgCI2 
10mM KCI
Buffer C -  Hypertonic Buffer (Nuclear and cytoplasmic fractioning)
20mM HEPES pH 7.9 
25% Glycerol 
420mM NaCI 
1.5mM MgCI2 
0.2mM EDTA
Nuclear proteins lysis buffer
25mM Tris-HCL pH 7.5 
150mM NaCI 
1mM EDTA 
10mM NaF
50mM p-Glycerophosphate 
1% NP-40 
5% Glycerol
NP-40 lysis buffer
20mM Tris -  pH 7.4 
150mM NaCI 
1mM MgCI2 
1 % Nonidet P-40 
10% Glycerol 
1mM DTT
50mM p-glycerophosphate 
50mM NaF
81
Rheb exchange buffer
50mM HEPES -  pH 7.4 
1 mM MgCb 
100mM KCI 
0.1 mg/ml BSA
Rheb elution buffer
0.5mM GDP 
0.5mM GTP 
5m M DTT 
5mM EDTA 
0.2% SDS
IP wash buffer
20mM H E P E S -p H  7.4 
150mM NaCI 
1mM EDTA 
1 % Nonidet-P40 
1mM DTT
50mM (3-Glycerophosphate 
50mM NaF
Buffer A -  S6K1 Kinase Assay
1 % Nonidet P-40
0.5% Sodium Deoxycholate 
100mM NaCI 
1mM EDTA
Buffer B -  S6K1 Kinase Assay
10mM Tris -  pH 7.2
0.1% Nonidet P-40
0.5% Sodium Deoxycholate 
1 M NaCI 
1mM EDTA
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ST Buffer -  S6K1 Kinase Assay
50mM Tris-HCI -  pH 7.2 
5mM Tris-base 
150mM NaCI
Cell Extraction Buffer
50mM (3-Glycerophosphate 
1mM EDTA 
1mM EGTA 
1% Triton X-10
Western Transfer Buffer x 10
144.07g Glycine 
30.285g Tris-Base 
2g SDS
Make up to 11 with dH20
Running Buffer x 10
144.07g Glycine 
30.285g Tris-Base 
10g SDS
Make up to 11 with dH20
Urea Sample Buffer
62.5 mM Tris-HCL pH 6 .8  
6 M Urea 
10% Glycerol 
2% SDS
0.00125% Bromophenol Blue 
5% G-mercaptoethanol
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Binding Assay Buffer
20mM HEPES 
10 mM MgCI2 
100 mM NaCI
Luciferase Reagent
50mM Tricine pH 7.8 
15mM M gS04 
15mM KH2P 0 4 
4mM EGTA 
2mM ATP 
1mM Luciferin
2.3 METHODOLOGY
2.3.1 Plasmid details
Plasmid details, Myc-tagged mTOR/pRK5 (Addgene plasmid 1861) and HA-tagged 
raptor/pRK5 (Addgene plasmid 8513) plasmids were kindly obtained from Dr. D. M. 
Sabatini, referenced here [74]. HA-Raptor mutant four (mutant 4 391SQ392-PA) and 
the active mTOR mutants myc-L1460P and Myc-E2419K were generated using site- 
directed mutagenesis by Dr Elaine Dunlop [76]. pcDNA3.1, pRK7,Flag-
Rheb/PRK7, Control 5’UTR bicistronic vector, 5 ’HIF-1aTOP reporter and GST-4E- 
BP1 were kind donations from Prof. John Blenis (Harvard University), GST-Flag- 
Rheb/PRK7, GST-Flag-Rheb-Q64L/PRK7, GST-4E-BP1-F1114A (TOS mutant), 
GST-4E-BP1-I15A and GST-4E-BP1-P16A were also generated using site directed 
mutagenesis by Dr. E. Dunlop.
pACATG, HA-HIF-1a HA-4E-BP1-YL>A were kind donations from Dr. 
Sonenberg (McGill University). HA-S6K1/pRK7, HA-S6K1-F5A/pRK7, HA-S6K1- 
F5A-R3A-pRK7 and HA-S6K1-F5A-R3A-E389-pRK7 were kindly donated from Dr. 
Stefanie Schalm [325].
pcDNA3.1, Flag-TSC2/pcDNA3, Flag-TSC2-R98W/pcDNA3, Flag-TSC2- 
L219P/pcDNA3, Flag-TSC2-L340P/pcDNA3, Flag-TSC2-L466P/pcDNA3, Flag- 
TSC2-N525S/pcDNA3, Flag-TSC2-K599M/pcDNA3, Flag-TSC2-R611 Q/pcDNA3, 
Flag-TSC2-R905G/pcDNA3, Flag-TSC2-R905Q/pcDNA3 and Flag-TSC2-
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R1720Q/pcDNA3 were provided by Dr. Mark Nellist for analysis in the HIF-1a 
transcriptional reporter assay.
Prof. Cheryl Walker’s laboratory kindly provided the Flag-TSC2/pcDNA3.1, 
Flag-TSC2-R1743G/pcDNA3.1, Flag-TSC2-R1743Q/pcDNA3.1 and the Flag-TSC2 - 
R1743W/pcDNA3.1 constructs.
Dr. E. Dunlop introduced mutations into the Flag-TSC2/pcDNA3.1 plasmid via 
site directed mutagenesis in order to produce TSC2-E92V, TSC2-R505Q, TSC2- 
H597R and TSC2-L1624P [326] (see below for site-directed mutagenesis 
methodology). 3xHA-HIF and the TOS mutant are described here [135] and were 
cloned into a GST-gateway vector (Invitrogen) in accordance with manufacturers 
protocol. The GST-gateway vector system from Invitrogen was also used to generate 
GST-Rheb-like-1 from pcDNA3.1-Rheb-L1 [62] and was utilised by Dr. E. Dunlop to 
create GST-STAT3 from a STAT3 cDNA purchased from ATCC. HIF-1a and STAT3 
luciferase reporters were purchased from Promega (cat no.’s LR0128 and LR0077) 
and used in accordance with manufacturers protocol, where indicated an alternative 
HIF-1a luciferase reporter was utilised which is described here [135].
2.3.2 Antibodies
Clone 9E10 anti-Myc antibodies (Sigma) were used for immunoprecipitation, while 
clone 9B11 anti-Myc antibodies (Cell Signalling) were used for western blotting. 
Phospho-4E-BP1 (Thr37/45), phospho-4E-BP1 (Ser65), phospho-4E-BP1 (Thr70), 
Total 4E-BP1, TSC2, phospho-rpS6  (Ser235/236), (3-actin, Lamin A/C, P-STAT3- 
Ser727, P-STAT3-Tyr705, Total STAT3, elF4E, and p70 P-S6K1-Thr389 were all 
purchased from cell signalling. a-HA was purchased from Roche, a-GST was 
purchased from Upstate (Millipore), a-Flag was purchased from SIGMA. For 
detection of human HIF-1a, an antibody from BD transduction laboratories was 
utilised and a HIF-1a antibody from Abeam was purchased to detect HIF-1a from 
mouse cell lines. For immunohistochemistry, a VEGF antibody was purchased from 
Millipore.
2.3.3 Molecular Biology
All cloning was carried out using Gateway recombination technology to produce 
GST-tagged recombinant vectors in accordance with manufacturer’s protocol. 
Vectors were then sent to be sequenced by Eurofins MWG Operon for verification.
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PCR was utilised to amplify the DNA for cloning, all primers were purchased from 
Eurofins MWG Operon unless otherwise stated.
The following PCR reaction mix was prepared:
1. 50ng DNA template (5pl x 10ng/pil solution)
2. 125ng forward primer (5pl x 25ng/pl solution)
3. 125ng reverse primer (5pl x 25ng/pl solution)
4. 10pl of x5 GC buffer
5. 1pl dNTPs
6 . 1.5pl of DMSO
7. 22.5pl dH20  (> 50pl)
8 . 0.5pl DNA phusion polymerase
Using the following cycle:
1. Denaturation at 98°C for 30sec
2. Annealing at 52°C for 30 sec
3. Polymerisation at 72°C for 3 min
This cycle was repeated 23 times.
2.3.3.1 Bacterial transformations
PCR products were separated on a 1% (w/v) agarose gel using x1 TAE buffer at 
150V for 30 min to check the size, purity and approximate concentration of the 
product. A recombination reaction was performed to introduce the PCR product into 
the entry vector p-DONR221 (Invitrogen), this was carried out in accordance with 
manufacturer’s protocol. The product was then transformed into ultra-competent 
E.Coli (Invitrogen) using the following heat shock protocol:
1. Chill DNA and thaw competent cells on ice.
2. Add DNA to cells at a ratio of 1:10 and gently agitate to mix.
3. Incubation on ice for 30 min.
4. Heat shock at 42°C for one min.
5. Recovery on ice for 5 min.
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6 . Add 200|jl of SOC media (Invitrogen) to the mix -  then incubate for 
30 min at 37°C with gentle agitation.
7. Spread 20pl of the mixture onto agar plates containing the 
appropriate concentration of antibiotic and incubate overnight at 
37°C.
The following day, colonies were picked and grown up in 5ml of LB media 
supplemented with antibiotics, DNA was extracted using the Qiagen Mini-prep kit 
and then sent for sequencing at Eurofins MWG Operon. Once the sequence was 
verified the DNA was cloned into the destination vector using the LR recombination 
reaction in accordance with manufacturer’s protocol. This product was then 
transformed into the ultracompetent E.Co//and grown overnight in LB broth. Cloning 
was again confirmed with sequencing carried out by Eurofins MWG Operon.
For larger quantities of DNA, bacteria were grown in 250ml of LB broth and 
the Qiagen Maxi-Prep kit was utilised to extract plasmid DNA in accordance with 
manufacturer’s protocol. DNA concentrations were checked using an ND-8000 8 - 
sample Nanodrop spectrophotometer.
2.3.3.2 Site directed mutagenesis:
Mutations were introduced into vectors using site-directed mutagenesis using the 
same PCR mastermix as described above, however the following cycle was 
followed:
1. 98°C for 5 min (denaturation)
2. 98°C for 1 min (denaturation)
3. 52°C for 1 min (annealing)
4. 72°C for 15 min (polymerisation)
5. 72°C for 18 min (polymerisation)
6 . 4°C 00
Cycle was repeated 18 times.
Products were then treated with dPN1 (1 pl/reaction) for 1h at 27°C and then 
transformed into one shot top 10 competent E.Coli (Invitrogen) using the heat shock
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protocol described above, grown over night and extracted for sequencing using the 
Qiagen miniprep kit. Sequencing was carried out by Eurofins MWG Operon.
2.3.4 Tissue culture and cell lines
Human embryonic kidney 293 (HEK293) and Cancer research UK HEK293 cell lines 
were purchased from ATCC. TSC1-/-, T S C 1 +/+, TSC2-/- (p53-/-) and TSC2+/+ (p53- 
/-) mouse embryonic fibroblast (MEF) cell lines were kindly provided by Dr. D. 
Kwaitowski (Harvard University). All cell lines were cultured in 75cm2 flasks with 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) Foetal 
Calf Serum (FCS) and 1% (v/v) Pen Strep. Cell lines were incubated at 37°C in 5% 
C02.
Once confluent, cells were passaged, HEK293 cell lines were washed twice in 
EDTA/Trypsin, this was removed via aspiration before a 5 min incubation at 37°C. 
Cells were then resuspended in DMEM and transferred to a new flask. MEF cell lines 
required 3 trypsin washes for removal.
For long term storage, cells were frozen down in freezing medium using 
cryogenic freezing container (FCS supplemented with 8 % (v/v) DMSO) and stored in 
cryogenic vials in liquid nitrogen.
2.3.4.1 Serum starvation:
HEKCRUK293’s were washed twice in Dulbecco’s Phosphate Buffered Saline (D- 
PBS), the second wash included a 5 min incubation at 37°C before the media was 
replaced with DMEM supplemented with 1% (v/v) pen-strep (serum free media). 
MEF cell lines and HEK 293 cell lines were washed twice with serum free media.
Cells were insulin stimulated with 10pg/ml. This was administered 20 min prior 
to lysis, except when used in luciferase reporter assays where the treatment was 
given overnight.
Cells were treated with 50nM rapamycin, this was administered 1 h prior to 
lysis or overnight in the case of luciferase reporter assays.
MG132 was administered at a concentration of 50pM for 2 h prior to lysis.
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2.3A .2 Amino acid starvation and stimulation:
Cells were starved in D-PBS supplemented with:
(For 500mls)
50mg CaCI2 
0.05mg Ferric Nitrate 
48.84mg Magnesium Sulfate 
100mg KCI
1.85g Sodium bicarbonate 
62.5mg Sodium phosphate monobasic 
1.75g d-glucose 
3.36mls Sodium Pyruvate
pH was re-adjusted to 8.060 and the media was filter sterilised. Media was 
then left in incubator overnight prior to use (37°C and 5% C 0 2) to equilibrate the pH. 
Vitamin supplements (GIBCO) were added 25% (v/v). Cells were cultivated in this 
media for 4 h prior to lysis.
For amino acid-stimulation, cells were treated in the above modified D-PBS 
media containing 4% (v/v) MEM -  amino acid solution (GIBCO). The MEM amino 
acid solution itself had also been further supplemented with 30 mg/l glycine, 42 mg/l 
l-serine, and 0.2 mM l-glutamine (GIBCO). Cells were stimulated for 4 h prior to lysis.
2.3.4.3 Cell lysis
To harvest the cells, plates were washed once in PBS before being resuspended in 
lysis buffer supplemented with protease inhibitors, 1mM Na3V 0 4,2 pM antipain, 10pM 
leupeptin, 1pg/ml pepstatin, 0.1 mM PMSF, 1mM DTT and 1mM benzamidine (cells 
for GST-purification were lysed without the addition of DTT). Cells were incubated on 
ice for 20 min to aid lysis then centrifuged for 13.000rpm, 8  min at 4°C.
Lysates for Q-PCR were lysed in RNA protect buffer (no protease inhibitors) 
then centrifuged at 5,000 rpm for 5 min at 4°C, supernatant was aspirated for 
removal and the pellet stored at -80°C until mRNA extraction.
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2.3.4.4 Hypoxic incubation
For cells cultured under hypoxia, a binder CB-150 hypoxic chamber was utilised. 
Cells treatments/media changes were implemented, cells were then placed into the 
hypoxic chamber for the indicated times. The incubator was then adjusted to 1% 0 2 
for the duration of the experiments. The binder series of hypoxic incubators allows 
precise control of oxygen concentrations down to 0,2 Vol.-% so was appropriate for 
this study.
2.3.5 Transfections
For large scale transfections (6cm2 plates and upwards) cells were split into plates 
on day one. DNA complexes were added to the cells 4 h later once they had re­
adhered to the plate. Media was changed on day two and cells were harvested on 
day three.
DNA complexes were prepared by combining the DNA with milliQ water (for 
volumes see table 1.4 below) CaCI2 was then added and the solution was vortexed. 
2xBES solution was then slowly added dropwise whilst aerating the sample with a 
drawn glass pasteur pipette. Mixtures were left to stand at room temperature for 15- 
20 min (until precipitate becomes visible) then added dropwise to the cells.
Table 1.4: Mastermix volumes for calcium chloride transfection
■6cm 2plate 10cm2plate Elephantplate
DNA 5pg lOpg 40pg
dH20 225pl 450pl 1.8ml
CaCI2 25pl 50pl 200pl
2xBES 250pl 500pl 2ml
For smaller scale transfections lipofectamine 2000 (Invitrogen) transfection reagent 
was utilised following manufacturers protocol, with 2.5pl of lipofectamine used per pg
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of DNA. Cells were split into plates on day one. On day two transfection complexes 
were added to the cells and incubated for 4 h before changing the media. Cells were 
then harvested on day three.
2.3.6 Generating nuclear and cytoplasmic fractions
Cells were harvested in PBS containing protease inhibitors, then pelleted for 10 sec 
at 13,000rpm before re-suspension of the pellet in 400pl of hypotonic buffer A (see 
buffers and solutions 2.2.) supplemented with protease inhibitors. Cells were then 
incubated on ice for 1 0  min to allow swelling of the cells before a 1 0  sec vortex cycle 
on full power. Cells were centrifuged again for 10 sec at 13,000rpm and the 
supernatant retained for the cytoplasmic fraction. The remaining pellet was 
resuspended in chilled buffer C (hypertonic -  see section 2.2) plus protease 
inhibitors and incubated on ice for 20 min for high-salt extraction. Cellular debris was 
removed by centrifugation for 2  min at 13,000 rpm.
2.3.7 Lysis protocol for detection of nuclear proteins
Cells were lysed in cell extraction buffer plus protease inhibitors and phosphatase 
inhibitors where indicated. Lysates were incubated on ice for 10 min before being 
passed three times through a QIA Shredder (invitrogen) using high speed 
centrifugation. Lysates were then subjected to GST-purification/immunoprecipitation 
or western blotting.
2.3.8 SDS-Page
The Invitrogen NuPage Novex gel systems and apparatus were used in accordance 
with manufacturer’s protocol. 3-8% Tris-acetate gels were utilised for separation of 
larger molecular weighted proteins and 4-12%  Bis-Tris gels were used for small to 
medium sized molecular weights.
Samples were prepared by dilution in 4 x NuPage LDS sample buffer 
(Invitrogen) and incubated at 70°C for 10 minutes. Gels were run in the respective 
Novex running buffer at either 150V for 1h (3-8%) or at 180V for 1h (4-12%).
The Protogel system was used as an alternative to visualise 4E-BP1 mobility 
shifts or in instances where samples were lysed directly in sample buffer, also in 
cases where more than 12 samples were run simultaneously. Small gels were run
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for 1h at 200V, larger gels (up to 25 samples) were run at 225V and 45mA until dye 
front reached the bottom (3-4 h).
Samples were diluted in 2x Protein loading buffer blue (National Diagnostics) 
Then subjected to a pulse centrifugation up to 13,000rpm, denaturing at 95°C for 5 
min and followed by a second pulse centrifugation. Gels were run with x10 running 
buffer (see section 2 .2 ).
2.3.9 Electrotransfer
For gels with 12 or less samples:
Proteins were transferred to a polyvinylidene fluoride membrane (PVDF) (Immobilon- 
P, Millipore) at 25V for 2 h in transfer buffer (see section 2.2) using the hoefer 
miniVE vertical electrophoresis system, in accordance with manufacturer’s protocol. 
Membranes were soaked in methanol for 1 min to increase porosity then equilibrated 
in transfer buffer prior to use.
The larger gel systems were transferred to membrane overnight (14h) at 25V 
using an omniPAGE maxi vertical electrophoresis system from Jencons.
2.3.10 Western blot analysis
After proteins were transferred, the membrane was blocked in 10mls of TBST plus 
5% (w/v) non-fat milk powder for a minimum of 1h. The membrane was then 
incubated in primary antibody diluted 1 /1 0 0 0  (unless stated otherwise in 
manufacturers guidelines) in TBST, supplemented with 2% (w/v) BSA (Sigma).
The following day membranes were washed twice in TBST before a 30min 
incubation in secondary antibody (conjugated with horse radish peroxidase - SIGMA) 
diluted 1/10.000 in TBST and supplemented with 5% (w/v) non-fat milk powder.
Membranes were washed four times in TBST before being subjected to 
Enhanced Chemiluminesence (ECL), this involved a 1 min incubation in ECL 
western blotting reagents in accordance with manufacturers protocol.
Konica Medical Film was used to visualise the signal and the exposed films 
were developed using a Konica Minolta SRX-101A developer. Scanned images were 
analysed for densitometry using Image J. software (v.1.44) where indicated.
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2.3.11 Far Western blotting
Raptor/Raptor mutant 4 lysates were produced by transient transfection of HEK293 
cells using calcium chloride transfection (see section 2.3.5) with HA tagged 
Raptor/Mutant 4. Cells were then harvested in cell extraction buffer (see section 2.2) 
supplemented with protease inhibitors (see section 2.3.5) incubated on ice for 20 min 
before centrifugation for 8  min at 13,000rpm at 4°C.
PVDF membrane was soaked in methanol then washed in TBST. 25 ng of 
purified protein was dotted onto the membrane which was then incubated in TBST 
containing 5% (w/v) non-fat milk powder for a minimum of 1h. Each potential 
substrate was dotted onto 3 separate membranes, after blocking, one membrane 
was incubated in GST antibody overnight (antibody was diluted 1/10,000 intolOmls 
TBST, 0.2% (w/v) BSA, 5% (w/v) non-fat powdered milk) to give total protein levels. 
The other two membranes were incubated in cell extraction buffer (see buffers and 
solutions section 2.2) containing 0.3% (w/v) CHAPs, 5% (w/v) non-fat milk powder, 
protease inhibitors and 4% (v/v) Raptor/Raptor mutant 4 lysate. Alternatively, 
substrates were separated out using SDS page and transferred (using electro- 
transfer, section 2.3.9) to a PVDF membrane before the blocking step,
After overnight incubation at 4°C, membranes incubated with raptor lysate 
were washed twice for 5 min each in TBS containing 0.2% Tween before incubation 
with HA primary antibody (diluted 1/3000 in TBS-T with 0.2% (w/v) BSA and 5% 
(w/v) non-fat milk powder.)
Membranes were subjected to three washes in TBS-T before incubation in 
secondary antibody and diluted 1/10,000 in TBST containing 5% (w/v) non-fat milk 
powder. Proteins were visualised following the western blotting ECL protocol (see 
section 2.3.10).
2.3.12 Immunoprecipitation
For each immunoprecipitation, lysates were diluted up to a 1ml volume in lysis buffer 
(for preparation of lysates see section 2.3.4.3) then rotated for 2 h at 4°C with 0.4% 
(v/v) antibody (unless otherwise stated). 40pl of a 50:50 slurry of protein-G beads 
was then added and samples were rotated for 1 h at 4°C. Beads were then washed 
3 times in lysis buffer (plus protease inhibitors) before elution in 40pl of x1 sample 
buffer.
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2.3.13 GST purification
For GST purifications, cells were harvested in Rheb Lysis Buffer (see 2.2 buffers and 
solutions) supplemented with 0.3% (w/v) CHAPs and protease inhibitors, excluding 
DTT. Cellular debris was removed by high centrifugation for 8  min at 4°C and 
remaining lysates was incubated for 2 h with 40pl of a 50:50 slurry of lysis buffer and 
glutathione Sepharose beads.
Immunoprecipitates were washed three times quickly with lysis buffer then a 
fourth time for 10 min at 4°C with rotation. They were then washed in Rheb storage 
buffer (plus protease inhibitors -  excluding DTT) with a second 10 min incubation at 
4°C with rotation. GST-bound proteins were eluted from the beads in Rheb Storage 
Buffer plus protease inhibitors, supplemented with 10mM Glutothione and adjusted 
to pH 8 .
2.3.14 m7-GTP-sepharose chromatography
For purification of elF4E and its associated proteins, HEK293s were transfected with 
HA-4E-BP1 or the mutant constructs using lipofectamine 2000 transfection protocol 
(see section 2.3.5). Cells were lysed with cell extraction buffer supplemented with 
protease inhibitors, incubated on ice for 2 0  min then subjected to high speed 
centrifugation for 8  min at 4°C. 20pl of m7-GTP-sepharose beads diluted to a 50:50 
slurry in lysis buffer was added to the supernatant from each lysate. Lysates were 
then incubated for 4 h at 4°C with gentle rotation. Beads were washed three times in 
cell extraction buffer plus protease inhibitors before elution in 40pl Novex sample 
buffer supplemented with 0.2mM DTT. Proteins were visualised using SDS-PAGE 
with western blotting for detection.
2.3.15 mTORCI kinase assay
2.3.15.1 Generating mTOR/Raptor complexes from HEK293 cells:
HEK293s were transfected using calcium chloride transfection (see section 2.3.5) 
with Myc-mTOR and HA-Raptor (or mutants) at a ratio of 4:1. One plate was utilised 
for three assays. Cells were serum starved and stimulated with insulin for 20 min 
prior to lysis. Cells were harvested in mTOR/Raptor lysis buffer (see 2.2 Buffers and 
Solution) containing 0.3% (w/v) CHAPs plus protease inhibitors. Cellular debris was 
removed by centrifugation for 8  min at 13,000rpm (4°C) and the remaining lysates 
was incubated for 2 h with 4pl of Myc or HA antibody per 1ml of lysate and rotated at
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4°C. For an additional hour, a 50:50 slurry of protein G beads was added to the 
lysates (enough for 30pl per assay).
Immunoprecipitates were washed once with low salt wash buffer then twice 
with high salt wash buffer (both containing 0.3% (w/v) CHAPs plus protease 
inhibitors) and finally once in HEPES KCL wash buffer plus protease inhibitors (see
2.2 Buffers and Solutions.)
2.3.15.2 Generating GST-Rheb from HEK293 cells:
HEK293s were transfected with GST-Rheb (or constitutively active Q64L mutant) 
and grown in the presence of serum. Cells were then harvested in Rheb Lysis buffer 
(0.3% (w/v) CHAPs plus protease inhibitors excluding DTT) and subjected to GST 
purification (see section 2.3.13.)
2.3.15.3 Rheb loading with GTPyS or GDP
To load: 10pl of GTP loading buffer (see 2.2 buffers and solutions) was added to 
10pl of purified Rheb protein (approximately 75ng/assay) plus 2pl of GTPyS of GDP 
(non-hydrolysable GTP analogue) the mixture was incubated at 37°C with agitation 
for 5 min. (GTPyS substituted for 100 pCi [a-32P] GTP in radiolabelled assays).
To stop the reaction, 1pl of 0.5M MgCb was added followed by 20pl of MgCb 
loading buffer (see section 2 .2 ).
2.3.15.4 Preparing the assays:
mTOR/Raptor complexes bound to protein G beads were split into the appropriate 
amount of reaction tubes and supernatant removed, 10pl of 3x mTOR kinase buffer 
was added to the beads in addition to 5pl of purified Rheb and 150ng of potential 
substrate. The reaction mix was made up to 30pl in dH20 . A start buffer mix 
containing 10pl per reaction of Start buffer (mTOR kinase assay see section 2.2) 
supplemented with 500pM ATP (and [32P] for radioactive assays) was added to 
initiate the reaction which was carried out at 30°C with gentle agitation for either 30 
min or 1 h. The reaction was stopped with the addition of 13.3pl of x1 sample buffer 
(plus 200mM DTT for running on a Novex gel.)
Samples were analysed for phosphorylation of substrates and mTOR/Raptor 
levels using SDS page and western blotting (see sections 2.3.8-10).
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2.3.16 mTORCI Binding Assay
Active mTORCI complexes were purified from HEK293 cells. Lysates were 
generated as described above for the m TO RCI kinase assay, immunoprecipitations 
were carried out using the HA-antibody conjugated to protein G beads (GE 
Healthcare) to purify the m TORCI complex.
Immunoprecipitates were washed three times in mTOR/Raptor lysis buffer 
containing 0.3% (w/v) CHAPs and protease inhibitors. mTORCI complexes captured 
onto protein G Sepharose beads were then divided into the appropriate number of 
reaction tubes. GST-Rheb was also purified from HEK293 cells and loaded with 
GDP/GTPyS also as described for m TO R C I kinase assay (see section 2.3.15.2-3) 
5pg of GTP/GDP loaded Rheb was added to the reaction tubes. Potential substrates 
were purified utilising GST-purification system (see section 2.3.13 above) and 150ng 
of substrate was added to the reaction. Reactions were made up to a 30pl volume in 
binding assay buffer and assayed at 37°C for 20 min with gentle agitation. Protein G 
Sepharose beads were then washed three times again in mTOR/Raptor lysis buffer 
to remove non-specific interactions, proteins were eluted in 40pl of Novex sample 
buffer supplemented with DTT.
Substrate binding and mTOR/Raptor levels were visualised using SDS-PAGE 
and western blotting.
2.3.17 S6K1 Kinase Assay
Cells were transfected with HA-S6K1 or mutants using the lipofectamine 2000 
transfection protocol (see section 2.3.5) and cultured in serum free media. Cells 
were then harvested in blenis lysis buffer plus protease inhibitors. After 20 min 
incubation on ice, cellular debris was removed via high centrifugation at 4°C for 8  
min, a portion of lysate was retained to check protein expression levels using 
western blotting. The remainder of the lysate was incubated with 4pl of HA antibody 
(Roche, Switzerland) per 1ml of lysate for 2 h with rotation at 4°C. Protein G 
Sepharose beads were added for an additional hour at 4°C with rotation (40pl of a 
50:50 slurry of beads and lysis buffer).
Immunoprecipitates were washed with 1ml each of buffer A, buffer B and ST 
buffer each containing protease inhibitors.
Kinase activity toward a recombinant GST-S6  peptide (32 final amino acids of 
ribosomal S6  -  purified using GST purification -  see section 2.3.13) in washed
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immunoprecipitates was assayed in a reaction containing 20 mM HEPES, 10 mM 
MgCI2, 50 mM ATP unlabeled, 5 mCi of [g-32P]-ATP (PerkinElmer Life Sciences), 3 
ng/ml PKI, pH 7.2, for 12 min at 30 °C.
Reactions were subjected to 1 2 % SDS-polyacrylamide gel electrophoresis, 
gels were then dried down using a BIORAD model 583 gel drier and the amount of 
[32P]-radiolabel incorporated into recombinant GST-S6  protein was assessed by 
autoradiography. Exposed films were developed as described for western blotting in 
section 2.3.10.
2.3.18 Rheb GAP assay
TSC1/2 complexes were purified from HEK 293 cells transfected with pRK7, Flag- 
TSC1, Flag-TSC2, or Flag-TSC2-R1743Q on 10cm2 culture dishes using calcium 
chloride transfection protocol (see section 2.3.5). 16 h after transfection, cells were 
treated with 100 nM wortmannin for 15 min before lysis in NP-40 lysis buffer (see 
buffers and solutions). Flag-tagged proteins were then immunoprecipitated for 2 h 
with 80 pi of an M2-agarose affinity gel slurry (Sigma). Immune complexes on beads 
were washed three times in IP wash buffer and once in 1 ml Rheb exchange buffer 
supplemented with protease inhibitors (see buffers and solutions). The washed 
beads were then separated into four aliquots. Three of these were used for separate 
GAP assays, and one was resolved by SDS-PAGE and immunoblotted to determine 
protein levels. GST-Rheb (10 pg) was loaded with 100 pCi [a-32P]GTP (see section 
2.3.15.3) or 10mM GDP. GAP assays were initiated by the addition of 20 pi GTP- 
loaded Rheb (approximately 1 pg GST-Rheb) to each aliquot of M2-agarose immune 
complexes described above. Assays were performed at room temperature with 
constant agitation for 20, 40, or 60 min. Reactions were stopped by the addition of 
300 pi Rheb wash buffer containing 1 mg/ml BSA. M2-agarose immune complexes 
were removed by brief centrifugation, and nucleotide bound GST-Rheb was purified 
from the supernatant with 20 pi of a protein G slurry as described above. After three 
washes with Rheb wash buffer, radiolabeled GTP and GDP were eluted from Rheb 
with 20 pi Rheb elution buffer at 6 8 °C for 20 min. Aliquots (1 pi) of each eluted 
reaction were resolved by thin-layer chromatography on PEI cellulose (Sigma) with 
KH2P 0 4 as the solvent. Dr. Andrew Tee assisted with these assays.
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2.3.19 Transcriptional Luciferase Reporter Assays
Luciferase reporter constructs were utilised to determine the activity of transcription 
factors HIF-1a and STAT3. These vectors contain multiple copies of the cis-acting 
enhancer element for HIF-1a and STAT3 (see sequence below).
HIF-1a sequence (5’-3 ’): GTGACTACGTGCTGCCTAGGTGACTACGTG
CTGCCTAGGT GACTACGTGCTGCCTAGGT GACTACGTGCT GCCTAG
STAT3 sequence (5 -3 ’): TGCTTCCCGAATTCCCGAATTCCCGAATTCC
CGAATTCCCGAATTCCCGAACGT
Response elements are inserted upstream of a minimal TA promoter and the 
TATA box from the Herpes simplex virus thymidine kinase promoter. This promoter 
drives firefly-luciferase production which correlates with the DNA binding of the 
transcription factor (see below for vector map). The phrase “transcriptional activity” 
therefore refers to DNA binding activity of the transcription factor and thus correlates 
with target gene expression rather than expression of the transcription factor.
Cells were transfected with the reporter constructs alongside genes of 
interest, the optimum ratio of reporter DNA to additional vectors transfected was 
determined to be a 2:1 ratio favouring the reporter. To activate HIF-1a, cells were 
grown either in the presence of 1mM DMOG (dimethyloxalylglycine) or sealed in a 
Binder CB-150 hypoxic chamber set to 1% O2 for 16 hours. DMOG was utilised in 
early experimentation before the acquisition of the hypoxic chamber to mimic 
hypoxic conditions (where indicated in figure legends). DMOG is an inhibitor of PHD 
enzymes required for oxygen-mediated degradation of HIF-1a (see introduction 
section 1.5.3) allowing its stabilisation in the presence of oxygen. This is not a 
perfect experimental model as PHD enzymes have roles outside oxygen sensing. 
Current evidence suggests that PHD activity is highly sensitive to amino acid levels. 
PHDs may therefore be involved in amino acid sensing and thus could signal to 
mTORCI [327]. For this reason, the hypoxic chamber has been utilised where 
possible. Conversely, DMOG was used in experiments involving short term drug 
treatments, to avoid re-oxygenation upon opening the hypoxic chamber door. Re­
oxygenation can cause a rapid induction of ROS which activate HIF-1a [328].
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Figure 2.1 Luciferase reporter vector map (panomics).
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The cytokine CNTF (ciliary neurotrophic factor) was utilised to activate 
STAT3, cells were cultured in the presence of 25ng/ml CNTF for 16 hours prior to 
lysis in order to allow the accumulation of luciferase over time.
Cells were harvested in blenis lysis buffer supplemented with protease 
inhibitors, incubated on ice for 2 0  min before centrifugation for 8  min at 13,000rpm. 
Luciferase activity was analysed using a TR717 Microplate Luminometer which was 
programmed to inject 50pl of luciferase reagent into each well containing 20pl of 
lysate, a measurement of the luminescence was taken 1 0  seconds later, data was 
collected using the Tropix WinGlow software. Experiments were performed in 
triplicate to check the consistency of the data, each lysate produced was also 
analysed in triplicate and an average was taken. Each experiment was repeated on 
at least three separate occasions. Luminescence was adjusted to total protein levels 
as determined by a Bradford protein assay (see below). Each lysate was measured 
three times for total protein levels, average luminescence was then divided by the 
average total protein to assess reporter activity.
2.3.20 Bradford protein assay
A standard curve was produced using BSA dissolved in dH20 at the following 
concentrations, Opg/ml, 0.25p/ml, 0.5pg/ml, 1pg/ml, 2pg/ml and 4p/ml. For each 
measurement, 2pl of the standard solution was diluted in 200pl of Bradford reagent 
and absorbance was measured using the Nanodrop spectrophotometer at 595nm. 
Three measurements were taken per concentration to generate a standard curve.
To analyse total protein, 2pl of sample was diluted into 200pl of Bradford 
reagent and absorbance measured and a standard curve generated using the 
Nanodrop software V .2 .1 .0.
2.3.21 Quantitative-PCR
For the extraction of mRNA, cells were harvested in RT-protect buffer and 
centrifuged at 5 ,0 0 0  rpm for 5  min to produce a pellet, the supernatant was 
discarded and the pellet saved for mRNA extraction.
mRNA was extracted using the Qiagen (West Sussex, UK) mRNA extraction 
kit in accordance with manufacturer’s protocol, QIA shredders (Qiagen) were utilised
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to homogenise the pellet. Resulting mRNA concentration was determined using the 
nanodrop spectrophotometer.
Total RNA from each sample (1 pg) was transcribed into complementary DNA 
using a Quantitect reverse transcription kit (Qiagen) in a thermal cycler (Applied 
Biosystems). The sequences of the VEGF-A primers used were forward 5'- 
GGAGAGCAGAAGTCCCATGA-3' and reverse 5-ACTCCAGGGCTTCATCGTTA-3', 
as described in [329]. The following primer sets were purchased from Qiagen, who 
have the right to withhold primer sequence information: HIF-1a (cat no. 
QT01039542) and BNIP3 (cat no. QT00100233). Quantitative real-time PCR 
reactions were conducted in 96-well plates using appropriate primer assays and 
Sybr Green PCR Master mix (Qiagen). Assays were performed as follows:
1. Initial denaturation step (95 °C, 15 min),
2. 40 cycles of denaturation (94 °C, 15 s),
3. Annealing step (55 °C, 30 s)
4. Extension step (72 °C, 40 s).
The amplification products were quantified during the extension step in the 
fortieth cycle. The results were then determined using the ddCT (delta-delta-Ct) 
method, and standardised to p-actin. A dissociation step was performed, which
verified that only one PCR product was produced with each primer set and shows
their specificity. The correct size of PCR products was also verified by resolution on 
a 2% polyacrylamide gel with p-actin giving an amplicon length of approximately 77 
bp, VEGF-A: 117 bp, BNIP3: 67bp and HIF-1a: 91bp. The efficiency of the primers 
was assessed by plotting ct values against the log concentration of the template, a 
linear trendline was applied. The Q-PCR standard curve slope to efficiency calculator 
(Stratagene) was used to assess the efficiency based on the equation: Efficiency = - 
1+10(-1/slope). A slope of -3 .3 2  represents optimal efficiency (100%). Assays with 
amplification efficiencies of between 90 and 100% considered acceptable. All qPCR 
assays in this study were calculated to be at least 96% efficient.
2.3.22 Immunohistochemistry
Paraffin embedded kidney samples extracted from Tsc1+/' and Tsc2+/' mice were 
kindly donated from Prof. Cheadle’s laboratory (Cardiff University). The Tsc1+/'
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mouse was previously designed by Wilson et al. [330] and contains a neomycin 
resistance cassette which replaces half of exon 6  and all of exons 7  and 8  of the 
Tsc1 gene. The Tsc2+/' mouse was generated by Onda et al. [331] using 
homologous recombination to insert a neomycin resistance cassette into the second 
coding exon of Tsc2. Kidneys were collected from Tsc1+/' and Tsc2+/‘ mice and 
processed into paraffin wax by Miss Rebecca Harris.
Sections were cut at 4pm and floated on to poly-L-lysine treated glass slides 
and dried onto slides overnight at 45°C and stored at room temperature.
Immunohistochemistry analysis was carried out by Cardiff University Central 
Biotechnology Services and kidney sections from each genotype were stained for 
VEGF and phospho-S6  ribosomal protein (Ser240/244) using the following protocol:
1. Dewax and rehydrate -10mM Citrate buffer pH 6.0 100°C for 20min then 
washed thoroughly in H20 .
2. Incubate in 20mM Tris + 0.9% NaCI pH 7.3 + 0.6% BSA (TBS/BSA) for 10 
min.
3. Primary antibodies were diluted 1/25 or 1/50 rabbit anti-PS6  and 1/200 or
1/400 rabbit anti-VEGF in TBS/BSA, incubation for 60 min.
4. TBS/BSA washes, 3 x 1  min
5. Secondary antibody was diluted 1/150, goat anti-rabbit Ig horseradish 
peroxidase conjugate in TBS/BSA, incubation for 60min.
6 . TBS/BSA wash, 1min
7. 50mM Tris pH 7.6 washes, 2 x 1min
8 . 0.05% (v/v) DAB in 50mM Tris pH 7.6 for 3 min then slides were washed
thoroughly in H20 .
9. Incubation in 0.02% (v/v) methyl green for 5min
10. Dehydrate, clear and mount.
Immunohistochemical samples were viewed using an Olympus BX51 BF light 
microscope and photographs taken by Mr. Chris Von Ruhland.
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2.4 ASSUMPTIONS
2.4.1. Luciferase reporter assays
The luciferase reporter assay system utilised in this project utilises a single reporter 
assay system as opposed to a more commonly implemented dual reporter system. A 
dual system requires a secondary Renilla based luciferase reporter which serves as 
a transfection control. These secondary reporters are primarily utilised to control for 
low and variable transfection efficiency, as well as variability in the cell lysis.
Initially, a secondary renilla reporter was co-transfected alongside the firefly 
reporters described, however the reporter appeared to be significantly affected by 
cellular treatments, specifically rapamycin. The use of a Renilla-luciferase reporter 
as an internal transfection control is entirely based upon the assumption that the 
Renilla luciferase reporter is constitutively expressed regardless of cellular 
treatments, therefore given that the two control reporters tested (pRL-TK and pRL- 
SV40 -  panomics) did not meet this criteria, it was not considered feasible to utilise 
this as a normalising control as it lead to aberrant normalisation of results, as has 
been reported within the literature [332] [333]. Rather than use a transfection control, 
lipofectamine 2000 transfection reagent (Invitrogen) was utilised which offers high 
transfection efficiency across a broad range of cell lines (predicted 99% efficiency in 
HEK293s). This reduces the need for a secondary transfection control reporter. 
Secondly, all data presented within this thesis is a product of three individual 
experiments, all conducted in triplicate. Greater n-numbers were utilised to 
counteract the potential variation in the sample preparation, i.e., inconsistencies 
across cell lysis. Finally, all luciferase data was standardised to total protein levels, 
as determined by a Bradford assay. This normalises against variations in sample 
preparation, and also global effects treatments such as rapamycin may have upon 
protein synthesis. This data is based upon the assumption that modern transfection 
techniques, in combination with high n-numbers will account for variations in 
transfection efficiency which might occur between samples.
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2.4.2 Densitometry analysis
Some densitometry analysis has been carried out throughout this thesis; however 
statistical analysis of these values was not carried out. It was not considered 
necessary to analyse the data in this manner as densitometry analysis is not a 
particularly reliable methodology. It is merely included in some studies to help the 
reader visualise the data and make comparisons between samples which are not 
adjacent to one another and should not be interpreted in any other way
2.4.3 Normoxia
This study examines the effects of hypoxia versus normoxia in various settings. For 
studies of normoxia, cells were cultured at 2 1 % 0 2 which is consistent with 
atmospheric oxygen and generally accepted practice. It is pertinant to note however 
that arterial blood oxygen partial pressure is likely to be significantly lower than 
atmospheric oxygen. It is therefore possible that the differences observed between 
hypoxic and normoxic conditions in this study may have been exagerated. For these 
reasons, within this study, normoxic conditions are used as a comparative control 
but little emphasis is placed upon differences between hypoxia and normoxia.
2.4.4. Statistical analysis
Numerical data obtained from luciferase assays and Q-PCR was analysed for 
statistical significance with a one-way anova using SPSS 16.0 software. A Levene’s 
‘F-test’ was utilised initially to determine whether equal variances were apparent. 
Tukeys post-hoc test was utilised to analyse multiple comparisons within the same 
data set. Initially, this data was analysed using a two sample t-test. Although this is 
an appropriate test for statistical comparisons of two means, it is not appropriate for 
multiple testing within the same data set. Therefore the data has since been 
reanalysed for statistical significance using the one-way anova. Adjustments have 
been made within the text to indicate changes.
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CHAPTER 3: CHARACTERISATION OF mTORCI DIRECTED
REGULATION OF HIF-1a
3.1 INTRODUCTION
mTORCI plays an extensive role in the regulation of protein translation through 
phosphorylation of its downstream substrates 4E-BP’s and S6 K’s (see introduction 
sections 1.4.1 and 1.4.2). Signalling through mTOR exerts a multitude of cellular 
effects and the range of diseases linked to mTOR dysregulation is vast and rising. 
For mTOR to affect such a wide range of cellular processes, its role as a 
serine/threonine kinase must extend beyond its regulation of protein translation.
Recent work has identified several potential novel substrates for mTORCI 
(see review [35]) including HIF-1a, STAT3 and Y Y 1 . This work aims to elucidate how 
mTORCI may regulate the cellular response to oxygen deprivation, specifically 
through regulation of HIFs. HIF-1a is considered the master regulator of the hypoxic 
response [334]. Furthermore, Land et a/, identified a putative mTORCI signalling 
motif within the N-terminus of HIF-1a which is not found in the HIF-2a or HIF-3a 
isoforms, therefore HIF-1a will be the focus of this study.
There are several potential ways by which HIF-1a could be regulated by 
m TO RCI. mTORCI may modulate HIF-1a via its transcription, translation, or by 
affecting its protein stability. m TO R C I may also directly phosphorylate HIF-1a to 
modulate its transcriptional activity. Alternatively, it is also possible that the roles of 
S6 K’s or 4E-BPs extend beyond the modulation of protein synthesis, therefore 
mTORCI modulation of HIF-1a could be due to an indirect mechanism involving one 
or both of these substrates.
There has also been speculation that the unusual 5’-TOP (tract of 
polvpyrimidine) structure of H IF-1a’s 5’-UTR (untranslated region) could also be 
involved in the regulation of its translation. Long pyrimidine tracts contained within 
the 5’-UTR may confer preferential translation of HIF-1a during hypoxia whilst the 
phosphorylation of other m TO RCI substrates is suppressed [335, 336].
I hypothesised that m TORCI directed regulation of HIF-1a is a multi-faceted 
process and therefore aimed to investigate the possible mechanisms governing this. 
Utilising a HIF-1a transcriptional luciferase based reporter construct to analyse HIF- 
1a mediated gene-expression, in conjunction with m TORCI and S6K1 kinases 
assays, this chapter characterises the m TORCI-H IF-1 a relationship.
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3.2 METHODS
3.2.1 Analysis of active mutants of mTOR and luciferase assays
Cell culture including amino acid starvation and resupply was carried out as 
described in section 2.3.4.2. Cells were stimulated with 100 nM insulin (where 
indicated in fig 3.1) for 30 min prior to lysis in Blenis lysis buffer supplemented with 
protease inhibitors. SDS-PAGE was carried out as described in section 2.3.8 and 
4E-BP1 mobility shift was visualised using the large scale omniPAGE vertical 
electrophoresis system. Luciferase assays was carried out as described in section 
2.3.19. For HIF-1a luciferase assay, cells were transfected with the HIF-1a reporter 
described here [135], cells were amino acid deprived and insulin stimulated for 4 h 
prior to lysis to allow the accumulation of luciferase.
3.2.2 S6K1 kinase assay and luciferase assay
Cells were treated overnight with 50nM rapamycin and 100nM insulin prior to lysis 
and harvested in 200 pi of blenis lysis buffer. Of this, 100 pi was reserved for 
luciferase assays and western blotting of total lysates whilst 1 0 0  pi was utilised for 
the radioactive S6K1 kinase assay as described in section 2.3.17. Cells were 
cultured under normal O2 tension but grown in the presence of 1 mM DMOG in order 
to stabilise HIF-1a.
3.2.3 Bicistronic reporter construct assay
Reporter assay carried out in same manner as the transcriptional luciferase assays 
(see section 2.3.19) but utilising Promega Dual Luciferase Reagent for analysis of 
Renilla and Firefly luciferase rather than standard Luciferase Reagent described in 
Materials and Methods.
3.2.4 Raptor/mTORCI interaction studies
Overlay, binding assay and m TO RCI kinase assay were carried out as described in 
sections 2.3.15-2.3.16 of ‘Materials and Methods’. For GST-purification of HIF-1a, 
cells were grown in the presence of DMOG and incubated in the hypoxia chamber 
for 4 h prior to lysis. Prior to lysis, cells were also treated for 2 h with 50 pM of 
MG132 to prevent proteasomal degradation of HIF-1a. Cells were quickly lysed in 
Rheb lysis buffer and sonicated for 3 x 5 s cycles on full power (30microns) before
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centrifugation at 13,000rpm for 8  min at 4°C. Washes (as described in section 
2.3.13) were executed as quickly as possible to preserve HIF-1a protein levels.
3.2.5 Quantitative-PCR
TSC1-/- MEFs or TSC2-/- MEFs and their wild-type counterparts were cultured 
overnight in serum free media under hypoxic or normoxic conditions in the presence 
and absence of 50nM rapamycin. mRNA was extracted as described in section
2.3.21 and analysed for HIF-1a mRNA levels using SYBR green detection. Results 
were standardised to p-actin expression and fold induction was calculated. (For 
primers see 2.3.21).
3.3 Results
3.3.1 HIF-1a transcriptional activity is upregulated by the expression of active 
mTOR mutants
The first aim of the study was to confirm that HIF-1a is regulated downstream of 
mTOR and to draw conclusions from comparisons to more bona fide mTORCI 
substrates. To do this, two active mutants of mTOR were utilised (L1460P and 
E2419K). mTOR is a family member of PI3-kinase-related kinases. These kinases 
share several conserved domains which are central to their function. Of importance 
are the HEAT domain, FAT domain, kinase domain and FATC domain (see figure 1. 
4). mTOR has an additional FRB domain which has been isolated as the binding site 
for the rapamycin:FKBP12 complex [337]. The active mutants used in this study 
were first employed by Urano et. al. Urano looked at Tor2 (the yeast homologue of 
mTOR) and found that point mutations to specific residues in the FAT domain and 
the kinase domain produced mutants that did not require Rheb for activation. 
Introduction of equivalent mutations in the mammalian homologue produced two 
mTOR mutants, L1460P and E2419K (mutations located in the FAT and kinase 
domains, respectively), which were constitutively active regardless of nutrient supply 
and in the absence of Rheb [338].
These mTOR mutants were generated and then utilised in this study to better 
characterise them against m TO RCI substrates. HEK293 cells were transfected with 
the mutant mTOR constructs under various conditions of nutrient-deprivation and 
insulin stimulation. The phosphorylation status of the direct mTORCI substrate 4E- 
BP1 was then analysed.
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Figure 3.1 HIF-1a transcriptional activity is upregulated by active mTOR 
mutants: A: HEK293 cells transfected with Myc-4E-BP1 and Myc-mTOR (wild-type 
or mutants) were treated for 4 h in either serum-free DMEM or supplemented PBS in 
the presence or absence of amino acids (labelled ‘AA’) and insulin stimulated where 
indicated. 4E-BP1 activity was analysed using primary antibodies. The a-, (3-, and y- 
species of 4E-BP1 are labelled. Densitometry analysis was carried out on the a-, (3-, 
and y-species of 4E-BP1 using ImageJ where the protein abundance between these 
three species is set to 100% (labelled as ‘% 4E-BP1 Isoforms’). B: HEK293 cells 
transfected with the mTOR mutants as above in conjunction with the HIF-1a 
inducible luciferase reporter. Cells were starved of amino acids and grown in media 
containing 1mM DMOG for four hours, cells were stimulated with insulin 30 minutes 
prior to lysis. Luminesence was measured and standardised to total protein. Error 
bars indicative of standard deviation from three independent experiments. ** 
indicates significance <0.001. Under amino acid deprived conditions, only the 
L1460P mutation showed significantly increased HIF-1a activity upon insulin 
stimulation.
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The extent of 4E-BP1 phosphorylation can be clearly visualised on a large 
gel, as the different phosphorylated isoforms of 4E-BP1 resolve as different bands. 
This change in the mobility of 4E-BP1 is demonstrated in figure 3.1 ‘A’ with 4E-BP1 
resolving as three different isoforms.
The least phosphorylated species of 4E-BP1 migrate the quickest through the 
gel (bottom band) and is referred to as the a-isoform while the hyperphosphorylated 
species of 4E-BP1 resolves as the top band and is referred to as the y-isoform.
As expected, m TORCI signalling was repressed under serum acid starved 
conditions, with 75% of 4E-BP1 present in the unphosphorylated a-isoform in cells 
expressing wild-type mTOR. Phosphorylation analysis revealed only a trace amount 
of phosphorylation at the Thr 36/45 site only which is likely to represent the slight 
resolving p band.
Both the L1460P and E2419K mutants demonstrated almost equal levels of 
the a and p isoforms (see densitometry figures for lanes 6  and 11). Increased 
phosphorylation at all phosphorylation sites in cells expressing the mutants (in 
comparison to wild-type) under serum-starvation was observed. This is in agreement 
with the work by Urano et al. indicating that these mutants were insensitive to serum 
withdrawal (compare lanes 1, 6  and 11). After insulin stimulation, the majority of 4E- 
BP1 was present in the phosphorylated p and y isoforms for cells expressing both 
the wild-type and the two mutants. In the case of wild-type, 69% of 4E-BP1 was 
present in the p and y isoforms combined whereas cells expressing L1460P and 
E2419K expressed 82% and 89% respectively in the phosphorylated p and y 
isoforms. Interestingly, the L1460P mutant exhibited a 30% shift to the hyper­
phosphorylated y-isoform in comparison with 15% and 9% for the wild-type and 
E2419K respectively (see lanes 2, 7 and 12).
As expected, after amino acid deprivation, the majority of 4E-BP1 was shifted 
to the least phosphorylated a-isoform in all cases. Unexpectedly 4E-BP1 
phosphorylation was enhanced upon insulin stimulation in cells expressing the 
L1460P construct even in the absence of amino acids (compare lanes 4, 9 and 14). 
The E2419K mutant only produced an 13% shift towards the p-isoform after insulin 
treatment whereas the L1460P mutant induced a 15% shift to the y-isoform. This 
highlights differences between the two active mutants of mTOR, with the L1460P 
mutant negating the requirement for a permissive amino acid input in the insulin 
response. Given that the L1460P mutation resides within the FAT domain of mTOR,
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this finding implicates the FAT domain in determining mTORCI localisation 
(discussed later).
To further characterise these active mTOR mutants and to examine mTORCI 
signalling towards HIF-1a, a HIF-1a transcriptional luciferase reporter was co­
transfected alongside each of the active mutants in the presence and absence of 
amino acids (Figure 3.1 ‘B’). As predicted, both mutants caused an approximate 3- 
fold increase in the levels of H IF-1 a transcriptional activity in the presence of amino 
acids. Similar to the effects observed on 4E-BP1 phosphorylation, cells expressing 
the L1460P mutant resulted in a higher level of HIF-1a activity which was partially 
resistant to amino acid deprivation (compare lanes 2, 4 and 6 ). Although expression 
of the E2419K mutant resulted in a higher level of HIF-1a activity, this activity was 
still sensitive to amino acid withdrawal. By employing these mTOR mutants, I have 
demonstrated that the activity of H IF-1 a in cells is tightly regulated by signal 
transduction through m TO R C I, suggesting that HIF-1a, like 4E-BP1, is a 
downstream target of m T O R C I. This data supports the work carried out by Land and 
Tee which demonstrated that heightened m TORCI signalling via Rheb over­
expression led to enhanced HIF-1a activity [135].
3.3.2 Elevated HIF-1a activity in TSC2-/- MEFs is normalised by mTORCI 
inhibition with rapamycin and abolished by re-expression of TSC2
By employing these active mTOR mutants, I revealed that increased signal 
transduction from mTOR potently activates HIF-1a in cells. However, to confirm that 
this mTOR-dependent regulation of HIF-1a involves Raptor and thus mTORCI 
rather than mTORC2, a mouse cell line model for TSC was utilised. Mouse 
embryonic fibroblasts which are deficient of TSC2 (and also p53 to confer viability) 
were selected due to their elevated m TO RCI pathway status. These were utilised in 
conjunction with the HIF-1a transcriptional reporter construct. HIF-1a activity was 
assessed under conditions of, rapamycin treatment, TSC2 reintroduction, or 
expression of wild-type or mutant 4 Raptor (experiment carried out under hypoxic 
conditions to prevent 0 2-dependent degradation of HIF-1a).
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Figure 3.2 Elevated HIF-1a activity in TSC2-/- MEFs is normalised by mTORCI 
inhibition with rapamycin and abolished by re-expression of TSC2 TSC2-/- 
MEFs were transfected as indicated alongside the HIF-a luciferase reporter. Cells 
were placed into serum free DMEM supplemented with 1mM DMOG and rapamycin 
treated where appropriate for 12 hours prior to lysis. Total lysate was analysed for 
HIF-1a transcriptional activity. The HIF1a activity from the pcDNA3.1 empty vector 
was standardised to 100%. Error bars indicate variation from three independent 
experiments. Western blotting was carried out to detect the expression levels of 
exogenously transfected TSC2 and HA-Raptor. * indicates p-value <0.05, ** 
indicates p-value of <0 .0 0 1 .
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Raptor mutant 4 contains a point mutation within the RNC domain (see figure 
1.4). Work carried out by Dunlop et a/. demonstrated that Raptor mutant 4 co-purified 
with mTOR, however the mTOR/Raptor mutant 4 complex was unable to bind to 4E- 
BP1 and thus facilitate 4E-BP1 phosphorylation. Therefore, Raptor mutant 4 acts as 
a dominant inhibitor of m TORCI substrate association and phosphorylation [76].
TSC2-/- cells expressing empty control vector alongside the HIF-1a reporter 
construct demonstrated high basal levels of HIF-1a transcriptional activity consistent 
with the elevation of m TORCI signalling observed in these cells (see lane 1 of figure 
3.2).
This elevated HIF-1a activity was sensitive to inhibition from the mTORCI 
inhibitor rapamycin which caused an average 70.9% suppression of HIF-1a 
transcriptional activity. This supports the hypothesis that signal transduction through 
mTORCI regulates HIF-1a.
Raptor mutant 4 expression was also able to inhibit HIF-1a transcriptional 
activation to a similar level of that of rapamycin (compare lanes 2 and 5 -  no 
significant difference was seen between data sets) and demonstrates the dominant 
inhibition of mTORCI by Raptor mutant 4 as predicted.
Interestingly, re-expression of TSC2 into these TSC2-deficient MEF cells 
completely abolished HIF-1a transcriptional activity. Rescued expression of TSC2 
was significantly more effective at inhibiting HIF-1a than inhibition of mTORCI via 
rapamycin or raptor mutant 4 expression. This suggests that TSC2 may inhibit HIF- 
1a via both mTORCI-dependent and independent mechanisms. Over-expression of 
wild-type Raptor serves as a control and as expected did not affect the activity of 
HIF-1a.
3.3.3 mTORCI directed modulation of HIF-1a occurs independently of S6K1
S6K1 is a key effector of m TO RCI signalling, as a regulator of cellular growth and 
proliferation (see table 1.2 for list of downstream substrates of S6K1) it seemed 
logical to hypothesise that HIF-1a may be regulated downstream of S6K1. In order to 
investigate this, I utilised mutants of S6K1 with varying levels of activity.
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Figure 3.3: mTORCI directed modulation of HIF-1a occurs independently of 
S6K1 A: Schematic showing S6K1 and mutant constructs. Domains: TOS refers to 
mTOR signalling motif, kinase domain, linker domain (containing mTORCI directed 
phosphorylation site) and auto-inhibitory RSPRR domain. B: HEK293 cells were 
transfected with S6K1 constructs alongside HIF-1a luciferase reporter construct, 
grown in media supplemented with 1 mM DMOG, 100mM insulin and 50nM 
rapamycin treated overnight. 100 pi of total lysate was analysed for phospho-rpS6  
and HIF-1a induced luciferase activity. The remainder of the lysate was subjected to 
a HA-immunoprecipitation and kinase activity towards recombinant rpS6  was 
analysed (see section 2.3.17). Error bars indicate standard deviation between three 
independent experiments. No significant difference was seen between S6K1 
mutants.
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The first mutant analysed was HA-S6K1-F5A which contains a point mutation 
to the phenylalanine residue contained within its mTOR signalling motif. In 2002, 
Schalm and Blenis [77] identified a conserved motif, which was later coined as the 
mTORCI signalling (TOS) motif found in both S6K1 and 4E-BP1 (see table 1.1 for 
list of known TOS motifs). Substitution of the first phenylalanine within this TOS motif 
to an alanine residue results in a mutant of S6K1 which does not interact with Raptor 
(Fig 3.3 A ’) and hence cannot be phosphorylated by mTORCI [77, 79]. Lack of 
phosphorylation from m TORCI renders this S6K1-F5A mutant inactive and unable to 
phosphorylate its downstream targets such as rpS6 .
Further examination into functional domains of S6K1 by Schalm et al. also 
resulted in discovery of an auto-inhibitory domain contained within the C-terminus of 
S6K1 (5 amino acid motif ‘RSPRR’).
The ‘RSPRR’ motif mediates a rapamycin sensitive and thus mTORCI - 
dependent repression of S6K1 that likely involves a phosphatase [325]. The work by 
Schalm et al. demonstrated that substitution of the three arginine residues within this 
‘RSPRR’ motif with alanines (‘ASPAA’) rescued the activity of S6K1-F5A to a level 
comparable to that of wild-type S6K1, this mutant ‘S6K1-F5A-R3A was also utilised. 
Finally, a third mutant, S6K1-F5A-E389-R3A, which is constitutively active and 
insensitive to inhibition by rapamycin (see figure 3.3 ‘A ’ for schematic of mutants) 
was also used. In this case the Thr389 residue within the linker region of S6K1, 
which is directly phosphorylated by m TO RCI and is required for S6K1 activation was 
substituted for glutamic acid. This phospho-mimetic mutant was used to give a 
constituent level of S6K1 activation in cells regardless of mTORCI activity.
Wild-type or mutant S6K1 was transfected alongside the HIF-1a inducible 
luciferase reporter construct in order to assay the activity of both HIF-1a and the 
S6K1 mutants (using rpS6  phosphorylation within the prepared lysate as a readout), 
as well as their phosphor-transfer activity (by examining activity in vitro activity 
against GST-S6  substrate) (Fig 3.3 ‘B’).
Lysates were subjected to an S6K1 radioactive kinase assay (Fig 3.3 ‘B’). As 
expected, cells stimulated with insulin exhibited heightened activity of wild-type S6K1 
and this activity was highly sensitive to inhibition of m TORCI with rapamycin (rows 5 
and 6 ). This result was also reflected in the phosphorylation of phospho-rpS6  within 
the lysates prepared. The activity of the TOS mutant of S6K1 (‘S6K1-F5A’) was not 
enhanced upon insulin-stimulation as expected and also dominantly impaired insulin
114
induced phosphorylation of rpS6  in cells (row 8 ). Insulin induced activation of S6K1 
was partially recovered by the secondary mutation to the auto-inhibitory domain in 
support of the work of Schalm et al. (compare lanes 8  and 11).
The activity of the ‘S6K1-F5A-E389-R3A’ mutant, (lanes 13-15) in the in vitro 
kinase assay was high under all conditions however rpS6  phosphorylation was 
almost undetectable under serum-starved or rapamycin treatment in the equivalent 
total lysate samples. This data suggests that serum-starvation and treatment of cells 
with rapamycin is causing activation of a phosphatase that is directed towards rpS6 . 
Indeed a rapamycin sensitive phosphatase towards rpS6  has been shown [157] and 
is discussed in more detail in section 3.4.
Figure 3.3 ‘B’ shows a comparison of S6K1 activity and HIF-1a activity, there 
is evidence that both S6K1 and HIF-1a are regulated downstream of mTORCI since 
both display increased activity upon insulin stimulation in a rapamycin sensitive 
fashion. However, despite the variation in S6K1 activity seen with expression of the 
S6K1 mutants, HIF-1a transcriptional activity remains consistent whether cells are 
expressing empty vector or the highly active HA-S6K1-F5A-R3A-S6K1. This data 
indicates that HIF-1a is being mediated in an m TORCI dependent manner 
independently of S6K1.
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3.3.4 Pyrimidine tracts found in HIF-1a 5’UTR do not confer preferential 
translation
Initially, S6K1 was thought to be involved in the regulation of a subset of mRNAs 
which contain additional long oligopyrimidine tracts in the 5’-terminus untranslated 
region of their mRNA. This subset of mRNAs are referred to as 5’-TOP mRNA, HIF- 
1a is often considered a member [339] [340]. It has been shown that 5’-TOP mRNAs 
are preferentially translated under conditions of nutrient deprivation when translation 
via the 5’-UTR has been shut down due to energy depletion or hypoxia [341]. It has 
also been demonstrated that this regulation is sensitive to rapamycin therefore may 
be an m TO RCI dependent mechanism [336]. However, more recent data suggests 
that there is not a cause and effect relationship between S6K1 and the translation of 
5’-TOP mRNAs [4, 15], it is now considered that the translation of 5’-TOP mRNA is 
independent of S6K1 [335, 342]. Subsequently, the question of how 5’-TOP mRNAs 
are translated during a general ‘shut down’ of the translational machinery during 
hypoxia remains unanswered. The next phase of this study was therefore to try and 
determine the significance of the 5’-TOP tract found in HIF-1a mRNA. To do this a 
bicistronic reporter construct was employed containing the 5’-TOP sequence of HIF- 
1 a upstream of a renilla luciferase reporter, with a firefly luciferase reporter located 
downstream of the IRES (see figure 3.4 ‘A ’). A second control reporter containing the 
HIF-1a 5’UTR without the 5’TOP motif was also utilised.
In order to see if the 5’TOP sequence could confer a translational advantage 
to HIF-1a, the luciferase activity under hypoxia was examined. Figure 3.4 ‘B’ 
demonstrates that over-expression of Rheb under hypoxia caused a general 
rapamycin sensitive increase in the translation of both reporters, indicating that the 
5’TOP sequence is unable to confer any advantage to HIF-1a when m TORCI is 
activated. Translation initiated at the IRES remained consistent under all conditions 
and is not regulated in an m TORCI dependent fashion (figure 3.3 ‘B’).
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Figure 3.4 Pyrimidine tracts found in HIF-1a 5 ’UTR do not confer preferential 
translation A: Schematic of HIF-5’UTR reporter, contains the HIF-1a 5’UTR without 
the 5’TOP motif upstream of a Renilla luciferase reporter with a firefly reporter 
downstream of the IRES. Efc The HIF-1a-5’TOP reporter is identical except it 
contains the complete HIF-1a 5’UTR including the 5 ’TOP motif. C: Renilla 
luminescence shows rate of translation during hypoxia, under conditions of Rheb 
over expression and rapamycin inhibition. D: Firefly luminescence is indicative of 
translation mediated via IRESs, no significant difference was seen under any 
conditions. Total lysate was also analysed to ensure consistent levels of Rheb 
expression.
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3.3.5 mTOR regulates HIF-1a at a translational level
The next logical step of this study was to establish whether HIF-1a is regulated via 
the other well characterised m TO RCI effector, 4E-BP1. 4E-BP1 acts as a 
translational repressor in its hypo-phosphorylated state by binding to and inhibiting 
elF4E. elF4E forms part of a heterotrimeric initiation complex which associates with 
the 5’-cap structure which is present on all eukaryotic cellular (except organellar) 
mRNAs (see introduction section 1.2.2) [343]. When m TORCI phosphorylates 4E- 
BP1, it causes its dissociation from elF4E and cap-dependent translation is initiated 
[344-347]. The first step of this investigation was to characterise this interaction 
further. A far western approach was utilised to demonstrate Raptor interaction with 
4E-BP1. Fig 3.5 ‘B’ shows clear binding of raptor to purified wild-type 4E-BP1. A 
TOS mutant of 4E-BP1 with a single alanine substitution to the phenylalanine at 
position one of the TOS motif ‘FEM DI’ was also utilised. It was previously 
demonstrated that this particular phenylalanine was crucial to the function of the 
TOS motif and that m TORCI signalling towards 4E-BP1 was disrupted if it is 
mutated to an alanine [80].
A second regulatory conserved motif was also identified in 2002 by Tee et al. 
which was located in the N-terminus of 4E-BP1, it is thought that this motif was 
essential for optimal phosphorylation of 4E-BP1 and was deemed the ‘RAIP’ motif 
after its amino acid sequence [169]. In order to further characterise the function of 
the ‘RAIP’ motif, 115A and P16A mutants were prepared from cells and used as a 
substrate for Raptor interaction alongside the wild-type and TOS mutant of 4E-BP1. 
It was previously demonstrated that complete mutation of the RAIP motif resulted in 
a mutant of 4E-BP1 which could not be phosphorylated at mTORCI sensitive sites 
[169, 171]. Therefore, single point mutations were introduced to the last two amino 
acids to determine whether these were critical residues within the motif (site directed 
mutagenesis carried out by Dr Elaine Dunlop).
Both of the RAIP mutants demonstrated binding to wild-type Raptor, see 
figure 3.5 ‘B\ in the Raptor overlay assay. To look at this interaction in more detail, 
larger amounts (3 pg compared to 50 ng) of purified 4E-BP1 (wild-type/mutants) 
protein were separated by SDS-PAGE then transferred to a PVDF membrane (figure
3.5 ‘C’) before incubation with Raptor expressing lysate.
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Figure 3.5 mTOR regulates HIF-1a at a translational level A: Schematic showing 
conserved domains of 4E-BP1 which are mutated. B: Far western, mutants of 4E- 
BP1 were purified from HEK293 cells using GST-purification (see section 2.3.13), a 
far western was carried out using HA-Raptor expressing lysate generated from 
HEK293 cells. C i To increase the 4E-BP1 protein load, substrates were instead 
separated using SDS-PAGE and transferred to a PVDF membrane using electro­
transfer. Far western was then repeated using lysates generated from HEK293 cells 
expressing either wild-type Raptor or Raptor mutant 7. D: m7-GTP-sepharose 
chromatography was utilised to purify elF4E from TSC2-/- MEFs over-expressing the 
different mutants of 4E-BP1 alongside the HIF-1a luciferase reporter cultured for 12 
hrs under hypoxic conditions. Western blotting was used to determine levels of 4E- 
BP1 co-purifying with elF4E. Total lysate was analysed for total and phospho-4E- 
BP1 to indicate activity. Total lysates produced from ‘D’ were also analysed for 
HIF-1a transcriptional activity, the HIF-1a from cells expressing pACATG empty 
vector was standardised to 100%. Error bars indicate variation across three 
independent experiments. * denotes p-value, 0.05.
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Interestingly the I15A and P16A forms of 4E-BP1 showed slightly weaker 
interaction with Raptor when compared to that of wild-type (37% and 7% reduction in 
binding, respectively). The binding was reduced even further when wild-type Raptor 
was substituted with Raptor mutant 7, despite the fact that Raptor mutant 7 showed 
complete binding to wild-type 4E-BP1. Raptor mutant 7 contains a point mutation 
situated close to the conserved HEAT repeats, studies utilising this mutant carried 
out within our research group demonstrated that it was able to form an active 
complex with mTOR which could mediate 4E-BP1 phosphorylation in the in vitro. 
mTORCI kinase assay [76]. This implicates the HEAT repeats within Raptor in 
mediating 4E-BP1 interactions.
Due to the fact that m TO RCI was still able to interact with and phosphorylate 
the RAIP mutants of 4E-BP1, an alternative mutant was examined in the context of 
HIF-1a activation. Work by Tee et al. demonstrated that a double mutation to the 
elF4E-binding domain resulted in a mutant of 4E-BP1 which was unable to bind to 
and inhibit elF4E (4E-BP1-Y54A/L59A) [344]. Therefore, this was used in 
conjunction with the TOS mutant (4E-BP1-F114A) of 4E-BP1 which in contrast is 
able to bind and inhibit elF4E but is not phosphorylated by mTORCI and therefore 
its inhibitory activity cannot be relieved.
Taking a similar approach to figure 3.4, the effects of these 4E-BP1 mutations 
upon HIF-1a transcriptional activity were examined. It was postulated that if 
mTORCI was regulating HIF-1a levels via cap-dependent translation, the TOS 
mutant of 4E-BP1 which has a stronger binding affinity for elF4E, would inhibit HIF- 
1a transcriptional activity. To investigate this, the TSC2-/- MEFs were transfected 
with the HIF-1a inducible luciferase reporter construct alongside either wild- 
type/mutant 4E-BP1. The lysates were analysed for HIF-1a transcriptional activity 
(figure 3.5 ‘E’) and their binding ability (to elF4E) was examined using m7GTP affinity 
chromatography (figure 3.5 ‘D’).
In concordance with work by Tee et a/.[344], increased levels of the TOS- 
mutant of 4E-BP1 co-purified with elF-4E. This indicates a stronger binding affinity 
than that of the wild-type (lanes 2 versus 3), hence the TOS mutant of 4E-BP1 is a 
more effective inhibitor of cap-dependent translation.
In contrast, the Y54A/L59A mutant was unable to bind to elF4E so was 
ineffective at inhibiting translation (lane 4). These samples were then analysed for 
HIF-1a transcriptional activity (figure 3.5 ‘E’). As before, high levels of HIF-1a
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activation were observed in the cell line so activity was standardised to 100%, 
whereby 100% was the average HIF-1a activity seen in TSC2-/-cells expressing 
empty vector. Expression of the Y54A/L59A mutant of 4E-BP1 had no significant 
effects upon HIF-1a activity as was the case for wild-type 4E-BP1. Over-expression 
of the inhibitory TOS-mutant of 4E-BP1 resulted in a significant (p-value of 0.05) 
decrease in HIF-1a transcriptional activity (figure 3.5 ‘E’). This indicates a potential 
mechanism whereby m TORCI regulates HIF-1a activity by inducing cap-dependent 
translation and triggering the formation of the elF4F complex. It could be argued that 
if HIF-1a translation was being regulated by m TORCI in this manner then over­
expression of wild-type 4E-BP1 would also inhibit HIF-1a activity. However, it is likely 
that the inhibitory effect of over-expressing wild-type 4E-BP1 was diminished by the 
high level of 4E-BP1 phosphorylation (see figure 3.5 ‘D’) resulting from the high 
basal activity of m TORCI signalling within these TSC2 -/- cells.
3.3.6 mTORCI binds to HIF-1a and this binding is augmented by the presence 
of Rheb
The next phase of the study was to establish whether or not HIF-1a could be directly 
phosphorylated by m TO R C I. Land and Tee first postulated that as HIF-1a is a 
phospho-protein, it is possible that mTOR may phosphorylate HIF-1a directly to 
promote its function as a transcription factor [135]. In figure 3.5 ‘B \ it was 
demonstrated that Raptor could bind to 4E-BP1 in an overlay assay, it was 
hypothesised that if HIF-1a was a direct substrate of mTOR then Raptor would bind 
to HIF-1a but not the inactive TOS-mutant of HIF-1a under the same conditions, 
Raptor mutant 4 was employed as a negative control (as stated earlier, raptor mutant 
4 co-purifies with mTOR but cannot facilitate substrate recognition [76]). However as 
the overlay assay in figure 3.6 ‘A ’ demonstrates, neither wild-type HIF-1a nor the 
inactive TOS mutant showed interaction despite strong binding between Raptor and 
4E-BP1.
This may reflect weakness in the methodology since the overlay assay only 
appears to detect strong interactions, evidenced by the fact that this technique is 
unable to show Raptor binding to S6K1 (data not shown) despite the fact that S6K1 
is a known interactor [77].
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Figure 3.6 mTORCI binds to HIF-1a and this binding is augmented by the 
presence of Rheb A: HEK293s expressing GST-4E-BP1/HIF/HIF-TOS were 
harvested and subjected to a GST-purification (cells expressing HIF proteins were 
cultured under hypoxia for 12 h prior to lysis). Purified protein was dotted onto PVDF 
membrane and a far western was carried out using lysates extracted from HA-Raptor 
or HA-Raptor mutant 4 expressing HEK293 cells. a-GST primary antibody was used 
to determine substrate levels. B: An active mTORCI complex was purified from 
HEK293 cells over-expressing HA-raptor and myc-mTOR, GST-HIF/GST-HIF-TOS 
were purified from HEK293s using a GST-purification and confirmed with western 
blotting (input). Purified m TORCI complexes were then incubated with the 
substrates in the presence and absence of purified GTP-loaded Rheb, non-specific 
interactions were then removed with washes. Samples were then analysed for 
mTOR/Raptor expression and substrate binding using a-GST antibodies.
Furthermore, Land and Tee demonstrated that mTORCI bound more readily to 4E- 
BP1 than to HIF-1a [135], indicating that perhaps this assay is not sensitive enough 
to show Raptor interactions with HIF-1a.
Sato et al. previously observed that Rheb enhanced recruitment of substrates 
to mTORCI in vitro [59], therefore to address the potential weaknesses in the far 
western methodology, I devised a similar technique to enhance Raptor-substrate 
interactions. This involved purification of m TORCI complex for incubation with 
substrates in the presence and absence of a constitutively active mutant of Rheb 
(Q64L). This was followed by a series of washes to remove non-specific binding.
Results indicate that binding of m TORCI to the substrate 4E-BP1 could be 
augmented with the inclusion of purified Rheb protein in the assay in concordance 
with the work by Sato et al. It also demonstrates binding of the mTORCI complex to 
HIF-1a which was again further augmented with Rheb inclusion, unexpectedly 
however, the TOS mutant also demonstrated binding (although to a lesser extent) to 
the mTORCI substrate.
3.3.7 HIF-1a could not be phosphorylated by mTORCI in an in vitro kinase 
assay
The next stage of this line of experimentation was to implement an mTORCI kinase 
assay to see if a purified m TORCI complex could phosphorylate HIF-1a or the TOS 
mutant in vitro. Work by Kim et al. in 2002 utilising non-ionic detergents for the 
purification of mTOR lead to the discovery of Raptor. Therefore a similar method was 
utilised for the purification of an mTOR/Raptor complex [74].
Later work by Sancak et al. revealed that under conditions of insulin 
deprivation, PRAS40 binds to and inhibits the m TORCI complex (see section 1.3.6). 
Sancak demonstrated that PRAS40 could be removed from the complex by high salt 
concentrations so a high salt wash was integrated into the methodology.
Sancak et al. also utilised MgCI2 based buffers to purify the active mTOR 
complex, previously used mTOR kinase assays had used MnCfe to artificially 
increase the weak phospho-transfer activity seen when mTORCI was purified. A 
similar methodology was employed to purify a physiologically relevant and highly 
active mTORCI complex. In addition to this, GST-Rheb was also purified from 
mammalian cells and added to the assay to enhance the specificity of substrate 
binding and facilitate phosphorylation.
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Figure 3.7 HIF-1a could not be phosphorylated by mTORCI in an in vitro 
kinase assay A: An mTOR kinase assay was performed from unstimulated Myc- 
mTOR and HA-Raptor transfected HEK293 cells (see section 2.3.15) with the 
addition of increasing amounts of Rheb (10-75 ng) or RhebLI (30-250 ng). mTOR 
activity was determined by analysis of 4E-BP1 phosphorylation on Thr37/46. B: A 
second mTORCI kinase assay was performed in the same manner to evaluate 
kinase activity of mTORCI towards purified GST-HIF-1a or GST-HIF-1a-TOS in the 
presence of GDP or GTP bound Rheb. GST-HIF-1a and GST-HIF-1a-TOS were 
purified using a GST-purification (section 2.3.13) from HEK293 cells cultured under 
hypoxia for 12 h. a-GST antibodies were used to check the purification (shown -  
input).
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Figure 3.7 ‘A ’ demonstrates how during optimisation, GTPyS-bound Rheb was 
able to potently activate phosphorylation of 4E-BP1 with addition of as little as 10 pg, 
it also confirmed that the Rheb-like-1 protein was also able to activate mTOR in vitro 
supporting the work of Tee et al. in 2005 which identified Rheb-like-1 as an activator 
of mTORCI and a substrate of the TSC1/2 complex [62].
After optimisation of the assay, the next stage in the investigation was to 
establish whether m TORCI could phosphorylate purified GST-HIF-1a protein in 
vitro. Potential m TORCI directed phosphorylation sites of HIF-1a have yet to be 
identified, I therefore utilised a radioactive kinase assay to visualise the incorporation 
of [32P]-radiolabel into purified GST-HIF-1a or the TOS mutant. 4E-BP1 was utilised 
as a positive control and was phosphorylated by m TORCI (see lanes 1 and 2 of 2.7 
‘B’), this was augmented by inclusion of GTPyS-bound Rheb into the assay. 
However as shown in figure 3.7 ‘B \ neither wild-type HIF-1a nor the TOS mutant 
were phosphorylated in this assay.
3.3.8 HIF-1a mRNA is regulated in an mTORCI-dependent fashion
It is likely that mTOR directed regulation of HIF-1a is a multi-faceted process, 
therefore it is important to explore each angle of potential modulation. TSC deficient 
cells lines were implemented to see if up regulation of the mTORCI pathway 
resulted in upregulation of HIF-1a mRNA levels as well as its translation and activity 
under various conditions. TSC1-/- and TSC2-/- MEFs were compared for HIF-1a 
mRNA levels (standardised to p-actin) against their wild-type counterparts under 
hypoxia or normoxia and in the presence and absence of rapamycin. These cell lines 
are particularly useful in this context because they exhibit unsuppressed mTORCI 
signalling so HIF-1a is elevated, furthermore HIF-2a is transcriptionally inactive 
within MEFs therefore the hypoxic response is primarily mediated via HIF-1a [348]. 
Interestingly, the mRNA levels of HIF-1a were not regulated in a hypoxia dependent 
fashion. Induction of hypoxia caused no significant difference in the HIF-1a mRNA 
between the TSC1-/- cells or the TSC2-/- cells. HIF-1a mRNA however did seem to 
be subject to rapamycin inhibition. In the case of the TSC1-/- MEFs, rapamycin 
caused repression of HIF-1a mRNA under all conditions, however the reduction was 
only significant under hypoxia.
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Figure 3.8 HIF-1a mRNA is regulated in an m TORCI-dependent fashion
Untransfected TSC1-/- MEFs (A) or TSC2-/- MEFs (B) and their wild-type 
counterparts were cultured overnight in serum free media under both hypoxic and 
normoxic conditions in the presence and absence of rapamycin as indicated. mRNA 
was then extracted and quantitative-PCR was utilised to determine HIF-1a mRNA 
levels and standardised to p-actin. Significant differences indicated, * = p<0.05. ** =
p>0.001.
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HIF-1 a mRNA levels were significantly higher in both the TSC1 and TSC2 
deficient cells lines compared with the wild types MEFs, indicating that mTORCI is 
able to modulate HIF-1a mRNA synthesis or stability, as well as regulating it’s 
translation. Therefore TSC patients are likely to exhibit increased HIF-1a mRNA 
levels as well as an increased rate of its translation. This will no doubt be 
contributing to the highly vascularised tumours which develop when mTORCI 
signalling is unrestrained.
3.3.9 Rapamycin does not alter HIF-1a protein stability
During this chapter I have explored how m TORCI regulates HIF-1a mRNA and it’s 
synthesis as well as its transcriptional activity through potential phosphorylation 
events. As discussed earlier, HIF-1a is primarily regulated in terms of oxygen 
content, whereby the HIF-1a protein is rapidly degraded under normoxia by PHD 
enzymes. It is therefore possible that m TO RCI is also able to regulate the stability of 
the HIF-1a protein, either by modulating the activity of PHDs or by directly enhancing 
the stability of HIF-1a to protect it from PHD mediated degradation. To investigate 
this possibility, I utilised the bacterial derived toxin cyclohexamide. Cyclohexamide 
reversibly interferes with ribosomal translocation to prevent protein translation, by 
blocking the synthesis of HIF-1a, I was able to observe the degradation of the protein 
over time in the presence and absence of rapamycin.
As figure 3.9 demonstrates, rapamycin caused no significant impact upon the 
degradation of HIF-1a in the presence of cyclohexamide. This indicates that 
mTORCI is not able to regulate the stability of the HIF-1a protein.
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Figure 3.9 HIF-1a protein stability is unaffected by rapamycin treatment
HEK293 cells were simultaneously treated with 10|jg/ml cyclohexamide and 50nM 
rapamycin where indicated. Cells were then cultured in the hypoxic chamber at 1% 
0 2 for the indicated time points prior to lysis. Lysates were sonicated and analysed 
for HIF-1a and P-actin protein levels using western blotting. Result is representative 
of three independent replicated experiments.
128
3.4 DISCUSSION
This study aimed to characterise m TO RCI dependent regulation of HIF-1a. It 
involved taking a varied approach, where I systematically investigated different ways 
in which mTORCI could enhance HIF-1a activity.
Initially I was able to show that the active mutants of mTOR could enhance 
the transcriptional activity of HIF-1a supporting previous work by Land et al. and 
validating HIF-1a as a potential therapeutic target in diseases where mTORCI 
signalling is abberant.
Urano et al. demonstrated that the mutants of mTOR were constitutively 
active under conditions of nutrient starvation. Figure 3.1 supports this work to an 
extent however by using a wider range of conditions of nutrient starvation and 
resupply it demonstrates previously unseen subtle differences between the L1460P 
mutant and the E2419K mutant. In the cases of wild-type and the E2419K mutant, 
insulin stimulation was able to enhance the phosphorylation of downstream 
substrates to a much greater extent in the presence of amino acids (figure 3.1 ‘A’ 
compare lanes 4 and 5 with 14 and 15). Conversely, the L1460P mutant was highly 
responsive to insulin stimulation even in the absence of amino acids. This was 
demonstrated more clearly in the HIF-1a transcriptional reporter assay, whereby the 
L1460P mutant was able to propagate much higher levels of HIF-1a activity in the 
absence of amino acids than both wild-type and the E2419K mutant. This 
demonstrates that HIF-1a is as responsive as the mTORCI substrate 4E-BP1 to 
changes in mTOR activity. It also indicates the potential significance of the FAT 
domain of mTOR (where the L1460P mutation is situated).
In a continuation of this work, Dunlop et al. was able to demonstrate that this 
L1460P mutant was resistant to inhibition of mTOR by inactive Rag complexes. As 
explained in the introduction, active Rag complexes are thought to localise mTOR to 
the lysosomes where Rheb is also contained [76, 116]. Sancak et al recently 
demonstrated that when m TORCI is forced to the lysosomes (through addition of an 
intracellular targeting sequence to Raptor) it loses sensitivity to amino acid 
withdrawal, creating a constitutively active complex. This is very similar to the 
signalling pattern I observed with the L1460P mutant of mTOR. This may therefore 
indicate that the L1460P mutant is mislocalised to the lysosomal membrane causing 
constitutive activation. This would explain why it is still activated by insulin in the 
absence of amino acids, and also why it was insensitive to inhibition from the
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inactive Rag complexes. This evidence therefore may hold clues as to how the 
mTORCI complex is localised to and from the lysosomal membrane, however 
further work is required to elucidate the mechanisms behind this.
After confirmation of a correlation between mTOR activity and HIF-1a, the 
next logical step was to investigate the dependence upon signal transduction 
through m TORCI. This was carried out in a cell line model for TSC with the view of 
establishing whether m TORCI inhibitors may be effective in normalising HIF-1a 
activity. If the high level of tumour vascularisation seen in patients with TSC could be 
therapeutically targeted in this way, it could significantly reduce the capacity for 
growth of the tumour. As predicted, rapamycin and expression of the dominant 
mTORCI inhibitor Raptor mutant 4 caused a similar level of inhibition. With an 
average 70.9% reduction in HIF-1a transcriptional activity upon rapamycin treatment, 
and an average 61.9% reduction in activity with raptor mutant 4 expression (no 
significant difference between the two means). However re-introduction of TSC2 into 
the cell line caused a much more substantial 96.3% reduction in HIF-1a 
transcriptional activity, this was significantly more inhibition than was seen with 
mTORCI inhibitors (p-value 0.001).
While it is possible that TSC2 was over-expressed to an unphysiological level 
within these cells causing a more complete inactivation, this seems unlikely given 
that over-expression of the dominant inhibitor Raptor mutant 4 did not have the same 
effect despite being over expressed to a similar level (see expression control blots 
figure 3.2). A more logical explanation may therefore be that TSC2 is also able to 
inhibit HIF-1a in an mTORCI-independent manner which may be contributing to the 
pathology of TSC. This hypothesis is supported by evidence within the literature 
indicating that both TSC1 and TSC2 have independent functions outside their role as 
a heterodimer tumour suppressor which may not involve m TORCI [349]. It has also 
been well documented that TSC2 can modulate transcriptional events regulated by 
steroid nuclear receptor function, extending its role to transcriptional regulation [350- 
352]. This evidence strengthens the possibility of a TSC2 dependent, m TORCI- 
independent mechanism of HIF-1a regulation and instigated the series of 
experiments shown in the fourth chapter of this thesis.
It is thought that m TO RCI regulates cellular growth primarily through 
regulation of S6K1 or4E-BP1. Given that HIF-1a regulates processes involved in cell
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growth such as glucose transport and angiogenesis, I hypothesised that HIF-1a may 
be regulated downstream of one of these m TO RCI effectors.
It has been previously postulated that HIF-1a translation under hypoxia may 
be regulated via S6K1 [340, 353]. It was thought that S6K1 could up-regulate 5’TOP 
mRNA translation during hypoxic conditions. However, this correlation has more 
recently been dismissed [335, 342, 354]. This study therefore aimed to establish 
whether S6K1, 4E-BP1 or the 5’TOP motif were required for mTORCI regulation of 
HIF-1a.
Initially, S6K1 mutants were utilised to see whether they could modulate the 
activity of HIF-1a. Figure 3.3 clearly demonstrates the varying degrees of activity 
demonstrated by the different S6K1 mutants employed. Intriguingly, the incorporation 
of [32P]-radiolabel into ribosomal protein S6 as observed in the in vitro S6K1 assay 
did not entirely mirror the levels of phospho-S6 seen in vivo. Schalm et al. 
demonstrated that the HA-S6K1-F5A-3A-E389 mutant was rapamycin resistant, 
however figure 3.3 ‘A ’ shows that this rapamycin resistance was only seen in vitro 
and did not translate to phospho-rpS6 levels observed in the total lysate (lane 15). 
The basal activity seen under serum starvation conditions was also significantly 
lower in vivo (lane 13). This is likely to be a result of phosphatase activity towards 
rpS6. It is known that both rapamycin treatment and conditions of serum deprivation 
can induce the phosphatase PP2A to act within cells causing its dephosphorylation 
[155, 157]. This could explain the differences seen in vivo as purification of HA-S6K1 
for the kinase assay would have removed any phosphatases from the reaction. 
Within cells however, there is an on-going homeostatic balance of fine tuning 
occurring between phosphatases and kinases to regulate the phosphorylation status 
of rpS6. Conditions of serum starvation and rapamycin treatment cause the balance 
to favour phosphatases such as PP2A, whereas conditions of insulin stimulation 
favour S6K1 kinase activity.
Interestingly, it has been shown that hypoxia mediated suppression of 
mTORCI has far greater suppressive effects upon S6K1 and rpS6 phosphorylation 
than 4E-BP1 [355]. This is consistent with the findings of this study since there are 
differences in the way HIF-1a and S6K1 are regulated despite them both showing 
mTORCI dependence, it also supports the evidence in this study demonstrating that 
the translation of HIF-1a is regulated by elF4E availability. This may be one of the
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ways in which mTOR is able to maintain HIF-1a production during a general 
suppression of protein synthesis during hypoxia.
Although it was originally thought S6K1 regulated the translation of 5’TOP 
mRNAs via phosphorylation of rpS6 [356], the involvement of S6K1 in this process 
was later dismissed [342, 356]. Given that HIF-1a has previously been considered a 
5’TOP mRNA and also appears to be regulated independently of S6K1, I wanted to 
determine whether the 5’TOP motif was essential for HIF-1a translation. HIF-1a had 
been considered a 5’TOP mRNA due to the presence of long pyrimidine tracts 
contained within the HIF-1a 5’UTR. Thomas et al. showed evidence that mTORCI 
did regulate HIF-1a via the 5’TOP, demonstrating that VHL-resistant HIF-1a mutant 
cDNAs lacking the 5' TOP sequence were resistant to a CCI-779 (a rapamycin 
analogue) induced growth suppression. Since they had also demonstrated that CCI- 
779 did not affect the protein stability of HIF-1a (in concordance with the results of 
this study) they attributed m TORCI dependent regulation of HIF-1a to translation 
mediated by the 5’TOP and predicted S6K1 involvement. Conversely, Kami et al. 
showed that the HIF-1a 5 -U T R  is not involved in the enhancement of translation by 
Src, which is an upstream activator of mTOR and that over-expression of elF4E 
could augment HIF-1a protein levels, in concordance with the results of this study. 
More recent studies have also indicated that HIF-1a is not a true 5’TOP mRNA and 
cannot be translated via the 5’TOP message [355, 357].
The results of this study clearly demonstrate that Rheb expression is able to 
enhance HIF-1a translation in a rapamycin sensitive manner, however the presence 
of the 5’TOP message did not seem to influence the rate of translation under any 
conditions. This conflicts with the observations of Thomas et al. [340]. The reasons 
for this are unclear since the same reporter constructs were utilised, it may indicate 
that different cell-types are able to differentially regulate HIF-1a translation. However, 
given the fact that Thomas et al. showed a loss of sensitivity to CCI-779 in the 
context of an over-expressed mutant which could not be degraded through 
ubiquitination or be translated specifically via a 5’TOP message, it is difficult to 
dissect whether it is the stability of the mutant or the 5’TOP sequence which is 
causing the effect. Furthermore, in an earlier experiment Thomas et al. reported that 
CCI-779 caused a 38% decrease in the protein levels of HIF-1a without the 5’TOP 
compared to a 65% in HIF-1a with the 5’TOP. If this was the case then it would be
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expected that CCI-779 was still able to cause some inhibition of the translation of the 
HIF-1a mutant cDNAs lacking the 5' TOP sequence, yet this was not apparent.
Furthermore, it does appear that although the cells expressing these mutants 
were insensitive to growth suppression, GLUT-1, a HIF-1a gene target does appear 
to show reduced protein levels upon CCI-779 treatment suggesting that it is not 
completely recalcitrant to CCI-779 as suggested (see Glut-1 protein levels, figure 3 
[340]). By over-expressing Rheb in this context I was able to look at the rate of 
translation whilst m TORCI signalling was enhanced as opposed to in Thomas et 
al.’s study where loss of VHL may have had effects on other signalling pathways. 
This is therefore a more appropriate model for investigating mTORCI signalling. It 
may be the case that HIF-1a translation is only initiated via the 5’TOP message 
under certain conditions of nutrient/ 0 2  availability, it appears however that when 
mTORCI is active (through Rheb over-expression), HIF-1a is not primarily regulated 
by the 5’TOP message during hypoxia.
The presence of a conserved putative TOS motif within HIF-1a implies that 
mTORCI could directly phosphorylate HIF-1a and may provide an additional 
governing mechanism contributing to mTORCI-directed regulation of HIF-1a. It is 
likely that the regulation of HIF-1a is multi-faceted given the fact that the TOS mutant 
of 4E-BP1 only repressed the activity of HIF-1a by approximately 40% (figure 3.5) 
whereas rapamycin/raptor mutant 4 expression caused an average 70.9% reduction 
(figure 3.2).
Land et al. found that the expression of a mutant of HIF-1a lacking the TOS 
motif (F99A mutant) resulted in dominant inhibition of HIF-1a activity [135]. In order 
to further characterise the TOS motif of HIF-1a, purified recombinant GST-HIF-TOS 
was utilised as a substrate for the Raptor overlay assay. No binding was seen 
between HIF-1a and Raptor using the far western approach, this was surprising 
since Land et al. had previously demonstrated a weak Raptor interaction. However, it 
was also demonstrated that Raptor bound more readily with 4E-BP1 suggesting a 
hierarchy of m TORCI substrate phosphorylation (where Raptor may preferentially 
bind to 4E-BP1 over HIF-1a). Alternatively it could suggest that the binding between 
mTORCI and HIF-1a is a more transient interaction. The Raptor overlay assay in 
figure 3.5 ‘A’ signified no difference between the binding of the RAIP mutants and 
the wild-type, calling into question the sensitivity of this assay. To address this, a 
more sensitive methodology was employed (as described in section 3.3.6). I was
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then able to demonstrate an interaction between Raptor to HIF-1a, which, in support 
of Sato’s work, was further augmented with the addition of GTP-bound Rheb into the 
assay.
Surprisingly, the TOS mutant of HIF-1a also exhibited Raptor binding, the 
interaction observed between m TO RC I and HIF-1a-TOS was weaker indicating that 
this motif is influential in m TO RCI mediated substrate binding but not essential. This 
was somewhat unexpected as characterisation of more bona fide mTORCI 
substrates have indicated that mutations to their TOS motifs could not be tolerated 
and caused complete disruption to Raptor binding. Although in this assay there was 
a distinct reduction in the binding of the TOS mutant compared to wild-type HIF-1a 
(compare lanes 1 to 3 and 2 to 4), it was still a significant interaction within both upon 
addition of GTP-Rheb. It is therefore possible that the TOS motif found within HIF-1a 
functions differently to the TOS motif found in 4E-BP1 or S6K1. This theory is 
supported by the fact that substrate binding is not as strong to HIF-1a as it is to 4E- 
BP1. Also work by Land et al. demonstrated that the TOS mutant of HIF-1a 
demonstrated reduced binding to the transcriptional co-activator p300, this suggests 
differing functions of this TOS motif relating to transcriptional activation.
The binding of HIF-1a was still significantly increased after Rheb incubation 
indicating a probable direct interaction between mTOR and HIF-1a. Land et al. saw 
small amounts of Raptor co-purified with the TOS-mutant of HIF-1a, supporting the 
notion that Raptor may be able to form interactions with the TOS-mutant of HIF-1a. 
However, it is also possible that the wash steps within the assay after substrate 
incubation were not sufficient to remove all non-specific binding. Conversely, if the 
binding between m TORCI and HIF-1a-TOS was non-specific, you would not expect 
inclusion of GTP-Rheb to increase the interaction. This study does therefore provide 
evidence of an interaction between m TO RCI and the purified HIF-1a complex, 
however further characterisation is required to determine the role of the TOS motif.
The implementation of an in vitro mTOR kinase assay was utilised to try and 
confirm this interaction and phosphorylation of HIF-1a, however no incorporation of 
[32P] was seen. This may indicate that p300 interaction is required for 
phosphorylation by mTOR and since HIF-1a was purified after treatment with 
rapamycin, it is unlikely that p300 would have co-purified with it. Alternatively, it may 
be the case that mTOR does not directly phosphorylate HIF-1a but simply facilitates 
the interaction with p300. It may also be possible that mTORCI directly
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phosphorylates p300 itself, although it is unclear from the literature how the function 
of p300 is related to its phosphorylation status [358]. However, since the assay is 
carried out in vitro and it has been previously demonstrated that mTORCI more 
readily binds to 4E-BP1 than HIF-1a, the possibility that mTORCI can directly 
phosphorylate HIF-1a can not be ruled out on the basis of this data.
Prof. John Blenis carried out a SILAC (Stable isotope labeling with amino 
acids in cell culture) screen of potential phosphorylation sites which are altered in 
response to rapamycin and revealed Thr798 as a possible site of modulation 
(unpublished data -  personal communication). Intriguingly this site is located directly 
within the transcriptional activation domain of the HIF-1a subunit so it is possible that 
mTORCI regulates the transcriptional activity of HIF-1a via phosphorylation at this 
site. Generation of antibodies against this site could provide a more insightful look 
into mTORCI dependent HIF-1a regulation in the future.
Finally, this study demonstrated that HIF-1a mRNA levels are also regulated 
by m TO R C I At this stage the mechanism behind this modulation can only be 
speculated. Previous work has identified several putative hypoxia response elements 
(HREs) in the HIF-1a promoter, this could imply an auto-regulatory loop whereby 
HIF-1a expression is able to up-regulate synthesis of its own mRNA [359, 360]. This 
may also contribute to the continued activation of HIF-1a under hypoxia when other 
substrates of mTOR show suppression. S6K1 activates 45s ribosomal gene 
transcription by phosphorylation of the rDNA transcription factor UBF which indirectly 
leads to an increase in transcription (see introduction table 1.2). A similar 
mechanism may be in place here, whereby m TORCI is able to modulate HIF-1a 
mRNA by phosphorylation of upstream transcription factors. Alternatively it may be 
possible that mTORCI directly or indirectly modulates the stability of the HIF-1a 
mRNA as opposed to its synthesis, however further research in this area is required 
to determine this mechanism.
Intriguingly, it was recently demonstrated that STAT3 was required for HIF-1a 
mRNA expression [361], furthermore there is evidence that STAT3 can be 
modulated by mTORCI (see introduction section 1.5.4) so mTOR may regulate HIF- 
1a mRNA synthesis downstream of STAT3.
mTORCI directed HIF-1a regulation is likely a multi-faceted process, I 
therefore wanted to explore different potential mechanisms of mTORCI directed 
HIF-1a regulation. A crucial factor governing HIF-1a activity is the stability of the
135
protein, Land et al. showed evidence that m TORCI regulated HIF-1a in an VHL- 
independent manner. This evidence further supports this hypothesis and clearly 
demonstrates that rapamycin does not affect the stability of the HIF-1a protein.
The aim of this study was to characterise the mechanism behind mTOR 
directed regulation of HIF-1a. There has been a high degree of conflicting evidence 
indicating potential mechanisms involving S6K1 and the 5’TOP structure of HIF-1a 
mRNA (see review [35]), this study presents clear evidence disputing the 
involvement of either. Although this study could not demonstrate direct 
phosphorylation from m TO R C I, it has shown interaction with Raptor indicating the 
potential for an additional mechanism of regulation via mTOR directed 
phosphorylation. It has also clearly demonstrated that mTOR can modulate the 
translation of HIF-1a through the phosphorylation of the 4E-BPs in addition to 
regulating HIF-1a mRNA expression.
There are increasing reports showing evidence for mTORCI as a 
transcriptional regulator and widening the implications of mTOR dysregulation in 
disease, HIF-1a mediates expression of a number of genes which contribute to the 
pathology in diseases where m TO R C I is dysregulated. This study has answered 
questions regarding this regulation, dispelling myths related to S6K1 regulation and 
how the 5’TOP-like message is interpreted by m TORCI. Just as importantly 
however, it has raised questions about how HIF-1a functions independently of 
mTORCI and how HIF-1a mRNA levels can also be modulated, thus providing a 
foundation for further research in this area.
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CHAPTER 4: HIF-1a IN THE CONTEXT OF TUBEROUS SCLEROSIS
4.1 INTRODUCTION
Research over the last decade has indicated that both TSC1 and TSC2 appear to be 
multi-functioning proteins, with evidence for over 50 binding partners for TSC2 and 
or TSC1 (see review [1]). There is growing evidence to suggest that TSC2 in 
particular has significantly more mTOR independent roles with repeated studies 
demonstrating its involvement in transcriptional events relating to steroid/nuclear 
receptor signalling [350-352, 362]. This evidence is compounded by the fact that 
TSC patients arising through TSC2 mutations tend to present with a more severe 
phenotype than those with TSC1 mutations [363]. This has implications particularly 
for TSC patients as current clinical trials are utilising mTOR inhibitors by means of 
potential treatment. Such therapy would be ineffective at treating symptoms within 
TSC patients arising from mTOR independent functions of TSC1/2.
In chapter 3, it was demonstrated that re-introduction of TSC2 back into 
TSC2-deficient cells was significantly more effective at inhibiting HIF-1a than the 
potent mTORCI inhibitor rapamycin, suggesting an additional role for TSC2 in the 
modulation of HIF-1a. TSC patients develop highly vascularised tumours and 
demonstrate high levels of VEGF secretions [135, 364] where the m TO RCI- 
independent mechanism(s) relating to loss of TSC2 function may be a contributing 
factor to these effects. Previous work suggested that TSC2 may regulate VEGF via 
mTORCI-independent mechanisms, however it was thought that this was 
independent of HIF-1a [365]. I utilise TSC2 mutational analysis in conjunction with 
both TSC 1-deficient and TSC2-deficient cell lines to attempt to further characterise 
mTORCI-dependent and independent regulation of HIF-1a.
4.2 METHODS
4.2.1 HIF-1a Luciferase Assays
TSC2-/- MEFs were co-transfected with the HIF-1a luciferase reporter (purchased 
from Panomics Ltd.) alongside empty vector, wild-type or mutant TSC2. Cell were 
cultured under serum starved conditions under hypoxia or normoxia for 12 h prior to 
lysis and treated with rapamycin where indicated. Cells were lysed as described in 
section 2.3.4.3 with Blenis lysis buffer supplemented with protease inhibitors. 100 pi 
of lysate was extracted for protein detection (where indicated) via western blotting
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and each sample was sonicated for three cycles of 5 s on maximum power 
(30microns) incubating on ice in between sonications. Lysates were then subjected 
to high centrifugation for 2 min at 4 °C, diluted in Invitrogen SDS-page sample buffer 
and subjected to separation by SDS-PAGE using the 3-8% novex gel system from 
Invitrogen.
Luciferase assays carried out as previously described in section 2.3.19, 
results shown are either comprised of or representative of three independent 
experiments (where indicated)
4.2.2 Quantitative-PCR
Cells were lysed in RNA protect lysis buffer then pelleted at 5,000 rpm for 5 min 
before mRNA extraction using Qiagen mRNA extraction kit in accordance with 
manufacturers protocol. 1 pg of each mRNA extraction was converted to cDNA using 
Qiagen reverse-transcriptase kit and analysed as described in section 2.3.21. Each 
cDNA was analysed in triplicate for p-actin, VEGF, BNIP3 or HIF-1a and fold 
difference was calculated using the ddCT (delta-delta-Ct) method (results 
standardised to p-actin). Results are comprised of three independent experiments.
4.2.3 S6K1 kinase assay of TSC1-/- and TSC2-/- MEFs
Cells were transferred to serum free media containing 1 mM DMOG and rapamycin 
treated overnight before lysis in Blenis lysis buffer (see section 2.2) supplemented 
with protease inhibitors. S6K1 kinase assay and HIF-1a luciferase assay were 
carried out as described in section 2.3.17 and 2.3.19 respectively.
4.2.4 GTPase-Activating Protein Assay
See section 2.3.18. Dr. Andrew Tee assisted with these assays.
4.2.5 Nuclear and Cytoplasmic Fractioning
Localisation of TSC2 was analysed after TSC2-/- MEFs expressing either pRK7, 
wild-type TSC2 or TSC2-R1743G were lysed in PBS supplemented with protease 
inhibitors then subjected to nuclear and cytoplasmic fractioning as described in 
section 2.3.6. Nuclear and cytoplasmic fractions were analysed with western blotting 
for detection of TSC2 expression using the Novex gel system as previously 
described (see section 2.3.8).
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4.2.6 Immunohistochemistry
Kidney samples extracted from TSC1 and TSC2 heterozygous mice and embedded 
in formaldehyde blocks were kindly donated from Prof. Jeremy Cheadle’s 
Laboratory, 30 x 0.4 pM sections were taken from 3 different mice of each genotype 
and staining for VEGF was carried out as described in section 2.3.22 by Cardiff 
University Central Biotechnology Services. Pictures were taken using light 
microscopy to visualise the sections.
4.3 Results
4.3.1 Rapamycin treatment of TSC2-/- only results in partial inhibition of HIF-1a 
transcriptional activity
The initial stage of this line of investigation was to analyse the transcriptional activity 
of HIF-1a in the context of cell line models for TSC. TSC2-/- MEFs were first utilised 
to examine changes of HIF-1a activity in the presence or absence of TSC2. This was 
carried out in both hypoxic and normoxic conditions to establish whether the effect 
was mediated by O2 levels. The effects of rapamycin treatment upon this activity 
were also examined. These cell-lines are particularly useful for specifically dissecting 
HIF-1a signalling as HIF-2a is not transcriptionally active in MEFs and therefore the 
hypoxic response is mediated via HIF-1a only [348, 363]. Confirming this, I did not 
observe HIF-2a expression in these cells (data not shown).
The data clearly demonstrates that HIF-1a activity is enhanced in the absence of 
TSC2 with an almost 10-fold increase in activity (compare lanes 5 and 7 of figure 
4.1). Transfection of TSC2 back into these cells resulted in an average 89.7%  
reduction in HIF-1a activity, this result was highly significant with a p-value of 0.001 
(compare lanes 5 and 7). Rapamycin treatment however only caused an average 
reduction of 61.1% (p-value 0.001). HIF-1a activity was significantly higher in 
rapamycin treated TSC2-/- cells demonstrating at least an average three-fold 
increase over the rapamycin untreated cells expressing TSC2 (p-value 0.05, 
compare lanes 5 and 8).
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Figure 4.1: Rapamycin treatment of TSC2-/- only results in partial inhibition of 
HIF-1a transcriptional activity (A) TSC2-/- MEFs were transfected with the HIF-1a- 
inducible luciferase reporter (Panomics) alongside either wild-type TSC2 or empty 
vector. Cells were serum starved and cultured under hypoxic (1%) or normoxic 
(21%) conditions in the presence and absence of rapamycin as indicated. Cells were 
then harvested in Blenis lysis buffer supplemented with protease inhibitors and total 
lysate was analysed for HIF-1a transcriptional activity. Results are representative of 
three independent experiments, and standardised to total protein levels as 
determined by a Bradford assay. Error bars indicative of standard deviation from 
three independent experiments. * indicates p-value significance <0.05, ** indicates 
significance <0.001, NS indicates not significant. (B) Untransfected TSC2-/- MEFs 
and their wild-type counterparts were cultured under same conditions described in 
‘A’, however cells were harvested directly in sample buffer, sonicated and then 
analysed for HIF-1a protein levels and p-actin as a loading control.
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Analysis of HIF-1a protein levels in the TSC2-/- MEFs compared to the wild- 
types (figure 4.1 ‘B’) demonstrates that HIF-1a protein levels appear to be highly 
sensitive to inhibition with rapamycin, consistent with the results of chapter 3 
indicating that mTORCI regulates the translation of HIF-1a mRNA. Interestingly the 
more sensitive transcriptional assay reveals that under hypoxia, HIF-1a 
transcriptional activity is still elevated after rapamycin treatment in the TSC2-/- MEFs 
when compared with the wild-types (compare lanes 5 and 8). The continued 
elevation of HIF-1a activity in the presence of rapamycin suggests that TSC2 is able 
to regulate HIF-1a independently of m TO RCI.
4.3.2 TSC2-/- MEFs are less sensitive to rapamycin inhibition of HIF-1a 
mediated gene expression than TSC1-/- MEFs
After demonstrating that TSC2 re-introduction could suppress HIF-1a activity to a 
greater extent than rapamycin inhibition, it was important to confirm that this was not 
a consequence of over-expressing TSC2 to a level that would be unphysiological. I 
also wanted to clarify whether specific loss of the TSC2 protein (and not the TSC1 
protein) was incurring mTORCI-independent inhibition of HIF-1a. Finally, I needed to 
confirm that this increased activity of HIF-1a translated to elevated gene-expression 
of HIF-1a targets. To address these points, q-PCR was utilised to analyse the gene- 
expression of two HIF-1a targets, VEGF-A and BNIP3.
The data includes a comparison of the gene-expression of these targets in 
both TSC1- and TSC2-deficient MEFs, in comparison to their wild-type counterparts. 
VEGF-A was selected as a target due to its association with pathogenic 
angiogenesis in TSC patients. BNIP3 (Bcl-2/adenovirus E1B 19-kDa interacting 
protein 3) was also selected as a HIF-1a target. BNIP3 is a member of the Bcl-2 pro- 
apoptotic family. Although traditionally BNIP3 was thought to regulate apoptosis, it 
has more recently been demonstrated to induce autophagy and necrosis (see review 
[366]). Shackleford et al. demonstrated that BNIP3 is upregulated in an LKB1 mouse 
model of Peutz-Jeghers syndrome in a rapamycin sensitive manner and it is 
therefore appropriate for this study [286].
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Figure 4.2 MEFs are less sensitive to rapamycin inhibition of HIF-1a mediated 
gene expression than TSC1-/- MEFs: TSC1-/- (A and B) or TSC2-/- MEFs (C and 
D) and their wild-type counterparts were cultured under serum starved conditions 
under normoxia (21% O2) or hypoxia (1% 0 2) for 12 h in the presence and absence 
of rapamycin. Cells were then lysed in RNA protect buffer, mRNA was extracted, 
VEGF or BNIP3 mRNA levels were quantified using SYBR green detection as 
described in section 2.3.21. Fold difference was calculated using the ddCT method. 
Error bars indicative of standard deviation from three independent experiments. * 
indicates p-value significance <0.05, ** indicates significance <0.001, NS indicates 
not significant.
142
It is notable at this point that BNIP3 also plays a role in the suppression of 
mTORCI under hypoxia by interacting with Rheb, which leads to a reduction in the 
phosphorylation of 4E-BPs and S6Ks (see section 1.4.5.4) [146]. Paradoxically, it 
may actually contribute to the survival of TSC-deficient cells by suppression of 
mTORCI signalling and induction of autophagy under additional hypoxic stress.
Gene expression was analysed under both hypoxic and normoxic conditions 
and in the presence and absence of rapamycin. Figure 4.2 ‘A ’ and ‘B’ demonstrate 
the gene-expression of VEGF-A and BNIP3, respectively in the TSC1-/- MEFs and 
their wild-type counterparts. Both HIF-1a target genes were upregulated by hypoxia 
as expected and were further augmented by TSC1 loss. The upregulation of HIF-1a 
activity seen in the TSC1-/- cells was highly sensitive to rapamycin with VEGF-A  
expression being inhibited by an average of 84.9%. BNIP3 showed an average 
reduction of 72.9% after rapamycin treatment (compare lanes 8 and 9 on both figure 
A and B).
Statistical analysis revealed that there was no significant difference in VEGF- 
A or BNIP3 induction when comparing the untreated TSC1+/+ cells and the 
rapamycin treated TSC1-/- cells under hypoxia. Therefore as expected, rapamycin 
normalises the elevation of HIF-1a activity induced by TSC1 deficiency. In contrast, 
this was not the case in the TSC2-/- cell lines. VEGF-A induction was elevated in the 
absence of TSC2 (under hypoxia) and although it was subject to inhibition from 
rapamycin, rapamycin caused an average inhibition of 31.6% (compared with 84.9%  
in the case of the TSC1-/- cells), giving a p-value of 0.05. BNIP3 was reduced by an 
average 32.4% with rapamycin treatment and this reduction was not statistically 
significant. Consistent with the transcriptional assay shown in figure 4.1, VEGF-A  
levels were significantly higher in rapamycin treated TSC2-/- MEFs than in the 
untreated TSC2+/+ MEFs giving a p-value of 0.05. Although intial statistical analysis 
indicated that BNIP3 was also higher in rapamycin treated TSC2-/- MEFs than in the 
untreated TSC2+/+ MEFs, once the data had been corrected for multiple testing 
using the one-way anova, the significant difference was lost. Although a similar trend 
is apparent therefore this is likely to be due to the increased experimental variation 
between the BNIP3 and VEGF-A analysis. . The VEGF-A Q-PCR and luciferase 
assays however still support the conclusion that rapamycin treatment normalises 
HIF-1a activity in the absence of TSC1 but not in the absence of TSC2. This 
suggests that in the TSC1-/- cells, the enhanced activation of HIF-1a induced gene
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expression observed is primarily through enhanced mTORCI signalling. In the 
TSC2-/- MEFs, elevation of m TORCI certainly accounts for a substantial increase in 
HIF-1a activity, however loss of TSC2 appears to cause an increase in HIF-1a 
activity which is also independent from m TORCI.
4.3.3 TSC1-/- MEFs exhibit similar mTORCI activity and sensitivity to 
rapamycin as TSC2-/- MEFs
After demonstrating that there appeared to be differences in HIF-1a activity and 
rapamycin sensitivity between the TSC1 and TSC2-/- MEFs it was important to 
confirm that the differences in HIF-1a sensitivity to rapamycin was not due to 
differences in mTORCI signalling between these cell types. To access the mTORCI 
activity in these cells, an S6K1 kinase assay was implemented alongside the HIF-1a 
reporter assay. Total lysates were analysed for both the activity of HIF-1a and the 
phosphorylation of ribosomal protein S6 at Ser235/236 in the presence of rapamycin. 
In addition to this, HA-S6K1 was immunoprecipitated from the total lysate and its 
kinase activity measured towards recombinant ribosomal protein S6 in vitro.
Results demonstrate once again that the TSC1-/- MEFs were significantly 
more responsive to rapamycin induced down-regulation of HIF-1a activity than 
TSC2-/- MEFs (p-value 0.05) -  figure 4.3 ‘A ’. Importantly, this experiment also 
confirms that the treatment of these cells lines with rapamycin was sufficient to block 
mTORCI signalling, as observed by reduced S6K1 activity and rpS6 
phosphorylation in rapamycin treated cells. This indicates that the TSC1-/- MEFs and 
TSC2-/- MEFs are equally as sensitive to rapamycin-mediated inhibition of mTORCI 
signal transduction. They are not however equally sensitive to rapamycin induced 
suppression of HIF-1a, adding further support to the hypothesis that TSC2 can also 
act independently of TSC1 and m TORCI to regulate HIF-1a transcriptional activity.
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Figure 4.3 TSC1-/- MEFs exhibit sim ilar m TORCI activity and sensitivity to 
rapamycin as TSC2-/- MEFs TSC1-/- MEFs and TSC2-/- MEFs were transfected 
with HA-S6K1 alongside the HIF-1a luciferase reporter construct. Cells were cultured 
in the presence and absence of rapamycin in serum free media supplemented with 1 
mM DMOG. Cells were lysed in Blenis lysis buffer supplemented with protease 
inhibitors. Total lysate was analysed for HIF-1a transcriptional activity which was 
standardised to total protein levels as determined by the Bradford assay. Phospho- 
rpS6 levels and total HA-S6K1 expression was determined by western blotting. The 
remaining lysate was subjected to an HA-immunoprecipitation and radioactive S6K1 
kinase assay utilising purified recombinant GST-rpS6 as a substrate. Error bars 
indicative of standard deviation from three independent experiments. * indicates p- 
value significance <0.05.
145
4.3.4 TSC2 mutational analysis
The disease TSC results in the development of benign tumours across multiple 
organ systems including the brain, heart, kidneys, lungs and skin. Some TSC 
patients present with severe autism, whereas some patients may suffer no 
neurological impairments. The development and incidence of the tumours are highly 
variable and thus the severity of the disease is equally variable. It is thought that the 
severity of the disease may be affected by positioning of the genetic mutation to 
either the TSC1 or TSC2 genes. The Uniprot website lists over 50 different naturally 
occurring point mutations within the TSC2 gene alone which have been reported to 
cause TSC. It has therefore been speculated that the position of the mutation may 
be a determining factor in the penetrance of the disease. Since mutation to the TSC2 
gene tends to manifest with more severe presentation of the disease than with TSC1 
mutations [367], I postulated that this may be contributed in part by loss of TSC2 - 
mediated mTORCI independent inhibition of HIF-1a.
The next stage of this study was to determine what impact TSC2 mutations 
could have on the modulation of HIF-1a. In order to do this, Dr. Mark Nellist 
(Erasmus Medical Centre) kindly provided a panel of mutants of TSC2 constructs, 
containing mutations within various conserved domains along the gene. I utilised the 
TSC2-/- MEFs to determine what how effective these disease causing mutations 
were at suppressing HIF-1a activity.
Results showed a good deal of variation in the degree of inhibition of HIF-1a, 
indicating that the R98W, L340P, N525S and K599M mutants were all able to inhibit 
HIF-1a activity to a level which was not significantly different to wild-type (see figure 
4,.4 ‘B’). Conversely, there are reports in the literature that the R98W mutant is less 
able to repress S6K1 activity in comparison to wild-type [368]. Nellist’s research 
group also identified the L340P mutant as being pathogenic and consistent with this, 
the L340P mutant is unable to suppress Thr389 phosphorylation of S6K1 
(unpublished data — personal communication). It is likely that these discrepancies 
are caused through differences in TSC2 expression levels as these studies utilised 
different expression vectors. From my earlier studies using the pcDNA3.1/Flag-TSC2 
vector I observed that the Flag-TSC2 expressed weakly, approximately three times 
lower than was seen with these TSC2 mutant constructs.
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Figure 4.4 TSC2 mutational analysis: A: Schematic of TSC2 demonstrating known 
functional and conserved domains. B: TSC2-/- MEFs were transfected with the HIF- 
1a luciferase reporter construct alongside empty vector, wild-type TSC2 or mutant 
TSC2. Cells were cultured under serum starved conditions in media supplemented 
with 1 mM DMOG for 12 h prior to lysis. Cells were harvested in Blenis lysis buffer 
and analysed for HIF-1a transcriptional activity, this was standardised to total protein 
levels as determined by a Bradford assay. The remainder of the lysate was analysed 
for TSC2 expression levels by western blotting. Error bars indicative of standard 
deviation from three independent experiments. NS indicates ‘Not significantly 
different to wild-type.
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TSC2 mutants provided by Mark Nellist were generated into the original but 
discontinued pcDNA3 expression vector. Western blotting of TSC2 levels confirmed 
that the mutants were expressing at a much higher level. See TSC2 expression blot 
(figure 4.4 ‘B’), whereby the control blot shown only required a 10 second exposure 
after ECL Furthermore the R1720Q mutation, which has previously been shown to 
be pathogenic and completely ineffective at inhibiting downstream mTORCI 
substrates [368], caused a 60.6% inhibition of HIF-1a. It is probable that therefore 
these TSC2 mutants are expressing at a higher level which is not physiologically 
relevant, this may be causing artificial inhibition of HIF-1a due to excess protein 
levels. In order to confirm this, a second panel of mutations was analysed which 
were cloned into the pcDNA3.1 expression vector to express the TSC2 protein at a 
lower level.
4.3.5 Point mutations to TSC2 confer differential abilities to inhibit HIF-1a when 
TSC2 is expressed at a lower and more physiological level
Once again, mutational analysis was carried out to analyse the inhibitory effects of 
TSC2 towards HIF-1a. These particular TSC2 missense variants were selected from 
a database of mutations identified in patient samples which were referred to the 
clinical genetics service laboratory in Medical Genetics, Cardiff University (with the 
exception of the wild-type TSC2 vector and the R1473Q mutant which were kind 
donations from Prof. Cheryl Walker). Five different patient derived mutations were 
selected from various domains within the TSC2 gene and introduced into the Flag 
tagged wild-type TSC2 construct using site directed mutagenesis (site-directed 
mutagenesis work carried out by Dr Elaine Dunlop). Figure 4.4 ‘A’ indicates the 
conserved regions of TSC2. To analyse the effects of these mutations, TSC2 mutant 
constructs were once again transfected into TSC2-/- MEFs alongside the HIF-1a 
transcriptional reporter. An additional rapamycin treated condition was included so 
that the inhibition levels could be compared as a control. Western blotting analysis 
revealed that these mutants were expressing at much lower levels making the 
results more physiologically relevant unlike the previous experimentation (figure 4.4) 
where the TSC2 protein was grossly over-expressed. As figure 4.5 shows, the 
results were much more comparable to the empty vector sample than was seen in 
figure 4.4. This is likely to be due to the reduced expression levels.
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Figure 4.5 Point mutations to TSC2 confer differential abilities to inhibit HIF-1q 
when TSC2 is expressed at a physiological lower level A: TSC2-/- MEFs were 
transfected with the HIF-1a luciferase reporter construct alongside empty vector, 
wild-type TSC2 or mutant TSC2. Cells were cultured under serum starved conditions 
in media supplemented with 1 mM DMOG for 12 h prior to lysis. Cells were 
harvested in Blenis lysis buffer and analysed for HIF-1a transcriptional activity, this 
was standardised to total protein levels as determined by a Bradford assay. The 
remainder of the lysate was analysed for TSC2 expression levels by western 
blotting. Error bars indicative of standard deviation from three independent 
experiments. NS indicates Not significantly different from wild-type. * indicates p- 
value of 0.05, ** indicates p-value of 0.001. B: Chart detailing variants examined, 
Polyphen and SIFT programmes were used to indicate predictive effects of 
mutations upon protein function. Arrow indicates WT/TSC2 mutant construct 
expression.
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Interestingly, the patient derived mutations did not exhibit an on/off effect of 
inhibition, instead, many of the mutants were able to inhibit HIF-1a to varying 
degrees with the exception of the R1473Q mutant which will be discussed in more 
detail later.
The E92V mutant was able to inhibit HIF-1a activity to the same degree of 
wild-type TSC2 and statistical analysis confirmed that there was no significant 
difference between the average inhibition from wild-type and E92V indicating that the 
E92V mutation may not be pathogenic. Polyphen analysis indicated that the mutation 
maybe ‘possibly damaging’ and SIFT analysis indicated that the protein function 
would be affected (see figure 4.5 ‘B’) however it is clear from figure 4.5 ‘A ’ that this 
E92V mutant is fully functional at rescuing the heightened activity of HIF-1a activity 
in these TSC2-/- MEFs.
Each mutant of TSC2 produced a different level of inhibition of HIF-1a, which 
interestingly gives insight into the variation upon function a single point mutation can 
have to the TSC2 gene. This mutational analysis also revealed that the R1743Q  
mutant was unable to suppress HIF-1a transcriptional activity. This mutant is 
equivalent to the R1720Q mutant analysed in figure 4.4 and therefore confirms that 
expression of the mutants at more physiological levels makes the inhibition levels 
much more comparable to empty vector. Work by Dunlop et al. demonstrated that 
both the L1624P mutant and the H597R mutant had no GAP activity towards Rheb in 
vitro and were unable to suppress phosphorylation of S6K1 or 4E-BP1 in vivo. 
However, both mutants suppressed HIF-1a transcriptional activity by an average of 
31.7% and 30.1% respectively. This supports the hypothesis that TSC2 may be able 
to influence the transcriptional activity of HIF-1a independently of m TO R C I.
Interestingly the R1743Q variant is completely non-functional at suppressing 
HIF-1a. The R1743Q mutation is situated within the Ca2+-dependent calmodulin 
(CaM) binding domain of TSC2 which interestingly overlaps a transcriptional 
activation domain (TAD), see figure 4.4 ‘A’. This region has previously been 
identified by Noonan et al. as essential for TSC2 mediation of transcriptional events 
relating to steroid hormone receptors [351]. Later work indicated that the oestrogen 
receptor binds directly to TSC2 via this domain which enables its regulation at a 
transcriptional level [350]. This could suggest that the Arg1743 residue of TSC2 is 
involved in mTORCI independent modulation of HIF-1a transcriptional activity.
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Figure 4.6 R1743Q-TSC2 has no GAP activity towards Rheb: TSC1/2 complexes 
were purified from HEK 293 cells transfected with pRK7, Flag-TSC1, Flag-TSC2, or 
Flag-TSC2-R1743Q. 16 h after transfection, cells were treated with 100 nM 
wortmannin for 15 min before lysis in NP-40 lysis buffer. Flag-tagged proteins were 
then immunoprecipitated for 2 h with 80 pi of an M2-agarose affinity gel slurry. 
Immune complexes on beads were washed three times in IP wash buffer and once 
in 1 ml Rheb exchange buffer supplemented with protease inhibitors. The washed 
beads were then separated into four aliquots. Three of these were used for separate 
GAP assays, and one was resolved by SDS-PAGE and immunoblotted to determine 
protein levels. GST-Rheb (10 pg) was loaded with 100 pCi [a-32P]-GTP or 10 mM 
GDP. GAP assays were initiated by the addition of 20 pi GTP-loaded Rheb 
(approximately 1 pg GST-Rheb) to each aliquot of M2-agarose immune complexes 
described above. Assays were performed at room temperature with constant 
agitation for 20, 40, or 60 min. Reactions were stopped by the addition of 300 pi 
Rheb wash buffer containing 1 mg/ml BSA. M2-agarose immune complexes were 
removed by brief centrifugation, and nucleotide bound GST-Rheb was purified from 
the supernatant with 20 pi of a protein G slurry. After three washes with Rheb wash 
buffer, radiolabeled GTP and GDP were eluted from Rheb with 20 pi Rheb elution 
buffer at 6 8 °C for 20 min. Aliquots (1 pi) of each eluted reaction were resolved by 
thin-layer chromatography on PEI cellulose (Sigma) with KH2PO4 as the solvent.
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4.3.6 R1743Q-TSC2 has no GAP activity towards Rheb
Since Dunlop et al. did not analyse the R1743Q variant it was important to determine 
whether it was defective at repressing mTORCI signalling as seen with the L1460P 
and H597R variants. The R1743Q mutant was therefore assessed in terms of its 
status as a GAP towards Rheb using an in vitro GAP assay (GAP assays assisted 
by Dr. Andrew Tee). As figure 4.6 demonstrates, Rheb stayed predominantly in its 
GTP-bound state during incubation with the R1743Q mutant. This indicates that the 
purified TSC2-R1743Q mutant protein has no measurable GAP activity towards 
Rheb in vitro. If HIF-1a was being regulated downstream of mTORCI alone, then 
you would expect to see similar levels of inhibition with L1460P, H597R and R1743Q 
since they all show similar defects in their GAP activity towards Rheb. As figure 4.5 
‘B’ indicates, the R1743Q mutant is not able to inhibit HIF-1a whereas expression of 
both the H597R and L1460P mutants results in significant inhibition of HIF-1a (p- 
value 0.05). This adds further support to the hypothesis that TSC2 can impact HIF- 
1a activity independently of m T O R C I.
4.3.7 The CaM-binding domain/TAD of TSC2 is necessary for direct TSC2 
mediated inhibition of HIF-1a
There are two reports within the Uniprot database concerning additional mutations 
within the Arg1743 site. SIFT analysis predicts mutation at that particular site to 
‘affect protein function’ and POLYPHEN suggests that mutation to this site to be 
‘benign’ (see figure 4.5 ‘B’). I demonstrated that a glutamine substitution of arginine 
at position 1743 abolishes the GAP activity of TSC2. On the Uniprot website, 
R1743Q is a known variant but there is limited information upon the effects of this 
point mutation. Prof. Cheryl Walker’s research group was also investigating these 
mutants but in the context of their localisation. They kindly provided three TSC2 
R1743X mutant constructs for analysis. These mutants were assayed for HIF-1a 
activity in the same manner to confirm the importance of this Arg1743 residue within 
the CaM binding domain of TSC2 with respect to HIF-1a regulation. As expected, 
none of the three Arg1743 site mutants were able to inhibit HIF-1a and the effect of 
introducing these mutants to the TSC2-/- MEFs was not significantly different to 
introducing empty vector. The GAP mutant of TSC2 (L1462P) however was able to 
inhibit HIF-1a activity by an average of 39.7% (p-value 0.05) despite its lack of ability 
to inhibit m TORCI as was shown by Dunlop et al. [326]
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Figure 4.7 The CaM-binding domain/TAD of TSC2 is necessary for direct TSC2 
mediated inhibition of HIF-1q TSC2-/- MEFs were transfected with the HIF-1a 
luciferase reporter construct alongside empty vector, wild-type TSC2 or mutant 
TSC2. Cells were cultured under serum starved conditions in media supplemented 
with 1 mM DMOG for 12 h prior to lysis. Cells were harvested in Blenis lysis buffer 
and analysed for HIF-1a transcriptional activity, this was standardised to total protein 
levels as determined by a Bradford assay. The remainder of the lysate was analysed 
for TSC2 expression levels by western blotting. Error bars indicative of standard 
deviation from three independent experiments. NS indicates Not significantly 
different from wild-type. * indicates p-value of 0.05, ** indicates p-value of 0.001. 
PRK7 indicates empty vector transfection control.
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This suggests that the Arg1743 residue is critical for HIF-1a regulation, It is likely 
from this data that no substitution can be tolerated at this site, signifying the 
importance of this residue in the functioning of TSC2.
4.3.8 Nuclear localisation is not significantly altered by mutation at the 
Arg1743 site
It is well documented that TSC2 can translocate to the nucleus upon serum 
withdrawal where it interacts with and modulates the activity of several steroid 
receptor family members [350-352, 362, 369, 370]. The results of this study indicate 
that this regulation may extend to HIF-1a as well. So far I have demonstrated the 
significance of the Arg1743 residue in this activity, intriguingly, Arg1743 is the first 
amino acid of what York et al. identified as being a nuclear localisation sequence. 
Given that activated HIF-1a translocates to the nucleus (see section 1.5.3) it may be 
possible that TSC2 is able to regulate HIF-1a within the nucleus as is seen with other 
transcription factors. I hypothesised that the Arg1743 mutants may therefore have 
lost their ability to translocate to the nucleus and hence were unable to suppress 
HIF-1a.
To investigate this, TSC2-/- MEFs were transfected with the wild-type TSC2 
or the mutant construct and cultured under serum starved condition. Nuclear and 
cytoplasmic fractions were prepared and western blotting was utilised to confirm the 
localisation of TSC2. However it is clear from figure 4.8 that the R1743G mutant has 
retained its ability to translocate to the nucleus. This confirms that the mutation to the 
Arg1743 site does not impair TSC2 nuclear localisation and the hypothesis is 
rejected.
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Figure 4.8 Nuclear localisation is not significantly altered by mutation at the 
Arg1743 site: TSC2-/- MEFs were transfected with either empty vector, wild-type or 
mutant TSC2 and cultured under serum starved conditions. Cells were then lysed in 
PBS and nuclear and cytoplasmic fractions were generated as described in section 
2.3.6. Western blotting was then utilised to determine the localisation of TSC2.
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4.3.9 Immunohistochemical analysis of HIF-1a targets
This study has so far demonstrated that rapamycin is able to normalise HIF-1a 
activity and VEGF expression in the absence of TSC1 but not TSC2. This suggests 
that TSC patients with TSC2 mutations may be less responsive to rapamycin 
treatment and may also exhibit higher levels of vascularisation than those with TSC1 
mutations. This is consistent with a more severe phenotype which appears to 
present with patients exhibiting TSC2 mutations. To investigate this further, 
immunohistochemical techniques were employed to see if there was differential 
expression of HIF-1a targets between TSC1 and TSC2 heterozygous mice.
TSC mouse models were engineered in Prof. David Kwiatowski’s lab to 
generate mice with heterogenous inactivating mutations to either the TSC1 or TSC2 
genes [331, 371]. Kidney samples extracted from these mice which had been 
embedded in paraffin blocks were kindly donated by Prof. Jeremy Cheadle’s 
laboratory. Sections were taken from both TSC1-/+ and TSC2 -/+ mice and then 
stained with VEGF-A antibodies.
Results demonstrated a fair degree of peripheral staining of the tubules which 
is to be expected as VEGF-A is thought to play a role in the maintenance of 
glomerular capillary endothelial fenestrations [372]. Unfortunately as figure 4.9 
demonstrates, staining of VEGF-A was highly variable between samples of the same 
genotype. It was, therefore, not possible to make justified comparisons between 
them. It is likely that the variable staining is a result of varying degrees of hypoxia 
within each region of the tissue. This may have produced the localised spots seen 
randomly across both genotypes (arrows in figure 4.9 indicate VEGF staining 
hotspots) or it may be indicating areas where mTORCI activity is increased. 
However, due to the variable nature of the results, it was decided that this route of 
enquiry would not be continued.
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Figure 4.9 Immunohistochemical analysis of HIF-1a targets: Paraffin embedded 
4 pm kidney sections were cut from Tsc1+/' (‘A ’ and ‘B’) and Tsc2+/" mice (‘C’ and 
‘D’). Immunohistochemistry analysis was carried out by Cardiff University Central 
Biotechnology Services and kidney sections from each genotype were stained for 
VEGF-A as described in section 2.3.22. Slides were viewed and photographed under 
a light microscope. Arrows indicate VEGF ‘hotspots’.
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4.4 Discussion
This study provides evidence of a secondary pathway by which TSC2 is able to 
suppress HIF-1a activity. In the comparison of HIF-1a gene targets between the cell 
lines (figure 4.2) it is clear that rapamycin exerts more of an inhibitory effect on the 
TSC1-/- cells rather than the TSC2-/- cells. Crucially, in TSC1-/- MEFs, rapamycin 
treatment normalises VEGF-A and BNIP3 expression to the same level as is seen in 
the TSC1+/+ cells indicating that the elevation in HIF-1a activity is wholly a result of 
enhanced m TORCI activity in these cell lines. This is not the case in the TSC2-/- 
cells whereby the inhibition of m TO RCI results in less than 50% inhibition of VEGF- 
A expression, inferring a role for TSC2 in the inhibition of HIF-1a which does not 
involve mTORCI signalling.
This has implications in the development of treatments for TSC patients 
particularly as the expression of HIF-1a target genes such as VEGF can contribute 
significantly to the manifestations of the disease.
This is not the first time that TSC2 has been implicated in the regulation of 
HIF-1a gene targets. It was noted in 2003 by Brugarolus et al. that VEGF-A 
expression was only partially reduced in TSC2-/- MEFs upon rapamycin treatment. It 
was found that under these conditions, HIF-1a levels protein levels were not 
elevated, leading to the conclusion that VEGF-A could be regulated by TSC2 
independently of m TORCI and HIF-1a. However, only HIF-1a protein levels were 
investigated. Previous investigations have demonstrated that HIF-1a transcriptional 
activity can be enhanced without affecting protein levels and this can be modulated 
by ERK kinase activity [373-375]. Figure 4.1 shows that although HIF-1a protein 
levels are undetectable by western blotting in the rapamycin treated TSC2-/- MEFs 
(‘4.1 ’B’), HIF-1a transcriptional activity was still significantly higher than in cells 
transfected with TSC2. So while Brugarolus et al. concluded that TSC2 could 
modulate VEGF-A independently from mTOR and HIF-1a [365], this study provides 
evidence that in fact HIF-1a is being modulated by TSC2 and this in turn modulates 
VEGF-A rather than a direct interaction between TSC2 and VEGF-A. This also 
highlights the benefits of using transcriptional assays as a more sensitive indication 
of gene activity compared with western blotting, particularly in the case of HIF-1a 
which given it’s short half life during normoxia, is notoriously difficult to purify and 
detect by western blotting.
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The cell lines used in this chapter were a kind donation from Prof. David 
Kwiatkowski. The TSC2-/- MEFs are also p53 deficient to confer viability and studies 
have demonstrated that p53 and its downstream substrate MDM2 can act to inhibit 
HIF-1a when activated or over-expressed [376]. Therefore, differences in HIF-1a 
activity between the cell lines could be as a result of differences in p53 status [376]. 
Brugarolus et al., however, demonstrated that TSC2 knockdown in p53+/+ U20S 
sarcoma cell lines also caused an elevation in HIF-1a activity [365], furthermore, 
TSC2+/+ cells exhibited very low levels of HIF-1a activity despite the lack of p53 so it 
is unlikely that this effect is caused by p53 deletion.
Figure 4.3 also demonstrates that S6K1 kinase activity can be abolished 
equally in both TSC1 and TSC2 deficient cell lines, yet the TSC2-/- cells are still less 
sensitive to rapamycin inhibition of HIF-1a. This indicates that m TORCI activity is 
similar between the two cell lines and that they are equally sensitive to rapamycin 
induced downregulation of m TO R C I. This supports the hypothesis that the elevation 
of HIF-1a transcriptional activity observed upon rapamycin treatment is mTORCI 
independent.
Functional analysis of TSC2 mutations in terms of their ability to inhibit HIF-1a 
also provided an interesting insight into the pathogenicity of TSC. Figure 4.5 ‘B’ 
demonstrates that pathogenic mutations of TSC2 do not result in a ‘switch-off’ of 
inhibition like you may expect, in fact the range of inhibition was quite varied. The 
HIF-1a assay of the mutants provided by Dr. M. Nellist produced variable results 
however quite a dramatic level of inhibition was seen in all cases (figure 4.4’B’). This 
was unexpected but as postulated earlier, may be a result of the much higher 
expression levels seen with the TSC2 mutant constructs. Since the HIF-1a assay 
comparing the TSC2 mutant constructs generated in the pcDNA3.1 vector produced 
results much more comparable to the empty vector sample (lane 2 of figure 4,5 ‘B’), 
it is likely that the differing effects observed were a result of increased expression of 
the constructs in the original pcDNA3 vector provided by Dr. M. Nellist in comparison 
to the expression constructs previously used. The higher level of protein expression 
within the cells may have interfered with the protein translational machinery and 
could have induced ER stress within the cell. This could cause an indirect reduction 
in HIF-1a activity as was seen in chapter 3, whereby inhibition of mTORCI mediated 
cap-dependent translation suppressed elevated HIF-1a activity within TSC2-/- MEFs 
(see figure 3.5’E’). Alternatively the increased protein levels within the cell may have
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interfered with DNA binding of HIF-1a within the nucleus to prevent its association 
with HIF response elements on target genes. It is also plausible however, that the 
mutants do retain some residual GAP activity towards Rheb and may only inhibit 
mTORCI when grossly overexpressed.
The HIF-1a assay of the mutants generated in the lower expressing 
pcDNA3.1 vector proved to be far more informative with a much higher degree of 
variations between the mutant constructs. For instance the E92V mutant of TSC2 
was able to induce complete inhibition of HIF-1a and was indistinguishable from wild- 
type in this assay.
Further work by Dunlop et al. showed the E92V mutant to be fully functional 
with regards to inhibition of S6K1 and 4E-BP1 and also demonstrated GAP activity 
towards Rheb [326]. Clinical details revealed that the patient carrying this mutation 
was suffering from seizures, a cortical tuber and had three or more hypomelanotic 
macules, fulfilling two of the major criteria considered when diagnosing TSC which is 
sufficient evidence to give a definitive diagnosis (in accordance with the TSC  
alliance). Further genetic analysis however revealed that the E92V mutation was 
also present in the parents of two unrelated patients presenting with this mutation. 
The parents did not meet any of the criteria for a diagnosis of TSC therefore it is 
likely that the E92V mutation is a non-pathogenic genetic polymorphism and thus is 
not the cause of TSC in this patient.
The R505Q mutation produced a moderate level of inhibition of HIF-1a, 
similar to that of rapamycin treatment. Patient information revealed that this 
individual suffered several neuropsychological manifestations similar to those seen 
in TSC patients, however they did not meet the full diagnostic criteria for TSC. The 
functional analysis carried out by Dunlop et al. indicated that TSC2 mutated at this 
site did not have GAP activity towards Rheb and was unable to inhibit 4E-BP1 
phosphorylation. It was, however, able to inhibit Rheb induced S6K1 activity. This is 
unusual and implies a partial loss of function of TSC2. Interestingly only the HIF-1a 
activity assay indicated partial function for this mutation. This suggests that the HIF- 
1a transcriptional assay could be a useful tool for examining subtle changes to 
function, and could be utilised as an indicator of TSC2 protein functionality in the 
analysis of uncharacterised mutations. Whilst other functional assays tend to result 
in a ‘functional’ or ‘non-functional’ assessment of TSC2, the quantitative nature of the
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HIF-1a assay could indicate TSC2 mutations which result in partial loss of function 
and therefore has potential for use as a prognostic tool.
The most significant finding from mutational analysis of TSC2 was the 
highlighted differences between apparently non-functional pathogenic mutations and 
the R1743G/Q/W mutants. Both H597R and L1460P mutations were shown to be 
non-functional in all aspects analysed by Dunlop et al., SIFT and Polyphen analysis 
indicated that both mutations would affect protein functionality and were likely to be 
damaging. In addition to this, clinical information of patients presenting with these 
mutations was obtained and both fulfilled the criteria for TSC diagnosis. Yet the 
functional HIF-1a assay revealed that both of these were able to cause significant 
inhibition of HIF-1a whereas the R1743Q mutant was not. This provides further 
evidence that TSC2 can modulate HIF-1a independently of m T O R C I It also 
indicates the potential significance of the CaM-binding domain/TAD within TSC2 in 
potentially modulating the transcriptional activity of HIF-1a, however further research 
is required for determining the mechanisms governing this.
There are reports in the literature indicating that calcium influx during hypoxia 
can cause an increase in the transcriptional activity of HIF-1a without affecting 
protein levels [375]. This is similar to the effect seen in figure 4.1, whereby 
transcriptional activity of HIF-1a was still elevated when mTORCI was inhibited yet 
protein levels were normalised. It has also been demonstrated that this effect can be 
inhibited with the use of ERK inhibitors [374, 375]. Further studies investigating 
independent functions of TSC2 demonstrated that TSC2 mediated inhibition of the 
oestrogen receptor is dependent upon attenuation of ERK1-2 MAP Kinase [362]. 
Since ERK1-2 MAP Kinase inhibition can also prevent calcium dependent 
enhancement of HIF-1a activity it is possible that a similar mechanism occurs in 
TSC2 mediation of HIF-1a. It could suggest a potential model for HIF-1a inhibition 
whereby calcium induced binding of calmodulin to TSC2 results in a displacement of 
HIF-1a, prompting its activation in an ERK1-2 MAP kinase dependent manner. 
However at this stage of the investigation it is only possible to speculate upon 
potential mechanisms. Further research into whether TSC2 is required for calcium 
dependent increases in HIF-1a activity could establish whether this mechanism is 
plausible. Furthermore, it would be useful to determine whether TSC2 can in fact 
interact directly with HIF-1a itself.
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Work by Kim et al. has also been carried out investigating how mutations to 
the Arg1743 site of TSC2 effect its localisation within the cell. Schluter et al. used in 
silico analysis to identify proteins containing PTS sequences, (peroxisomal targeting 
sequences) and demonstrated that TSC2 contains a PTS1 sequence in its carboxy- 
terminus. PTS sequences are located on proteins which contribute to peroxisome 
mediated metabolic processes. Peroxisome mediated processes include (3-oxidation 
of long and very long chain fatty acids, prostaglandins and leukotrines. They are also 
involved in the synthesis of bile acids and cholesterol. The cell relies on specific 
peroxisomal import receptors (PEX’s) to identify proteins required for these 
processes and they do so via recognition of PTS sequences. This is the first time 
TSC2 has been implicated in peroxisome mediated processes.
Kim et al. showed that TSC2 could localise to the peroxisome and that 
mutation to the Arg1743 site prevented TSC2 interaction with the peroxisome import 
receptor PEX5. The work also indicated that TSC2 was able to modulate ROS 
(reactive O2 species) induced suppression of m TORCI signalling, it was revealed 
that none of the CaM mutants analysed in this study (R1743G/W/Q) were able to 
mediate this suppression. The study suggests that TSC1, TSC2 and Rheb are able 
to translocate to the peroxisome where TSC1 and TSC2 function together as a 
heterodimer to inhibit the small G-protein Rheb in response to ROS.
Interestingly, ROS has been shown to propagate HIF-1a activity through very 
loosely defined mechanisms [377]. Furthermore it has been shown that mutant forms 
of TSC2 can increase ROS production through Rac-1 [378], this may therefore 
indicate that the elevation of HIF-1a activity seen with rapamycin treatment is a result 
of increased ROS production due to non-functional TSC2. The Arg1743 mutants 
which are unable to translocate to the peroxisome may be completely ineffective at 
suppressing ROS or inhibiting mTOR, explaining the high levels of HIF-1a activity. 
Further work is required to determine the exact relationship between ROS, TSC2 
and HIF-1a.
There is also some evidence in the literature indicating that HIF-1a and its 
associated hydroxylases can locate to the peroxisome in hepatocytes [379], it is 
thought that this may be an additional mechanism of HIF-1a regulation. This has only 
been demonstrated in hepatocytes but if this mechanism does extend to other cell 
types, it is possible that TSC2 causes localisation of HIF-1a to the peroxisome as a 
way of mediating its inhibition. This would explain why the R1743G/Q/W mutants of
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TSC2 which are incapable of peroxisome localisation are unable to inhibit HIF-1a. 
This may also explain the elevated HIF-1a protein levels seen in TSC2-/- MEFs.
There are reports in the literature implicating the Arg1743 site with Ca2+- 
dependent calmodulin binding of TSC2, modulation of steroid receptor transcription 
and to peroxisomal localisation. Disruption of any of these processes could be 
responsible for the inability of the R1743G/W/Q mutants to inhibit HIF-1a and may 
hold the key to understanding TSC2 mediated mTORCI independent regulation of 
HIF-1a, however further experimentation is required to clarify the mechanism.
Importantly however, this data indicates that rapamycin may not be sufficient 
to normalise VEGF expression in TSC patients with specific TSC2 mutations to the 
CaM-binding domain or exhibiting c-terminal truncations. It may therefore be 
appropriate to trial a combinational therapy approach for these patients,who may 
respond more favourably to the use of mTORCI inhibitors in conjunction with 
specific VEGF of HIF-1a inhibitors.
The focus of research in TSC has now switched towards clarifying TSC1 and 
TSC2 independent functions which may also become dysregulated in TSC patients 
but would not be treatable with rapalogues. It is important to determine these 
functions particularly in the light of the current clinical trials in order to assess the 
usefulness of these therapeutics effectively and to improve our understanding of the 
pathology of the disease.
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CHAPTER 5: CHARACTERISATION OF mTORCI DIRECTED
REGULATION OF STAT3
5.1 Introduction
It was initially thought that each STAT protein had a specific receptor and therefore a 
specific regulatory role within the cell. Knockout studies have indicated that this is 
true for the most part, with one exception being STAT3 [188]. STAT3 is activated by 
a wide range of stimuli and influences a multitude of biological processes including 
the acute phase immune response, angiogenesis, cell growth, survival and 
migration, cell cycle progression and tumorigenesis. It has also been demonstrated 
to play a seemingly contradictory role in the regulation of apoptosis [188, 380-382].
STAT3 directed responses are mediated primarily via activation of the gp130 
receptor subunit by cytokines [380]. This in turn activates the JAK/STAT signalling 
pathway, where STAT3 plays a central role in mediating signals to the nucleus to 
regulate gene expression [188, 380]. When STAT proteins are activated they 
dimerise and translocate to the nucleus where they bind to promoter regions of 
target genes in order to activate their transcription. (See section 1.5.4).
As described in section 1.5.4, STAT3 dimerisation and activation is primarily 
modulated via phosphorylation of Tyr705. A serine phosphorylation site has been 
identified on STAT1, 3, 4, 5a and 5b which appears to influence STAT transcriptional 
activity. There is clear evidence within the literature that phosphorylation of the 
Ser727 residue of STAT1 increases its transcriptional activity [383-385]. However 
there are mixed reports defining the role of Ser727 phosphorylation in STAT3 
activation.
The majority of studies in this area are based around S727A mutants of 
STAT3. Wen et al. demonstrated an approximate 50% reduction in the activation of a 
transfected IRF-1 promoter (a specific STAT3 target) in cells expressing the S727A  
mutant in comparison to wild-type, suggesting that Ser727 phosphorylation is 
required in addition to Tyr705 phosphorylation for maximal activation of STAT3 [383].
However a similar study saw no difference between the S727A mutant and 
the wild-type in the activation of the haptoglobin acute phase reporter [386], 
indicating that its activity is not dependent upon phosphorylation of the Ser727 site. 
This may suggest that the phosphorylation status of these critical residues may 
effect what genes are transcribed. Consistent with this Ser727 phosphorylation of
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STAT3 in the absence of Tyr705 phosphorylation appears to promote prostate 
tumourigenesis which may suggest that the Ser727 site is more influential in the 
over-proliferation phenotype produced with constitutive STAT3 activation [382]. It 
has also been suggested that Ser727 phosphorylation may function to negatively 
regulate Tyr705 phosphorylation [201] [387]. Furthermore, in contrast to traditional 
thinking, recent research has indicated that Ser727 phosphorylation alone is 
sufficient to activate STAT3 in the absence of Tyr705 phosphorylation [382]. This is 
supported by more recent studies revealing that STAT3 can translocate to the 
nucleus in the absence of Tyr705 phosphorylation via interaction with importin-a3, 
indicating a mechanism by which Ser727 phosphorylation may be sufficient to induce 
STAT3 dimerisation [388, 389]. Furthermore, it has also been demonstrated that 
Ser727 phosphorylation of STAT3 is essential for Ras mediated oncogenic 
transformation. Intriguingly Gough et al. demonstrated that STAT3 was actually 
targeted to the mitochondria and oncogenic transformation was dependent upon 
Ser727 phosphorylation but not Tyr705 phosphorylation, the SH2 domain or its DNA 
binding. STAT3 therefore has functions outside of it’s role as a transcription factor 
governed by Ser727 which appear to increase the chance of malignant 
transformation [113].
There are mixed reports within the literature concerning the identity of the 
kinase(s) responsible for Ser727 phosphorylation. Tyr705 phosphorylation is known 
to be modulated primarily by JAK1/2 however several kinases have been linked with 
Ser727 phosphorylation including JNK-1 [390], MEKK1 [391] ERK [392], Protein 
Kinase C [393, 394] and mTOR [202, 395]. A study by Yokogami et al. demonstrated 
that CNTF (ciliary neurotrophic factor) stimulation could activate both Tyr705 and 
Ser727 phosphorylation causing maximal STAT3 activation. They provided evidence 
that mTOR was able to phosphorylate a STAT3 peptide corresponding to residues 
720-731 in an In vitro kinase assay, indicating the first evidence for mTOR as a direct 
regulator of STAT3. This study aims to verify this and clarify the role of mTOR in the 
regulation of STAT3. Furthermore, there are several studies in the literature linking 
HIF-1a and STAT3. It has been suggested that STAT3 is required for full activation 
of HIF-1a [209]. Other studies have indicated that inhibition of STAT3 results in 
inhibition of HIF-1a mediated gene expression and that STAT3 is required for HIF-1a 
activation [211]. Activation of STAT3 has also been demonstrated to result in
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stabilisation of HIF-1a protein [381]. This study also aimed to establish whether 
mTOR is involved in regulating this interaction.
STAT3 has been described as an oncogene and its inappropriate activation is 
associated with pathogenesis, aberrant Ser727 phosphorylation has been linked to 
both chronic lymphocytic leukaemia [396] and oncogenic transformation by v-src 
[397]. Elevation of m TO R C I, HIF-1a and STAT3 are common in many cancers and 
may contribute to cancer pathogenesis through dysregulation of cellular growth, 
survival, proliferation and angiogenesis. Establishing the regulatory mechanisms 
behind this could provide potential new pharmacological targets and also facilitate 
our understanding behind hamartoma disorders resulting from inappropriate 
mTORCI activation. This work utilised a STAT3-inducible luciferase reporter (see 
section 2.3.19) which contains multiple copies of the STAT3 response element 
upstream of a firely-luciferase reporter in order to observe effects of mTORCI upon 
STAT3 mediated gene-expression.
5.2 Methods 
5.2.1 Plasmids
Gateway recombination cloning technology (Invitrogen) was utilised to generate 
GST-STAT3 from an I.M.A.G.E. clone (purchased from ATCC), in accordance with 
manufacturers guidelines.
5.2.2 STAT3 luciferase assays
The STAT3 luciferase reporter construct was transfected into HEK293 cells 
cultivated in 12 well plates. Cells were grown under serum starved conditions and 
treated with 25ng/ml CNTF and 50mM rapamycin overnight prior to lysis. Each 
luciferase assay was carried out in triplicate at least three times. Cells were 
transfected using lipofectamine 2000 and lysed with Blenis lysis buffer as described 
in section 2.3.4.3. Half the lysate was retained for western blotting analysis of over­
expressed proteins (see below). Cells were analysed for luciferase assay as 
described in section 2.3.19, with three measurements being taken per lysate to 
check the consistency of the readings. Samples were also analysed for total protein 
using a NanoDrop spectrophotometer and standardised accordingly. Results are 
representative of at least three independent experiments.
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5.2.3 Wetern blotting
Western blotting was carried out as previously described in section 2.3.10. Lysates 
analysed for the phosphorylation of STAT3 (P-STAT3 Ser727/Tyr705) were either 
subjected to three 5 second sonication cycles (30 microns) with incubation upon ice 
between cycles. Or, where indicated lysates were passed through a QiaShredder 
(Qiagen) three times in quick succession via centrifugation in order to visualise 
nuclear proteins. Where indicated, western blotting was subjected to densitometry 
analysis using Image J software to help provide a clearer picture of differential 
protein expression or phosphorylation.
5.2.4 Far westerns
Recombinant GST-STAT3 was generated from HEK293 cells transfected with the 
GST-STAT3 vector using calcium chloride transfection reagent (as described in 
section 2.3.5) from rapamycin treated and untreated cells (rapamycin treatment was 
for 1hour prior to lysis at 50nM). Cells were lysed in Rheb lysis buffer containing 
protease inhibitors (excluding DTT) before being subjected to 3x5 second sonication 
cycles as described above. Lysates were then subjected to high centrifugation for 
removal of cellular debris before being incubated with glutathione-Sepharose beads 
for 2 h at 4°C. IP’s were then washed as described in section 2.3.13, GST- 
purification. Recombinant proteins were then dotted onto membranes and the far 
western was carried out as described in section 2.3.11.
5.2.5 mTORCI kinase assay
Recombinant GST-STAT3 was purified as described above from HEK293s. 
Recombinant GST-4E-BP1 was purified from serum starved cells in the same 
manner. mTORCI kinase assays were carried out as described in section 2.3.15 at 
30°C for 1 h with gentle agitation.
5.2.6 Radiolabelling
Cold assay: HEK293 cells were transfected using lipofectamine 2000 transfection 
reagent as described in section 2.3.5. Cells were cultured under serum starved 
conditions, 2 h prior to lysis cells were stimulated with 25ng/ml of CNTF, 1 h prior to 
lysis cells were treated with 50nM of rapamycin and 5nM okadaic acid for 30 min 
prior to lysis. Cells were then stimulated with 10pg/ml insulin where indicated. Cells
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were lysed in Nuclear Proteins Lysis buffer (see section 2.2) supplemented with 
protease inhibitors (excluding DTT), 20nM Okadaic acid and a phosphatase inhibitor 
cocktail (GE Healthcare). Lysates were homogenised using QIAShredders (Qiagen) 
and were passed through the column three times using high speed centrifugation. 
50pl of total lysate was retained for analysis via SDS-PAGE and western blotting. 
The remainder of lysate was then incubated with glutathione-Sepharose beads for 2 
hs at 4°C with rotation. Beads were washed 3 times with lysis buffer (supplements as 
above) before a final 10 min wash with rotation. GST-STAT3 was then eluted in 
Rheb storage buffer supplemented with 30mM glutathione plus protease and 
phosphatase inhibitors and analysed for P-STAT3 Ser727 and Tyr705 using SDS- 
PAGE and western blotting.
Hot assay: HEK293 cells were cultured in phosphate free media for 4 h, cells were 
then treated (as above) and pulsed with 5 mCi of [32P]-orthophosphate for 2 h. A 
GST-purification was carried out as described, eluted proteins were analysed for 
incorporation of radiolabel using SDS-PAGE, with autoradiography for visualisation.
5.3 Results
5.3.1 Effects of rapamycin treatment upon Ser727 phosphorylation of STAT3.
It was reported in the literature that Ser727 phosphorylation was required for 
maximal activation of STAT3 during CNTF signalling, Yokogami et al. showed 
evidence that Ser727 phosphorylation may be mediated by mTORCI under CNTF 
stimulation, I therefore decided to look at STAT3 phosphorylation in this context.. To 
do this, the effects of rapamycin treatment upon CNTF mediated phosphorylation of 
STAT3 were investigated in vivo. Untransfected HEK293 cells were analysed for 
STAT3 phosphorylation under conditions of CNTF stimulation in combination with 
rapamycin pre-treatment. As reported in the literature, just 15min of CNTF 
stimulation robustly induced Tyr705 phosphorylation (compare lanes 1 and 2) of 
STAT3. This phosphorylation was unaffected by rapamycin treatment. CNTF 
appeared to weakly increase Ser727 phosphorylation of STAT3 (compare lanes 1 
and 2) after 15 min of treatment, supporting the notion that Tyr705 may act as a 
priming phosphorylation site.
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Figure 5.1: Effects of rapamycin treatment upon P-STAT3 Ser727
phosphorylation: Untransfected HEK293 cells were cultured under serum starved 
conditions. Cells treated with rapamycin were pre-treated for 1h prior to stimulation 
with CNTF. Cells were stimulated with CNTF and lysed at the indicated time points. 
Lysates were then analysed for phosphorylation of STAT3 at Tyr705 and Ser727 
with (3-actin implemented as a loading control using SDS-PAGE and western blotting 
with phospho-specific antibodies. Image-J software was used to determine 
densitometry of Ser727 phosphorylation, with results being standardised to 
unstimulated (lane 1).
169
Rapamycin reduced the level of phosphorylation of STAT3 at Ser727 in 
unstimulated cells and at the first time point. After 15min of CNTF stimulation, the 
level of Ser727 phosphorylation in the rapamycin pre-treated samples was 
significantly reduced (compare lanes 2 and 5) in agreement with Yokogami’s study.
In contrast to Yokogami’s work however, there appears to be a reduction in 
the basal level of Ser727 phosphorylation in the rapamycin treated cells (compare 
lanes 1 and 4) which may suggest that mTOR is able to phosphorylate STAT3 in the 
absence of CNTF stimulation.
This difference may be occurring due to the difference in cell lines as Yokogami’s 
study utilised human neuroblastoma NBFL cells whereas this experiment was 
carried out in HEK293 cells. This data supports the hypothesis that mTORCI is 
involved in the fine tuning of STAT3 activation.
5.3.2 STAT3 Ser727 phosphorylation shows sensitivity to rapamycin inhibition
There has been much debate within the literature regarding how the phosphorylation 
status of the Tyr705 and Ser727 relates to the transcriptional activity of STAT3. 
Dogma dictates that like other STAT proteins, Tyr705 phosphorylation is necessary 
for translocation to the nucleus and hence activation. However, several studies have 
shown evidence that STAT3 can translocate to the nucleus through direct interaction 
with importin-a3, this appears to be modulated via the Ser727 site independently of 
Tyrosine phosphorylation [388, 389]. I therefore wanted to determine how the 
phosphorylation status of both sites corresponded to STAT3 transcriptional activity.
To do this I obtained a STAT3 transcriptional luciferase reporter construct 
from Panomics and transfected it into HEK293 cells to observe the effects of CNTF 
and rapamycin treatment upon STAT3 transcriptional activity. Cells were treated 
overnight with both rapamycin and CNTF to allow an accumulation of luciferase and 
analysed the following day. CNTF induced a substantial increase in STAT3 
transcriptional activity -  compare bars 1 and 3, however, this is in contrast with 
Yokogami’s results that showed a 40 fold increase in STAT3 transcriptional activity 
upon CNTF stimulation. In the case of unstimulated cells, Yokogami saw virtually no 
STAT3 transcriptional activity within the NBFL cell lines, this could indicate therefore 
that the HEK293s used within this study have a significantly higher basal level of
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STAT3 activity than the NBFL cell line. This could explain why they were only able to 
detect mTORCI input in the context of CNTF signalling.
The luciferase assay also revealed that STAT3 transcriptional activity was 
sensitive to inhibition from rapamycin, particularly in the context of CNTF signalling. 
Rapamycin caused an average 55.8% reduction in the transcriptional activity of 
STAT3 in CNTF treated cells, giving a highly significant p-value of less than 0.001. In 
the case of unstimulated cells, rapamycin caused an average 30% reduction in 
STAT3 activity but this result was not significant. This supports Yokogami’s work 
which demonstrated a similar level of inhibition by rapamycin in CNTF stimulated 
cells.
Western blot analysis was carried out upon lysates to assess the 
phosphorylation levels. Tyr705 phosphorylation was robustly induced by CNTF 
stimulation and unaffected by rapamycin treatment, as is consistent with the 
literature. I hypothesised that the Ser727 phosphorylation would mirror the 
transcriptional assay results, this however did not prove to be the case.
Ser727 phosphorylation was fairly weak in the absence of CNTF, although 
retained its sensitivity to rapamycin inhibition as was seen in figure 1. Interestingly, 
there was an increase in Ser727 phosphorylation with CNTF stimulation which was 
not seen in figure 5.1. This may be a result of the prolonged overnight CNTF 
treatment as opposed to the shorter lysis time points utilised in figure 1. Furthermore, 
this increase did not appear to be effected by rapamycin, although the transcriptional 
assay did indicate a reduction in STAT3 transcriptional activity. There are several 
possible explanations for this discrepancy which are discussed later. I concluded that 
the sonication of the sample prior to running SDS-PAGE was not sufficient to break 
down the nuclear membranes within the sample and therefore may not represent all 
of the activated STAT3 within the cells. This would explain the weak phosphorylation 
levels seen at Ser727 and why phosphorylation levels did not correspond with 
STAT3 transcriptional activation levels. In order to address this, a different approach 
was taken to extract nuclear STAT3, described later.
It was reported in Yokogami’s paper that CNTF treatment was able to activate 
JAK/STAT signalling leading to Tyr705 phosphorylation of STAT3 mediated by 
JAK1. In addition to this, Yokogami’s study demonstrated that CNTF treatment of 
HEK293T cells also caused upregulation of the PI3K pathway, resulting in mTOR 
activation.
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Figure 5.2 Basal STAT3 Ser727 phosphorylation shows sensitivity to 
rapamycin inhibition: HEK293 cells were transfected with the STAT3 inducible 
luciferase reporter construct (Panomics), cells were cultured under serum starved 
conditions but treated with CNTF/Rapamycin where indicated for 12 h prior to lysis. 
Cells were then harvested in Blenis lysis buffer supplemented with protease 
inhibitors and sonicated as described in section 2.3.4.3. Total lysate was analysed 
for STAT3 transcriptional activity. Results are representative of three independent 
experiments, and standardised to total protein levels as determined by a Bradford 
assay. Error bars indicative of standard deviation from three independent 
experiments. * indicates p-value significance <0.05, ** indicates significance <0.001. 
The remainder of the lysate was analysed for phosphorylation of STAT3 at Tyr705 
and Ser727 as well as rpS6 to observe the effects of rapamycin using SDS-PAGE in 
conjunction with western blotting using phospho-specific antibodies.
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To confirm whether this was the case in the HEK293E cells utilised in this 
study, and also to check the efficacy of the rapamycin treatment, the lysates were 
also analysed for phosphorylation of rpS6 as readout of m TORCI activity within the 
cells. Unexpectedly, CNTF treatment was not able to significantly upregulate 
phospho-rpS6 levels, although phospho-rpS6 levels did appear to be less sensitive 
to inhibition from rapamycin in CNTF treated cells compared to untreated. (See lanes 
2 and 4). This may be a difference between the HEK293 subtypes of cell line, or it 
could indicate that CNTF stimulation is causing down-regulation of phosphatases 
acting towards rpS6.
5.3.3 Cells expressing an active mTOR mutant demonstrate increased Ser727 
phosphorylation
An alternative approach was taken in the preparation of lysates for the following 
experiment. In previous chapters, nuclear and cytoplasmic fractions were produced 
utilising hypertonic and hypotonic buffers (see methods section 2.3.6). Since these 
buffers were not compatible with the luciferase assays or GST purification using 
glutathione-Sepharose-beads, a new approach had to be devised for nuclear 
preparations. To address this, QIA shredders were obtained from Qiagen. QIA 
shredders were used to uniformly homogenize lysates and shred DNA and were 
utilised for mRNA extraction in chapters 3 and 4. Cells were lysed normally and 
instead of sonication, were passed three times through the QIA shredder before 
being subjected to SDS-PAGE. In this experiment, the constitutively active mutant of 
mTOR, E2419K was utilised in conjunction with the Raptor mutant 4 construct. 
These mutants proved useful in the analysis of m TORCI directed substrate 
phosphorylation in chapter 3, where I was able to demonstrate that E2419K mutant 
expressed higher kinase activity towards 4E-BP1 and HIF-1a as well as identifying 
Raptor mutant 4 as a dominant inhibitor of mTORCI signalling. I therefore decided to 
examine STAT3 activation within cells expressing either the wild-type or active 
mutant of mTOR alongside either Raptor/ or Raptor mutant 4 to establish whether 
mTORCI activity corresponded with STAT3 activity.
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Figure 5.3 Cells expressing an active mTOR mutant demonstrate increased 
Ser727 phosphorylation: HEK293 cells were transfected with the STAT3 inducible 
luciferase reporter construct (Panomics) in conjunction with mutants of 
mTOR/Raptor as indicated. Cells were cultured under serum starved conditions and 
harvested in Blenis lysis buffer. Lysates were then passed three times through the 
QIA shredder for homogenisation using high centrifugation. Lysates were then 
analysed for STAT3 transcriptional activity as described in section 2.3.19 and 
western blotting with phospho-specific antibodies was used to determine 
phosphorylation of STAT3 and mTOR/Raptor expression. Image J was used to 
determine densitometry of Ser727 phosphorylation. Luciferase results are 
representative of three independent experiments, and standardised to total protein 
levels as determined by a Bradford assay. Error bars indicative of standard deviation 
from three independent experiments. * indicates p-value significance <0.05.
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As hypothesised, STAT3 activation (as determined by the transcriptional 
assay) is increased in cells expressing the constitutively active E2419K mutant in 
comparison to those expressing wild-type (compare lanes 1 and 3, p-value: <0.05). 
Furthermore this increased activity is inhibited when the active E2419K mTOR 
mutant is co-expressed with the dominant inhibitor of m TORCI, Raptor mutant 4 
(compare lanes 3 and 4, p- value, <0.05). This is consistent with the behaviour of 
other mTORCI substrates 4E-BP1 and HIF-1a (see figure 3.1 and 3.2).
When co-expressed with wild-type mTOR, Raptor mutant 4 appeared to 
cause a reduction in STAT3 transcriptional activity as expected, however, this was 
coupled with an increase in Ser727 phosphorylation (see densitometry figures, 
compare lanes 1 and 2). These discrepancies between the phosphorylation status 
and the transcriptional activity of STAT3 indicates the possibility that STAT3 
activation could be modulated via phosphorylation at another and yet undetermined 
site.
Alternatively, and perhaps more likely is the possibility that prolonged 
mTORCI inhibition due to expression of Raptor mutant 4 may have initiated 
feedback mechanisms from other pathways that further increase STAT3 activation. 
Since there have been several kinases reported to phosphorylate STAT3 at Ser727 
this seems plausible. The transcriptional assay is a result of overnight accumulation 
of luciferase levels and the readout is a summary of STAT3 activity over time, 
whereas western blotting measures the phosphorylation level at the time of lysis. It is 
therefore possible that the long-term suppression of m TORCI through raptor mutant 
4 expression may have triggered upregulation of other kinases functioning to 
phosphorylate STAT3 by the time of lysis. Feedback pathways may not have been 
activated in the cells expressing the active mutant alongside Raptor mutant 4 since 
these cells would have exhibited a higher basal m TORCI activity due to expression 
of the E2419K mutant. This theory is supported by the transcriptional assay which 
shows that Raptor mutant 4 is only able to reduce the activity of STAT3 in these cells 
to a level similar to those expressing wild-type mTOR and Raptor (Lane 4 compared 
to lane 1).
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5.3.4 4E-BP1 binds avidly to mTORCI while STAT3 does not
This work so far shows evidence of a role for mTORCI in STAT3 Ser727 
phosphorylation, however, it can be difficult to dissect specific phosphorylation 
events using in vivo experimentation as it is impossible to rule out cross talk between 
different pathways. There is clear evidence in the literature that Raptor is a key 
component of the m TORCI complex and is required for substrate recognition (see 
section 1.3.4). I demonstrated in chapter 3 how purified recombinant 4E-BP1 protein 
binds to Raptor using a far western approach (figure 3.5’B’).
I wanted to establish whether m TO RCI could interact directly with STAT3 as 
is seen with the bona fide mTOR substrate 4E-BP1. In order to do this, cDNA of 
STAT3 was obtained from ATCC as an I.M.A.G.E. clone (integrated molecular 
analysis of genomes and their expression) and using the Invitrogen gateway system, 
was cloned into an expression vector containing an N-terminal GST-tag. STAT3 was 
then transfected into cell lines and purified using GST-purification protocol (see 
section 2.3.13). Purified recombinant protein was dotted onto PVDF membrane and 
incubated with lysates containing expressed Raptor.
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Figure 5.4 4E-BP1 binds avidly to m TORCI while STAT3 does not: Purified 
recombinant GST-4E-BP1 and GST-STAT3 were purified using a GST-purification 
(see section 2.3.13), STAT3 was purified from cells either treated or untreated with 
rapamycin. 50ng of the purified proteins were dotted onto PVDF membrane before 
blocking and then overnight incubation with Raptor/Raptor mutant 4 expressing 
lysates (generated from HEK293 cells) or GST antibody. Western blotting was then 
utilised to determine Raptor binding and protein levels.
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4E-BP1 was utilised as a positive control. Cells were also incubated in lysates 
expressing Raptor mutant 4 as a negative control. Results demonstrate once again 
robust binding of m TORCI to 4E-BP1, however no interaction was seen between 
Raptor and STAT3. This does not exclude the possibility of mTORCI directed 
substrate phosphorylation of STAT3, however it does suggest that the interaction 
between STAT3 and m TO R C I is certainly not as robust as between 4E-BP1 and 
mTORCI. The interplay between m TO R C I and STAT3 is likely to be more transient 
and fragile and may suggest a hierarchy between the substrates of mTORCI 
whereby higher binding substrates are more readily phosphorylated.
5.3.5 mTORCI phosphorylates purified STAT3 protein in vitro
Since I was unable to show Raptor interaction, I decided to investigate whether 
STAT3 could be phosphorylated directly in vitro by mTORCI utilising the mTORCI 
kinase assay optimised in chapter 3. GST-STAT3 and GST-Rheb were purified from 
HEK293 cells separately (as described in section 2.3.13) alongside the active 
mTOR/Raptor complex. The purified complexes were incubated together in the 
presence and absence of Rheb, and with ATP. Lysates were then analysed for 
phosphorylation of substrates using SDS-PAGE and western blotting. Purified 4E- 
BP1 was also utilised within the assay as a positive control.
As previously shown, 4E-BP1 was robustly phosphorylated by the purified 
mTORCI complex at Thr36/45. This was further enhanced by the inclusion of GTP- 
bound Rheb within the assay as expected, albeit not as strongly as was seen with 
4E-BP1. However the fact that phosphorylation of STAT3 was further enhanced by 
inclusion of GTP-bound Rheb suggests that STAT3 is a direct substrate for 
m TO R C I This is the first time that the full STAT3 protein has been demonstrated to 
be phosphorylated in vitro using m TO R C I at Ser727. Rheb was able to produce a 
significant increase in Ser727 phosphorylation confirming that this residue in STAT3 
can be directly phosphorylated by m TO R C I.
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Figure 5.5: mTORCI phosphorvlates purified STAT3 protein in vitro: An active 
mTORCI complex was purified from insulin stimulated HEK293 cells grown under 
serum starved conditions (as described in section 2.3.15), GST-STAT3 and GST-4E- 
BP1 were purified from serum starved HEK293 cells, as was GST-Rheb, which was 
then loaded with GTPyS. Purified m TORCI complex was incubated alongside 
potential substrates with ATP with and without GTPyS-Rheb (as indicated) for 1h at 
30°C with gentle agitation, as described in 2.3.15. SDS-PAGE and western blotting 
with phospho-specific antibodies was utilised to determine specific phosphorylation 
events as well as mTOR/Raptor purification.
179
In this assay, greater phosphorylation of 4E-BP1 in comparison to STAT3 was 
observed. This work supports the hypothesis that a hierarchy exists among 
mTORCI substrates, with 4E-BP1 being one of the most readily phosphorylated. 
This goes some way to explaining why no interaction was observed between Raptor 
and STAT3 in figure 5.4.
5.3.6 mTORCI phosphorylates Ser727 in response to insulin stimulation 
during CNTF signalling
A study by Ceresa et al. in 1996 was the first study to establish a link between insulin 
stimulation and STAT3 activation. Ceresa’s study demonstrated that insulin 
treatment specifically induced Ser727 phosphorylation of STAT3 although did not 
find evidence for a specific kinase responsible for this [398]. Since insulin also 
stimulates m TORCI activity and I have shown that mTORCI can phosphorylate 
STAT3 directly, it is not unreasonable to hypothesise that insulin induced STAT3 
Ser727 phosphorylation is mediated by m TO R C I.
In order to investigate this further, an experiment was set up to view the 
phosphorylation events of STAT3 in response to insulin and rapamycin treatment. 
This was carried out in the presence of CNTF to activate Tyr705 phosphorylation. I 
decided to use [32P]-radiolabelling for this experiment as this enabled me to view the 
phosphorylation events after short-term stimulation and in vivo. Cells expressing 
myc-mTOR, HA-Raptor and GST-STAT3 were treated with CNTF 2 h prior to lysis, 
insulin 30 min prior to lysis and rapamycin and okadaic acid 1 h prior to lysis (where 
indicated). Okadaic acid is a potent inhibitor of PP1 and PP2A phosphatases which 
have been associated with m TO R C I. This ensures that any dephosphorylation seen 
upon rapamycin treatment is a result of relieved mTORCI activity specifically 
towards STAT3. STAT3 was then purified from cells and the phosphorylation status 
determined by western blotting.
Incorporation of [32P]-radiolabel into the STAT3 protein was visualised using 
autoradiography whilst phospho-specific antibodies were used to determine the 
Ser727 phosphorylation levels. Figure 5.6 shows that insulin causes an increase in 
phosphorylated STAT3 as determined by the incorporation of [32P]-radiolabel, 
western blotting of cold samples revealed that this was a result of increased Ser727 
phosphorylation whilst Tyr705 phosphorylation remained unaffected, in agreement 
with the work by Ceresa et al.
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Figure 5.6 m TORCI phosphorvlates Ser727 in response to insulin stimulation 
during CNTF signalling: Hot assay: HEK293 cells expressing GST-STAT3, HA- 
Raptor and myc-mTOR were treated with CNTF for 2 h, rapamycin and okadaic acid 
for 1 h and insulin for 30 min prior to lysis. Total lysate samples were taken to 
determine expression levels. GST-STAT3 was then purified and examined for 
phosphorylation status and potential interactors using western blotting. Hot assay, 
cells were starved of phosphate for 4 h, CNTF, Rapamycin, okadaic acid and insulin 
were administered as above before re-addition of radiolabelled [32P]-Phosphate for 
1h. STAT3 was then purified to determine incorporation of the [32P] radiolabel into 
STAT3.
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Furthermore, as predicted, rapamycin treatment was able to abolish insulin 
induced Ser727 phosphorylation. This demonstrates that mTORCI is responsible for 
insulin induced Ser727 phosphorylation in cells and also indicates that the rapamycin 
induced dephosphorylation seen with STAT3 is not a result of activating the 
phosphatase PP2A.
The remaining lysates from the cold assay were analysed by western blotting 
for possible interactors. Figure 5.6 ‘C ’ demonstrates that trace amounts of HA-Raptor 
co-purified with GST-STAT3, which was seemingly unaffected by rapamycin/insulin 
treatment. Since rapamycin treatment is thought to inhibit mTORCI at least in part 
by interfering with its Raptor binding [69], this may suggest that Raptor is still able to 
bind to substrates during rapamycin treatment but not mTOR in the presence of 
rapamycin.
There are several studies implicating STAT3 with HIF-1a and I have so far 
demonstrated a role for m TO R C I in both HIF-1a and STAT3 regulation, I therefore 
decided to see if HIF-1a formed part of the mTOR/Raptor/STAT3 complex. 
Interestingly, HIF-1a was detected under all conditions (excluding the mTOR/Raptor 
control). There is evidence within the literature that in some cell lines HIF-1a, STAT3 
and p300 form a transcriptional complex to modulate the hypoxic response [209]. 
This experiment supports this theory as HIF-1a co-purified with STAT3 regardless of 
mTOR expression or activation.
5.3.7 Expression of the TOS mutant of HIF-1a results in an increase in STAT3 
transcriptional activity
In order to further explore the relationship between STAT3 and HIF-1a, I examined 
whether expression of the TOS mutant of HIF-1a had any effect on the 
transcriptional activity of STAT3. In 2007, Land et al. demonstrated that expression 
of the TOS mutant of HIF-1a dominantly inhibited HIF-1a activity and that the mutant 
exhibited reduced binding to its transcriptional co-activator p300 [135]. I wanted to 
see what effect dominant inhibition of HIF-1a had upon STAT3 activity since STAT3 
also binds to p300 to form a transcriptional complex. To do this, the STAT3 
transcriptional luciferase reporter was utilised and the effects that over-expression of 
wild-type HIF-1a or the TOS mutant had on STAT3 activity were examined.
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Figure 5.7 Expression of the TOS mutant of HIF-1a results in an increase in 
STAT3 transcriptional activity: HEK293 cells were transfected with the STAT3 
inducible luciferase reporter construct alongside pACATG/GST-HIF/GST-HIF-TOS 
as indicated. Cells were serum starved and CNTF treated for 12 h prior to lysis. Cells 
were then harvested in Blenis lysis buffer and analysed for luciferase activity 
(standardised to total protein levels as determined by a Bradford assay), the 
remainder of the lysate was analysed using SDS-PAGE and western blotting to 
determine HIF-1a expression levels with p-actin used as a loading control. Data is 
representative of three independent experiments, * indicates p-value or 0.05.
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Over-expression of wild-type HIF-1a had no significant effects upon STAT3 
transcriptional activity in cells (compare lanes 1 and 2). However, expression of the 
HIF-1a TOS mutant significantly propagated STAT3 transcriptional activity. Since 
previous work demonstrated that an increase of STAT3 activity increased HIF-1a 
protein levels and synthesis [210], it is very probable that the cell signal transduction 
through these two transcription factors are closely linked. This result is consistent 
with the hypothesis that STAT3 has a regulatory role over HIF-1a, it is likely that 
reduction of HIF-1a activity by expression of the HIF-1a-TOS caused the cell to 
compensate by increasing STAT3 activation. It is also a possibility that STAT3 
activity is enhanced upon inhibition of HIF-1a transcriptional events as they both 
share the same transcriptional machinery, i.e., STAT3 is not competing with HIF-1a 
for p300 hence it’s activity is increased.
5.3.8 STAT3 can be inhibited by mutants of TSC2 deficient at inhibiting 
mTORCI
Kwiatowski et al. recently reported upregulation of STAT3 in TSC2-/- cells [399], this 
is in concordance with the evidence shown here of mTORCI mediated STAT3 
phosphorylation. In chapter 4 I showed evidence of an mTORCI independent 
mechanism of regulation towards HIF-1a governed by TSC2. Since I have also 
shown a functional link between HIF-1a and STAT3, I wanted to establish whether 
STAT3 was also subject to transcriptional regulation from TSC2. To do this, I 
repeated the TSC2 rescue experiment utilising the various TSC2 mutant constructs 
to assess their ability to suppress STAT3 activity. The experiment was carried out as 
described in chapter 4, however cells were grown in the presence of CNTF as 
opposed to under hypoxia. As expected, STAT3 transcriptional activity in the TSC2-/- 
MEFs could be supressed by rapamycin treatment or re-introduction of wild-type 
TSC2. Interestingly, the effects of rapamycin treatment and over-expression of TSC2 
were not significantly different in their ability to repress STAT3 as was seen with HIF- 
1a. This suggests that in cells lacking TSC2, the main mechanism for STAT3 
elevation is via an m TO RCI dependent mechanism.
This data shows that this m TO R C I independent mechanism does not extend 
to STAT3 activation in TSC2-/- MEFs since the rescued expression of wild-type 
TSC2 caused a similar level of inhibition as m TORCI inhibition with rapamycin.
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Figure 5.8: STAT3 can be inhibited by mutants of TSC2 deficient at inhibiting 
mTORCI: TSC2-/- MEFs were transfected with the STAT3 luciferase reporter 
construct alongside empty vector, wild-type TSC2 or mutant TSC2. Cells were 
cultured under serum starved conditions in the presence of CNTF for 12 h prior to 
lysis. Cells were harvested in blenis lysis buffer and analysed for STAT3 
transcriptional activity, this was standardised to total protein levels as determined by 
a Bradford assay. The remainder of the lysate was analysed for TSC2 expression 
levels by western blotting. Error bars indicative of standard deviation from three 
independent experiments. NS indicates No Significant inhibition (compared with 
pACATG). * indicates p-value of 0.05, ** indicates p-value of 0.001.
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STAT3 is therefore not subject to the same m TO RCI mediation as HIF-1a Figure 5.8 
however does indicate that m TO R C I inhibition can suppress STAT3 activity in the 
context of TSC1/2 loss, supporting the conclusions of this work and validating 
STAT3 as a potential therapeutic target for TSC.
5.4 Discussion
Yokogami’s study provided the first evidence of a link between mTORCI signal 
transduction and STAT3 [202]. Since this study, there has been a significant volume 
of research in this field however there is conflicting evidence between studies. This 
study aimed to clarify some of the discrepancies within the literature.
There are several studies providing evidence for upregulation of STAT3 under 
conditions of m TORCI activation, particularly in cancer cell lines [400-402]. Each of 
these studies provides evidence that STAT3 is located downstream of m TO R C I 
Yokogami’s study is so far the only evidence that STAT3 is a direct substrate of 
mTORCI. Yokogami’s evidence however, should be treated with caution as they 
were only able to show in vitro m TO R C I directed phosphorylation of a short STAT3 
peptide of just 11 amino acids. Therefore one of the first aims of this study was to 
confirm that m TORCI could directly phosphorylate STAT3.
Yokogami’s study suggested that CNTF stimulation was required for 
mTORCI mediated phosphorylation of STAT3. In figure 5.1, I demonstrated that P- 
STAT3 Ser727 phosphorylation showed some sensitivity to rapamycin inhibition in 
vivo whilst Tyr705 phosphorylation appeared unaffected. In contrast to Yokogami’s 
study however, the biggest difference between the rapamycin treated and untreated 
samples occurred in the absence of CNTF stimulation. This may therefore reflect 
differences between the HEK293E cells utilised in this study and the NBFL cell line 
used by Yokogami. In addition, it indicates that m TORCI is able to regulate STAT3 
in the absence of CNTF stimulation. This is in agreement with more recently 
published studies utilising cancer derived cell lines where mTORCI and STAT3 
signalling are inappropriately elevated in the absence of STAT3 stimulation [400, 
402]. Interestingly, Yokogami’s study saw the greatest suppression of P-STAT3 
Ser727 with rapamycin treatment after 15min of CNTF stimulation, Figure 5.1 also 
shows a substantial decrease in Ser727 phosphorylation at this time point (see 
densitometry analysis, compare lane 2 with lane 5) indicating that mTORCI does 
regulate Ser727 phosphorylation during CNTF signalling. Interestingly though, the 30
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min CNTF time point shows no repression of Ser727 phosphorylation in rapamycin 
treated cells in contrast with Yokogami’s study. Again, this may reflect differences 
within the cell lines, since CNTF is a neuropoietic cytokine and Yokogami was 
utilising a neuronal cell line for his study, the effects of CNTF may differ between 
these two cell types.
HEK293E cells were selected for this investigation as they express CNTF 
receptors, however they enabled me to look at STAT3 expression in a more general 
context. Yokogami showed evidence that CNTF stimulation activated mTORCI 
signalling within the NBFL cell lines, this has also been previously demonstrated 
within cardiac myocytes [403]. However, an analysis of phospho-rpS6 levels as an 
indicator of m TORCI activity in figure 5.2 does not support this, which may indicate 
that HEK293E cells do not respond in the same manner as NBFL cells to CNTF, 
although the possibility of very short term m TORCI activation cannot be ruled out.
Figure 5.2 shows STAT3 transcriptional activity correlates with mTORCI 
transcriptional activity, surprisingly however, the transcriptional activity did not 
appear to correlate with phosphorylation at either of the regulatory sites of STAT3 
under CNTF stimulation (see columns 3 and 4 of figure 5.2). I postulated that the 
lysis protocol implemented was not sufficient to breakdown nuclear membranes and 
devised an alternative method.
Figure 5.3 once again demonstrates that STAT3 transcriptional activation 
correlates with m TORCI activity. In addition to this, much greater levels of P-STAT3 
Ser727 phosphorylation were observed when the QIA shredder was utilised to 
breakdown nuclear membranes (although this may also be a result of over 
expression of mTOR and Raptor). All cells were stimulated overnight with CNTF 
therefore Tyr705 phosphorylation was consistent across all conditions, P-STAT3 
Ser727 phosphorylation however did show some differentiation. It appeared that 
expression of the active mutant of mTOR increased phosphorylation as indicated by 
the densitometry analysis (compare lanes 3 and 4 to 1 and 2) and this was inhibited 
by co-expression of Raptor mutant 4 as opposed to wild-type. However in the case 
of wild-type mTOR, Raptor mutant 4 expression appeared to increase the P-STAT3 
Ser727 levels. This reason for this discrepancy is not clear, although a likely 
explanation may be that the luciferase levels are more representative of STAT3 
activity over time whereas western blotting indicates the phosphorylation status at 
time of lysis.
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As stated in the introduction, there are several different kinases known to 
phosphorylate STAT3 at the Ser727 site, it may therefore be likely that when 
mTORCI was dominantly inhibited by Raptor mutant 4 that negative feedback loops 
were activated to increase Ser727 phosphorylation whilst mTORCI was inhibited. 
The increased intrinsic activity of the active mutant may have prevented the 
activation of feedback mechanisms.
Due to the difficulty in dissecting specific mTORCI mediated signalling events 
in vivo, I decided to investigate whether I could show evidence of mTORCI activity 
towards STAT3 in vitro. I was unable to demonstrate Raptor interactions with STAT3 
using a far western approach, this is likely to indicate that mTORCI does not interact 
with STAT3 as readily as it does 4E-BP1 and supports a theory of a hierarchy 
amongst mTORCI substrates. It is also a reflection of the lack of sensitivity of this 
particular methodology. This assay can be utilised to indicate positive interactions, 
however it is not sensitive enough to rule out interactions if they occur transiently.
The in vitro kinase assay was particularly useful in this instance as it allows 
for much greater control over experimental conditions and prevents cross talk 
between other signalling pathways. Using the in vitro approach, I was able to 
demonstrate for the first time that the full STAT3 protein can be phosphorylated 
directly by m TORCI at Ser727 and that this could be propagated by the presence of 
Rheb. This confirms STAT3 as a direct substrate specifically for mTORCI rather 
than any of its downstream effectors. It also suggests that the lack of Raptor 
interaction observed using the far western approach was likely to reflect the lack of 
sensitivity of the methodology as hypothesised.
To reinforce these findings, a radiolabelling experiment was carried out to 
establish whether rapamycin sensitivity could be replicated within mammalian cells. 
Over-expression of mTOR/Raptor alongside STAT3 allowed me to look at specific 
phosphorylation events under different treatments, something which the 
transcriptional luciferase assay does not permit. The radio-labelling experiment 
showed that Ser727 phosphorylation could be stimulated in an insulin dependent 
fashion which was subject to inhibition from rapamycin.
Insulin, as reported by Ceresa et al. caused a significant increase in the level 
of Ser727 phosphorylation whilst Tyr705 remained unaffected. I have demonstrated 
this and also shown that this can be inhibited by the specific mTORCI inhibitor 
rapamycin. This experiment was carried out in the presence of the phosphatase
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inhibitor okadaic acid, thus indicating that the rapamycin induced dephosphorylation 
of STAT3 is not a result of phosphatase activity. Further to this, I was able to co- 
purify trace amounts of Raptor with STAT3, indicating that mTORCI specifically 
interacts with STAT3 in vivo. This taken in conjunction with the in vitro kinase assay 
confirms that STAT3 is a direct substrate for m TORCI and is consistent with several 
cancer cell line studies indicating that STAT3 is activated downstream of mTORCI 
[400, 401].
Interestingly, a series of papers by Prof. David Kwiatowski’s research group 
has investigated STAT3 regulation in the context of TSC. Kwiatowski observed 
upregulation of both Tyr705 and Ser727 phosphorylation of STAT3 in TSC1/2 
deficient null murine neuroepithelial cells. This is unexpected given that I have seen 
no mTORCI directed effects towards Tyr705. It could be explained however by a 
recent paper by Dr Elizabeth Henske, Henske’s group showed that Notch signalling 
could be activated directly by Rheb in an m TORCI independent fashion (see 
introduction section 1.7.1.1) [279]. It has previously been identified that expression of 
Hes 1 and Hes 5 (direct Notch targets) can induce Tyr705 phosphorylation of STAT3 
[404]. Therefore, this may explain why Tyr705 phosphorylation of STAT3 was 
reportedly elevated in TSC 1/2-/- cells [399].
Kwiatowski also later demonstrated that rapamycin treatment of TSC1/2-/- 
cells induced IFN-y secretion which triggered dephosphorylation of Tyr705-STAT3. I 
saw no effects upon Tyr705 phosphorylation in this study, suggesting that the 
rapamycin induced IFN-y effect is caused by the lack of TSC1/2. Constitutive 
activation of m TORCI in these cells may be causing repression of IFN-y through 
unknown m TORCI targets, which is then reversed upon rapamycin treatment.
Alternatively, it may indicate that the IFN-y or rapamycin treatment is inducing 
dephosphorylation of Tyr705-STAT3 through induction of a PP1/2A type 
phosphatase which would have been inhibited by the inclusion of okadaic acid within 
the radiolabelling experiment. A similar scenario has been described for S6K1, 
whereby rapamycin treatment induces dephosphorylation of all sites not just those 
targeted by m TORCI [157].
Further research is required to elucidate the mechanism behind this 
regulation, it would be particularly interesting to see if administering IFN-y directly to 
TSC 1/2-/- MEFs could induce Tyr705 dephosphorylation in the presence of okadaic
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acid, or indeed whether rapamycin does affect IFN-y expression in HEK293s as well 
as TSC1/2-/- MEFs.
Interestingly, Kwiatowski’s group demonstrated that IFN-y and rapamycin 
could act in synergy to not only suppress Tyr705 phosphorylation of STAT3 but also 
to induce apoptosis and reduce proliferation in TSC deficient cells [399]. This data 
indicates that STAT3 elevation in TSC cells is likely to contribute to the survival of 
these cells and therefore STAT3 should be considered a target for therapeutic 
intervention in TSC patients.
The next objective of the study was to examine the relationship between 
STAT3 and HIF-a. The first report of a functional link between STAT3 and HIF-a was 
reported in 2005, a study by Gray et al. showed evidence that Src activation was 
required for hypoxia induced HIF-a expression and activation. They showed that this 
activation coupled with hypoxia also lead to an increase in STAT3 expression. 
Furthermore, they isolated an Src induced transcriptional complex consisting of 
STAT3, HIF-1a and their transcriptional co-activators p300 and Ref-1. This 
transcriptional complex was able to bind to and activate the VEGF promoter. They 
suggested that simultaneous binding of both STAT3 and VEGF caused maximal 
activation of VEGF [209]. An earlier study examining HIF-1a activation demonstrated 
that Src could activate HIF-1a via increased translation and demonstrated a reliance 
upon the mTOR signalling pathway [405]. Src activation is associated with oncogenic 
transformation and its activation is a feature of several cancers, since inappropriate 
activation of HIF-1a and STAT3 can promote the survival of the tumour cell 
phenotype, it is important to understand the mechanisms behind their regulation.
This data taken together with the results of this study demonstrating mTORCI 
mediated regulation of both STAT3 and HIF-1a may suggest that the STAT3/HIF- 
a/p300/Ref-1 transcriptional complex is in fact mediated by mTORCI. I therefore 
decided to investigate whether HIF-1a co-purified with STAT3.
Interestingly, an interaction between HIF-1a and STAT3 was indeed 
observed. Endogenous HIF-1a co-purified with GST-STAT3 under all conditions. 
There was no apparent increase with mTOR/Raptor over-expression, although it 
could be argued that there may be a slight increase in HIF-1a binding in the insulin 
treated sample compared with the insulin and rapamycin treated cells (compare HIF- 
1a blot figure 5.6 ‘C ’, lanes 4 and 5). As modest differences in binding of HIF-1a to
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STAT3 was observed, it is probable that this interaction is not primarily regulated by 
mTORCI, and may in fact be a result of increased HIF-1a translation in response to 
insulin rather than increased binding. Even under serum starved non-hypoxic 
conditions, HIF-1a is constitutively bound to STAT3. Given that I was unable to show 
direct mTORCI mediated HIF-1a phosphorylation but did show Raptor interaction, it 
is possible that m TORCI directed regulation of HIF-1a might be mediated by STAT3 
phosphorylation. Since activated STAT3 translocates to the nucleus, it is possible 
that STAT3 phosphorylation also increases nuclear accumulation of HIF-1a as well, 
thus contributing to its activation.
Further studies are required to reveal whether STAT3 plays a regulatory role 
over HIF-1a or whether they have more of a symbiotic relationship. To try and gain 
insight into this, I decided to utilise the dominant HIF-1a negative mutant to observe 
the effects upon STAT3. Interestingly, STAT3 transcriptional activity was increased 
in response to expression of GST-HIF-TOS, with over-expression of wild-type HIF-1a 
having no effect. This is consistent with the notion that STAT3 is upstream of HIF-1a, 
suggesting that the increase in STAT3 activity is the result of a feedback loop 
initiated due to HIF-1a repression.
Although we are unsure of the mechanisms governing this regulation, it is of 
particular importance to note that inhibition of HIF-1a triggers an elevation of STAT3. 
If HIF-1a inhibitors are used in this context therapeutically, they may also function to 
promote the survival of the targeted cancer cells through activation of STAT3. This 
provides a case for the use of HIF-1a inhibitors in conjunction with STAT3 inhibitors 
to reduce the tumour cell phenotype.
Interestingly, HIF-1a appears to be bound to STAT3 in figure 5.6 ‘C’ 
regardless of m TORCI activity. This would support the argument for a regulatory 
role of STAT3 over HIF-1a. Furthermore, western blotting analysis determining 
expression levels of GST-HIF and GST-HIF-TOS revealed a substantial previously 
unseen mobility shift between the wild-type and TOS mutant of HIF-1a. (Compare 
lanes 2 and 3 of figure 5.7). The TOS mutant of HIF-1a showed a significant 
increase in mobility in comparison to the wild-type construct. This is likely to 
represent differences in phosphorylation status, whereby the GST-HIF-TOS protein 
is less phosphorylated as it resolves as a lower band. GST-HIF-1a may therefore be 
part of a protein complex that is targeted by a kinase or kinase(s), which may include
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mTORCI, whereas GST-HIF-TOS is not and may be a direct result of activating 
STAT3 with CNTF treatment for the transcriptional assay.
To take this study further, I would have liked to be able to investigate whether 
GST-HIF-TOS was able to form a complex with STAT3. Furthermore, STAT3 
contains two potential TOS motifs, FPMEL are amino acids 26-30 and FDMEL at 
amino acids 756-760. Therefore, it would be of interest to establish whether 
disruption of these possible TOS motifs could affect both HIF-1a binding and 
activation, as well as m TO RCI mediated phosphorylation of STAT3 on Ser727.
The final stage of this line of investigation was to look at STAT3 activation 
under the context of TSC. In chapters 3 and 4, I was able to demonstrate that 
mTORCI can mediate HIF-1a regulation, however I also provided evidence for a 
TSC2 mediated, m TO RCI independent regulation of HIF-1a which may be 
contributing to the pathogenesis of TSC. Since I have shown evidence of a functional 
link between STAT3 and HIF-1a, I wanted to determine whether or not STAT3 was 
regulated in the same manner as HIF-1a in TSC-deficient cells. It seemed that the 
most logical way to compare the regulation of STAT3 was to establish whether or not 
re-expression of the TSC2 mutant constructs into TSC2 deficient cell lines produced 
similar effects upon STAT3 as they did HIF-1a. The transcriptional assay produced a 
similar looking graph, however there were some key differences indicating that 
STAT3 is not subject to modulation from TSC2 in the same manner as HIF-1a. 
Firstly, re-introduction of wild-type TSC2 back into these TSC2 null MEF cell lines 
caused suppression of STAT3 transcriptional activity as you would expect, however 
it caused an approximate 50% reduction in activity, whereas HIF-1a transcriptional 
activity was reduced by around 85%. The rapamycin treated sample also caused a 
similar level of inhibition towards STAT3. Crucially, there was no significant 
difference in STAT3 activation between rapamycin treated samples and those where 
TSC2 was re-expressed. This indicates that the elevation in STAT3 activity I 
observed is mediated solely by m TO R C I and is not directly modulated by TSC2 as 
observed with HIF-1a. The inhibition of STAT3 activity observed when mTORCI was 
inhibited by rapamycin was significant, although no conditions saw a complete 
abolishment of STAT3 activity, this is likely to be due to the suppression of IFN-y in 
TSC deficient cells as reported by Kwiatowski [399].
Finally, this assay supports the hypothesis that the L1460P ‘GAP’ mutant of 
TSC2 does retain some ability to inhibit HIF-1a but not mTORCI as was
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hypothesised in chapter 4, since no significant inhibition of STAT3 was observed 
with expression of this ‘GAP’ mutant. This suggests that the quantifiable 
transcriptional assay is sufficiently sensitive to measure subtle changes in activity, 
while other methods were unable to detect differences. This supports the work 
carried out in chapter 4, as I have demonstrated that HIF-1a is subject to differential 
regulation in the absence of TSC2 to that of STAT3. Furthermore I have identified 
STAT3 as being a direct downstream for m TORCI and demonstrated mTORCI 
directed phosphorylation of Ser727 both in vivo and in vitro. This may be contributing 
to the increased risk of malignancy seen with the hamartoma disorders effecting 
mTORCI, given that Ser727 phosphorylation has been demonstrated to play a role 
in Ras-mediated oncogenic transformation [113].
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CHAPTER 6: FINAL DISCUSSION
6.1 SELECTION OF mTORCI TARGETS
The initial aim of this study was to identify and characterise downstream substrates 
of m TORCI. At the commencement of this study, a report by Land et al. was 
published which showed evidence for m TORCI involvement in the regulation of HIF- 
1a, this provided a starting point for my research. I was particularly interested in HIF- 
1a for a number of reasons. Firstly, it was one of the first examples of evidence that 
mTORCI functions as a transcriptional regulator. There is a wealth of evidence 
concerning the role of m TO R C I in the regulation of translation (detailed within the 
Introduction -  see section 1.2.2), however the role of mTORCI in regulating gene 
transcription is much more vague. I therefore wanted to investigate how mTORCI 
could manipulate transcriptional events and HIF-1a appeared to be an ideal 
candidate. Furthermore, the gene targets of HIF-1a are known to contribute 
significantly to the pathophysiology of a number of human diseases. For example, 
HIF-1a elevation plays a significant role in the tumourigenesis associated with Von- 
Hippel Lindau syndrome, whereby shRNA mediated depletion of HIF-1a prevents the 
formation of tumours in VHL defective renal cell carcinoma cell lines [406].
Furthermore, dysregulation of HIF-1a and its gene target VEGF is now 
considered to be a unifying feature of the familial hamartoma disorders which include 
TSC, Peutz-Jehgers syndrome, Cowden’s syndrome and Bannayan-Riley- 
Ruvalcaba syndrome (BRRS). These diseases are characterised by loss of function 
mutations to tumour suppressors acting upstream of mTOR [285].
mTORCI dysregulation has been reported in numerous cancer types, 
cervical, ovarian and pancreatic cancer all exhibit elevation of kinases upstream of 
mTORCI, including PI3 kinase and Akt, and are therefore likely to exhibit 
inappropriate m TORCI activation [407]. In addition, the phosphatase PTEN which is 
a negative regulator of PI3 kinase/Akt signalling towards mTOR (see figure 1.5) is 
frequently mutated in a number of different sporadically occurring cancers including 
prostate cancer, glioblastoma, breast cancer and endometrial tumours [408, 409]. A 
recent study also carried out a mutational screen of the human cancer genome 
database and found two incidences of direct point mutations to mTOR which 
conferred constitutive activation, one was identified in a large intestine 
adenocarcinoma whilst the other was identified within renal cell carcinoma [301]. It is
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likely that m TORCI is inappropriately activated by point mutations in a variety of 
cancers as well as through mutations to upstream regulators [301, 410].
The selection of HIF-1a as a target for this study was based upon three 
premises. Firstly, m TORCI signalling is elevated in many types of cancer and the 
familial hamartoma disorders. Secondly, HIF-1a is upregulated downstream of 
mTORCI as demonstrated by Land et al. [135], and finally, upregulation of HIF-1a is 
sufficient to induce tumourigenesis in Von-Hippel Lindau disease which makes it a 
potential therapeutic target in the treatment of cancers where mTORCI regulation is 
lost. Elucidating the mechanisms of signal transduction downstream of mTORCI is 
paramount to developing suitable therapeutic interventions to target diseases where 
mTORCI is upregulated.
STAT3 was also selected as suitable potential mTORCI signalling target. It 
was also thought to be acting downstream of m TORCI, although had not been 
confirmed as a direct substrate. STAT3 also has a prominent role to play in the 
pathology of many of the diseases associated with mTORCI activation. STAT3 
activation is associated with increased cell growth, increased angiogenesis (VEGF is 
also a target for STAT3) and metastases [243, 411]. STAT3 is also thought to play a 
role in tumour induced immunosuppression [412]. Upregulation of STAT3 is seen in 
pancreatic and breast cancers, melanomas and undoubtedly many other cancer 
types. Many human tumours produce factors such as IL-6 and IL-10 which also 
function to activate STAT3, therefore STAT3 is often subject to ‘feed-forward’ 
mechanisms which further propagate its expression [412]. Of particular interest in 
this study however was the reported association between HIF-1a and STAT3.
As described in chapter 5, STAT3 was reported to form a transcriptional 
complex with HIF-1a and co-factors p300 and Ref-1 [211]. It was also reported that 
activated STAT3 stabilised HIF-1a protein and increased HIF-1a mRNA levels [413]. 
This study aimed to elucidate the mechanisms behind mTORCI mediated regulation 
of both HIF-1a and STAT3 to determine how they may be disrupted in disease.
6.2 SIGNIFICANT FINDINGS
6.2.1 Relationship between HIF-1a and mTORCI
I initially began to investigate the relationship between HIF-1a and m TO R C I I was 
able to verify the findings of Land et al. to demonstrate that HIF-1a was regulated in
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an mTORCI dependent fashion. The mechanism(s) behind this was unknown, 
however Land et al. previously demonstrated that the TOS-mutant of HIF-1a was 
degraded at the same rate as wild-type HIF-1a, furthermore they showed that the 
high levels of HIF-1a activity in VHL-/- MEFs were still highly sensitive to rapamycin 
[135]. I showed further support for this by demonstrating that rapamycin is unable to 
influence the degradation of the HIF-1a protein during hypoxia when its synthesis is 
inhibited. I postulated that m TO R C I must instead regulate the activity of HIF-1a 
directly and/or enhance the gene-expression of HIF-1a at the transcriptional or 
translational level (or a combination of all these processes).
Under hypoxia, the cell alters mRNA expression and translation to cause a 
general suppression of protein synthesis. However, simultaneously it is also able to 
upregulate proteins which are associated with the hypoxic response, including HIF- 
1a. The mechanism behind this selection is unclear but there has been speculation 
within the literature. The S6 kinases were originally thought to selectively enhance 
the translation of 5’-TOP mRNA’s which are a subset of mRNAs associated with 
cellular growth pathways, for example the ribosomal proteins [414]. HIF-1a mRNA 
contains large 5’-terminal oligo-polypirimidine tracts (5’-TOP-structures) within the 5’- 
untranslated region [415]. It was, therefore, speculated that during a general 
suppression of mTOR and cap-dependent translation (i.e., during hypoxia, see 
section 1.4.5) the long pyrimidine tracts found within HIF-1a 5-UTR confer a 
translational advantage that was mediated by S6K1 activation [416]. However, my 
results indicated that S6K1 was not involved in mTORCI directed regulation of HIF- 
1a. Interestingly, as this thesis was being compiled, a paper was published which 
demonstrated that shRNA-mediated knockdown of S6K1 suppressed HIF-1a 
expression in PTEN deficient cells without effecting mRNA levels. Tandon et al. 
concluded that S6K1 regulates the translation of HIF-1a [417]. This is in direct 
contrast with the results reported in this study demonstrating that 4E-BP1 is able to 
regulate the translation of HIF-1a independently of S6K1 activity. Conversely, S6K1 
is known to phosphorylate proteins involved in regulating cap-dependent translation 
(see figure 1.8 ‘Introduction’), this may therefore suggest that S6K1 is required for 
HIF-1a translation but is not a rate-limiting factor. This is consistent with recent 
evidence suggesting that the 4E-BP1 component of the mTORCI signalling pathway 
is protected from hypoxic induced repression in contrast to S6K1 which is severely 
repressed during hypoxia [355]. It is likely that 4E-BP phosphorylation is protected
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from hypoxia induced suppression of m TORCI so that some cap-dependent 
translation may still occur under hypoxia, presumably to allow the cell to respond to 
the lack of oxygen, at least in part through activation of HIFs.This may therefore 
explain how m TORCI is able to continue HIF-1a translation under a hypoxia-induced 
general repression of protein translation. I therefore propose that the reduction in 
HIF-1a seen with S6K1 knockdown by Tandon et al. [417] is caused by a reduction 
in the levels of the translational machinery required for protein synthesis. Figure 1.8 
(introduction) demonstrates the role S6K1 plays in protein translation and indicates 
how protein translation may be inhibited through S6K1 knockdown, the results of this 
study however suggest that the availabillity of elF4E is a rate limiting step in the 
specific translation of HIF-1a mRNA.
Recent evidence suggested that S6K1 is not involved in the translation of 5’- 
TOP mRNAs therefore it was important for this study to determine whether the 5’- 
TOP motif could confer a translational advantage to HIF-1a during hypoxia. However 
a comparison of HIF-1a translation with and without the 5’-TOP motif saw no 
difference between the rate of translation under any condition. This is in 
concordance with current thinking that HIF-1a is not a genuine 5’-TOP mRNA [355, 
357]. This notion is also supported by work from Choo et al. who reported that the 
rate of 5’-UTR driven translation of HIF-1a correlated with the phosphorylation status 
of 4E-BP1 [418]. Furthermore, a study by Young et al. reported that actually the rate 
of HIF-1a translation was proportional to the abundance of HIF-1a mRNA rather than 
selective properties of the mRNA enhancing the rate of translation [419].
Analysis of HIF-1a mRNA levels revealed that they are regulated in an 
mTORCI dependent fashion that is sensitive to rapamycin inhibition. This indicates a 
secondary facet by which m TO R CI is able to regulate HIF-1a. I also revealed that 
the mTORCI substrate recognition component, Raptor could interact directly with 
HIF-1a and less well to a mutant of HIF-1a containing a mutated mTORCI signalling 
motif. This implies that HIF-1a is a direct substrate for mTORCI however I was 
unable to demonstrate direct phosphorylation of HIF-1a by mTORCI in our in vitro 
kinase assays. These findings are discussed later in relation to STAT3.
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6.2.2 TSC2 regulation of HIF-1a
Tuberous sclerosis is a genetic disease arising from genetic mutation to either the 
TSC1 or TSC2 gene (see section 1.7.1.1). There is evidence to suggest that patients 
presenting with mutations to the TSC2 gene present with a more severe phenotype 
compared to those containing a mutation to the TSC1 gene [367]. This is surprising 
given that TSC1 and TSC2 exert their activity by forming a tumour suppressor 
complex, therefore loss of function of either TSC1 or TSC2 should exert the same 
effects downstream. TSC2 may therefore play a more integral role in tumour 
suppression than TSC1. Clinical trials utilising rapamycin or its derivatives (termed 
rapalogues) in the treatment of TSC have shown some promising results with 
rapamycin causing shrinkage of AM L’s in TSC patients with long term treatment (12 
months) [420]. However the results of clinical trials in this field have not been as 
dramatic as first hoped, causing a switch in the focus of research in the field of TSC. 
Research is now devoted towards understanding functions which are insensitive to 
rapamycin inhibition, and uncovering feedback mechanisms which are disrupted 
upon rapamycin treatment.
As described in chapter 4, there is now evidence to suggest that TSC1 and 
TSC2 are multi-functioning proteins and characterising these mTORCI independent 
interactions is paramount to understanding the mechanisms leading to the 
manifestations seen in TSC patients, as well as determining the efficacy of mTORCI 
inhibitors in therapeutic strategies.
During my investigations into the regulation of HIF-1a, I observed that re- 
introduction of TSC2 into TS C 2-/- MEFs induced a more robust inhibition of HIF-1a 
transcriptional activity than rapamycin treatment alone. Given the emphasis upon 
discovering m TORCI independent functions of TSC1 and TSC2, I decided to 
analyse the activation of H IF-1a gene targets in the context of TSC1 and TSC2 loss. 
My analysis revealed that rapamycin treatment normalised HIF-1a activity in the 
absence of TSC1 but not TSC2. Rapamycin treatment of TSC1-/- MEFs normalised 
HIF-1a mediated gene expression to a level which was not significantly different to 
that of the TSC1+/+ MEFs. Conversely, rapamycin treated TSC2-/-MEFs showed 
significantly higher levels of H IF-1a mediated gene expression in the presence of 
rapamycin than the untreated wild-types. This suggests that TSC2 is able to regulate 
HIF-1a both dependently and independently of m TORCI. This could imply that TSC
198
sufferers exhibiting mutations to the TSC2 gene may benefit from the use of specific 
HIF-1a inhibitors in conjunction with m TO RCI inhibitors.
This hypothesis was further supported by the functional analysis of patient 
derived TSC2 mutations whereby every TSC2 variant exhibited some level of HIF-1a 
inhibition, with the exception of the Arg1743 variants. This evidence suggests a role 
for this Arg1743 residue in negative regulation of HIF-1a by TSC2 which occurs 
independently of m TO R C I. The mechanism behind this has yet to be elucidated, 
however the location of the Arg1743 mutation provides some clues as to the 
mechanism. This Arg1743 residue is found within a transcriptional activation domain, 
overlapped by a calmodulin binding domain [421] and a peroxisome targeting 
sequence-1 motif (Kim et al. unpublished data). The potential significance of each of 
these is described below.
TSC2 has previously been associated with the regulation of transcriptional 
events. A series of publications by Noonan et al. provide intriguing evidence 
concerning the role of TSC2 in the mediation of transcriptional events relating to 
steroid hormone receptors [350-352, 362, 369, 422]. TSC2 mediated regulation of 
the oestrogen receptor is the most well defined mechanism of TSC2 independent 
function, This finding of TSC2 independent funciton is particularly significant when 
you consider that a particularly severe manifestation of TSC is LAM (see introduction 
section 1.7.2.1) which appears almost exclusively in women [423] and also shows a 
higher incidence of TSC2 mutations [424], York et al. describes how calmodulin and 
the oestrogen receptor compete for binding to the carboxyl terminal of TSC2 [350]. It 
appears that calmodulin and TSC2 function in opposition to co-ordinate the activity of 
the oestrogen receptor, i.e., when the oestrogen receptor is bound to calcium loaded 
calmodulin, its transcriptional activity is enhanced. Conversely, when the oestrogen 
receptor binds to TSC2, DNA binding is inhibited. York et al. identified a 
CaM/oestrogen receptor binding domain which also functioned as a nuclear 
localisation sequence, the first residue of which is Arg1743. York reported that the 
nuclear localisation of TSC2 was induced by phosphorylation of Ser1798 by p90- 
RSK and was also required for TSC2 mediated inhibition of the oestrogen receptor 
[369]. Due to the similarities seen between the regulation of the oestrogen receptor 
and HIF-1a, I hypothesised that the nuclear localisation of TSC2 may be required for 
its mTORCI independent HIF-1a regulation. I predicted that the Arg1743 mutants 
may be defective in their nuclear translocation since Arg1743 is the first residue in
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the nuclear localisation sequence and this may prevent interactions with nuclear HIF- 
1a. However as described in chapter 4 the Arg1743 mutation does not impair the 
ability of TSC2 to translocate to the nucleus.
Interestingly, Motet et al. demonstrated that calcium induced calmodulin 
activity promoted phosphorylation of ERK1/2 and activation of HIF-1a [375]. p90- 
RSK is a known downstream substrate of ERK1/2 which phosphorylates TSC2 at 
Ser1798 and or Ser664 which is inhibitory of the tuberous sclerosis tumour 
suppressor complex [425]. Therefore, it is possible that Ca2+/CaM/ERK1/2 may up- 
regulate HIF-1a by two mechanisms, firstly via mTOR activation and secondly by 
relieving TSC2 mediated inhibition of HIF-1a. In order to determine this, the effects of 
TSC2 phosphorylation upon HIF-1a would have to be examined outside of the 
capacity to activate m TO R C I. It would be of interest to repeat the analysis of TSC2 
mutations upon HIF-1a activity in the context of shRNA mediated Raptor knockdown 
(or Raptor mutant 4 expression) to eliminate m TORCI from the equation. This would 
give insight into the role TSC2 plays outside of its ability to downregulate mTORCI 
signalling.
The work by Kim et al. in Prof. Cheryl Walker’s lab (unpublished data and 
personal communication) indicated that the R1743G/Q/W mutations are defective at 
inhibiting m TORCI due to mislocalisation of TSC2. They show localisation of 
mTORCI, Rheb and the TSC to the peroxisomes and argue that the R1743G/Q/W  
mutants of TSC2 lose their ability to inhibit m TORCI because they are unable to 
translocate to the peroxisomes and interact with TSC1. They show evidence that the 
Arg1743 mutation prevented interaction of TSC2 with peroxisomal import receptors.
This may suggest that the loss of TSC2 mediated inhibition of HIF-1a is a 
product of its mislocalisation away from the peroxisomes. Intriguingly, Kim et al. 
reported that by ataxia telangiectasia mutated (ATM)-dependent kinase also 
contained a PTS sequence and thus also localised to the peroxisome. ATM is a 
kinase from the phosphatidylinositol 3'-kinase (PI3K)-related kinase (PIKK) family of 
which mTOR also belongs to. mTOR and ATM share significant sequence homology 
suggesting similar mechanisms of regulation [72]. When exposed to DNA damage, 
cells respond by activating repair pathways as well as suppressing cellular 
proliferation. ATM is responsible for this regulation and mediates it’s effects by 
phosphorylation of multiple downstream substrates, for example, p53, Chk2 and 
MDM2 are all regulated downstream of ATM and modulate cell cycle arrest [426].
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Interestingly, as this thesis was being compiled, a paper was published 
revealing that ATM kinase activity was activated in response to hypoxia 
independently of the DNA damage response [427], Furthermore, it was 
demonstrated that ATM could directly phosphorylate HIF-1a at Ser696 in an in vitro 
kinase assay resulting in HIF-1a stabilisation. Cells deficient of ATM failed to 
accumulate the HIF-1a protein and also failed to suppress mTORCI signalling in 
response to hypoxia indicating that the HIF-1a target REDD1 was not expressed 
(see section 1.4.5.2) [427]. This may imply an association between localisation of 
ATM and TSC2 to the peroxisome and HIF-1a stability. It may be of interest to 
compare the localisation of ATM in TSC1 and TSC2 deficient cells to see if it differs. 
Equally it may also be of significance that ATM is an upstream regulator of p53, the 
TSC2-/-MEFs utilised for this study are p53 deficient to confer viability, this however 
may cause disturbances in negative feedback signalling to ATM which could affect 
HIF-1a. This is one of the disadvantages of utilising cell lines as a model for disease 
as inevitably there are physiological differences. In chapter 4, I also attempted to use 
immunohistochemistry to assess the levels of HIF-1a gene target expression in 
TSC1 and TSC2 heterozygous mice however VEGF expression was too variable to 
make any reasonable comparison between genotypes and this line of enquiry was 
not pursued.
Peroxisomes are heavily involved in the regulation of metabolic cellular 
processes and have been demonstrated to co-ordinate the metabolism of lipids and 
reactive oxygen species (ROS) in conjunction with the mitochondria [26]. 
Interestingly ROS have been demonstrated to activate the transcription of HIF-1a in 
a mechanism dependent upon NF-kB (nuclear factor kappa B) [428].
It may therefore be possible that TSC2 is involved in the metabolism of ROS 
at the peroxisome and that the elevation of HIF-1a in TSC2-/- MEFs is a product of 
increased ROS levels as well as unrestrained mTORCI signalling. Interestingly 
TSC2 has been previously linked to ROS production, Suzuki et al. demonstrated 
how mutant forms of TSC2 caused activation of Rac1 stimulating NAD(P)H oxidase 
which results in the generation of ROS [378].
This may explain why the Arg1743 mutants of TSC2 were ineffective at 
inhibiting HIF-1a as they are unable to translocate to the peroxisome to assist in 
ROS metabolism or to inhibit m TO R C I signal transduction in concert with TSC1 this 
potential mechanism (see figure 6.1 for potential mechanism). Other mutant forms of
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TSC2 may retain some partial inhibitory activity towards mTORCI or Rac1 allowing 
some suppression of HIF-1a. This theory is demonstrated in figure 6.1 overleaf, 
along with other proposed mechanisms of regulation.
It may therefore be of interest to investigate the levels of ROS production in 
the TSC1 and TSC2-/- MEFs, if indeed TSC2 is involved in ROS metabolism then 
this may be contributing to the pathology of TSC and may be a factor in the more 
severe pathology seen with TSC2 mutations compared with TSC1. Further work is 
required to determine the exact mechanism governing TSC2 mediated regulation of 
HIF-1a.
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Figure 6.1 Potential mechanisms governinq HIF-1a and STAT3: G P130 receptor is 
activated by several different cytokines causing activation of JAKs, JAKs then phosphorylate 
the receptor and STAT3 a tT y r7 0 5  promoting dimerisation and nuclear translocation. 
Activated STAT3 can promote H IF -10 mRNA expression through undefined mechanisms. 
HIF-1 and STAT3 appear to form a transcriptional complex for maximal activation of target 
genes. m TO RCI can also phosphorylate STAT3 at Ser727 to promote transcriptional 
activity. m TO RCI can promote translation of H IF-10 mRNA to increase its synthesis through 
4E-BP1 phosphorylation, S6K1 activity may be required but is not rate limiting. m TORCI 
may also be able to phosphorylate HIF-1 directly to propagate its transcriptional activity 
(Thr798). TSC 2 can suppress HIF-1 a  through m TO R C I inhibition but also through 
suppression of R a c 1 . Rac1 activates NAD(P)H to promote ROS production. ROS is able to 
influence the transcription of HIF-1 as well as the protein stability, this is dependent upon 
NFkB.
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6.2.3 STAT3, mTOR and HIF-1a
In chapter 5, I analysed the relationship between mTORCI and STAT3. I 
demonstrated that Tyr705 was constitutively activated upon CNTF stimulation. Under 
these conditions, m TO RCI regulated the transcriptional activity of STAT3, most 
likely via it’s direct phosphorylation of STAT3 at Ser727. Intriguingly, I also observed 
co-purification of both HA-Raptor and endogenous HIF-1a with STAT3, despite a 
lack of hypoxia to stabilise HIF-1a. This may suggest that both HIF-1a and STAT3 
are part of a larger regulatory complex which may be regulated by mTORCI. The 
hypothesis is supported by the fact that p300 functions as a transcriptional co-factor 
for both HIF-1a and STAT3.
Furthermore, Land and Tee demonstrated that the inactive TOS mutant of 
HIF-1a showed reduced binding to p300 [135], which suggests that the TOS motif in 
HIF-1a facilitates protein interactions. Other groups have also reported STAT3 
mediated regulation of HIF-1a. One group suggested that it was modulated by IL-6 
stimulation [429], whilst another showed a dependency upon hypoxia induced Src 
activation [209]. While both studies demonstrated that Tyr705 phosphorylation of 
STAT3 was required for this, neither studies investigated STAT3 Ser727 
phosphorylation levels. I propose that cytokine stimulation via the gp-130 receptor 
(or hypoxic induction of Src), induces robust Tyr705 phosphorylation of STAT3 
allowing complex formation with HIF-1a. Tyr705 phosphorylation was rapidly induced 
by CNTF treatment and unaffected by m TORCI activity in all experiments, 
additionally the level of HIF-1a co-purified with STAT3 correlated with Tyr705 
phosphorylation not Ser727 phosphorylation or m TORCI activity.
I also propose that m TO R C I propagates the transcriptional activity of both 
HIF-1a and STAT3 at least in part by phosphorylating STAT3 at Ser727. This notion 
is supported by my findings, where I saw that m TORCI interacted with but did not 
phosphorylate HIF-1a, whereas STAT3 co-purifies with both HIF-1a and Raptor, and 
is phosphorylated at Ser727 by m TO RCI to achieve maximal transcriptional 
activation. This mechanism is in concordance with current thinking that STAT3 and 
HIF-1a form a transcriptional complex in response to activation by IL-6 [429], since 
both IL-6 and CNTF activate STAT3 via the GP-130 receptor [67].
In addition, Gray et al. demonstrated that Src inhibition prevented nuclear 
translocation of the STAT3/HIF-1a complex and hence it’s activation [209]. Src is a 
protein tyrosine kinase which is activated by growth factors and hypoxia, it is also
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upstream of PI3 kinase and promotes m TORCI signalling. In addition, it has been 
demonstrated to activate STAT3 via Tyr705 phosphorylation [106], likely through 
direct phosphorylation of STAT3 and through activation of JAKs. This is consistent 
with my proposed mechanism of regulation as it provides a mechanism by which 
hypoxia could upregulate both branches of the pathway. Consequently, it is likely 
that mTORCI activates a STAT3/HIF/p300 transcriptional complex and this is 
regulated in part by m TO R C I directed phosphorylation of STAT3 at Ser727 and 
maybe at other unidentified phosphorylation sites. This possible mechanism may 
explain why I was unable to demonstrate direct phosphorylation of HIF-1a by 
mTORCI despite showing Raptor interaction. It may be that crucial components of 
the HIF transcriptional complex were lost during purification, i.e. STAT3/p300 which 
prevented it’s in vitro phosphorylation. This mechanism is also consistent with the 
fact that a large mobility shift was observed upon expression of the TOS mutant in 
comparison to the wild-type GST-HIF-1a and is indicative of differential 
phosphorylation events between the two HIF-1a constructs. In my previous analysis 
of the TOS mutant of HIF-1a and the wild-type I had not observed a shift in mobility. 
However, this experiment was carried out under the context of CNTF stimulation (to 
activate the STAT3 transcriptional assay) and is likely to be a result of upregulation 
of STAT3 and or m T O R C I.
Further work is required to confirm this mechanism, however time and 
financial constraints prohibited this within the scope of the PhD project. To test 
whether this hypothesis is correct, one would have to address several questions that 
are raised. For instance, the nature of the p300 interaction with both HIF-1a and 
STAT3 needs to be further elucidated. Land and Tee reported that the TOS mutant 
of HIF-1a bound less well to p300 [135], suggesting that p300 may play a role in 
regulating the transcriptional activity of HIF-1a, it also highlights the possibility that 
p300 may be a direct substrate for m TORCI itself. I demonstrated that the TOS 
mutant of HIF-1a bound less well to Raptor, therefore it is likely that the TOS motif 
within HIF-1a is necessary for optimal protein interactions. Interestingly, the HIF-1a 
TOS mutant is still able to translocate to the nucleus [135] so the lack of activity 
within this HIF-1a TOS mutant is likely due to absent phosphorylation events or a 
result of co-factor dissociation. It is still unclear whether this HIF-1a TOS mutant is 
able to interact with the HIF response elements on DNA, I attempted EMSA 
(enhanced mobility shift assays) to examine interactions of HIF-1a to [32P]-radio-
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labelled dsDNA possessing a HRE, but these EMSA assays where inconsistent for 
both HIF-1a and STAT3. Robust EMSA assays could prove useful to further 
characterise the interactions of HIF-1a with DNA as well as protein interactions such 
as Raptor and STAT3 could be of use for future work in this field.
It would also be of interest to determine whether the TOS mutant of HIF-1a 
could also bind with STAT3 and if so what affects this has upon STAT3 
phosphorylation sites and transcriptional activity. Furthermore, STAT3 has two 
potential TOS motifs, the significance of these motifs remains unknown. It would 
therefore be informative to establish what effect mutations to one or both of these 
motifs has upon STAT3/HIF-1a activity and to determine the role of mTORCI 
interactions in governing this complex.
In addition, Jung et al. reported in 2005 that over-expression of STAT3 
resulted in increased levels of HIF-1a mRNA [413]. In chapter 3, I observed that HIF- 
1a mRNA levels are regulated in an m TO RCI dependent fashion, this taken with the 
evidence in chapter 5 indicating that STAT3 activity and Ser727 phosphorylation is 
regulated by m TORCI could indicate that HIF-1a mRNA levels are being regulated 
downstream of m TO RCI and STAT3. STAT3 may therefore be responsible for 
regulating the expression or stability of HIF-1a mRNA.. It would be interesting to see 
whether STAT3 inhibitors could suppress HIF-1a mRNA levels. The use of specific 
STAT3 inhibitors or shRNA mediated knockdown of STAT3 may have a similar effect 
to rapamycin treatment upon HIF-1a mRNA levels if STAT3 functioned as a 
feedforward mechanism to drive HIF-1a gene expression.
Recent publications have also highlighted a potential role of heat-shock 
protein 90(Hsp90) in the modulation of HIF-1a and STAT3. It was demonstrated that 
IL-6 induced both STAT3 activation (as measured by Tyr705 phosphorylation) as 
well as HIF-1a nuclear accumulation in a human pancreatic cancer cell line in 
agreement with the results of this study. Interestingly, they also demonstrated that 
IL-6 mediated upregulation of STAT3 and HIF-1a could be repressed with the use of 
Hsp90 inhibitors. Lang reported that this was independent of PI3K signalling since 
wortmannin did not suppress STAT3 activation, however this was only assessed in 
the context of Tyr705 phosphorylation which I have shown to be independent of 
mTORCI signalling. Furthermore, they revealed that activation of signalling via IL- 
6/STAT3/HIF-1a also increased levels of IL-6. This represents an autocrine loop
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whereby STAT3 and HIF-1a are able to propagate their own activation, although this 
may be unique to the cancer cell line utilised [429].
Hsp90 inhibitors may therefore provide an exciting new branch of anti-cancer 
therapeutics in the future with their ability to target multiple signalling pathways which 
contribute significantly to the pathogenesis of many different cancers.
In addition to the link between Hsp90 and STAT3/HIF-1a, there is also a 
reported link between STAT3 and ATM, as indicated earlier, ATM phosphorylates 
HIF-1a to promote its stability. This is interesting when you consider that ATM 
signalling is suppressed in STAT3 deficient cells, suggesting that STAT3 is a 
modulator of ATM [33]. Cam et al. showed that ATM phosphorylated HIF-1a directly 
to promote its stability [427]. If STAT3 can modulate ATM signalling in response to 
DNA damage, it is plausible that STAT3 can also modulate ATM signalling in 
response to hypoxia. Induction of ATM by STAT3 could represent a mechanism by 
which STAT3 promotes the accumulation of HIF-1a protein. Conversely, a paper 
published in 2003 claimed that STAT3 Ser727 phosphorylation could be induced by 
UV light and that ATM was required for this [430]. This is consistent with the report 
associating STAT3 with the DNA damage response since UV light is known to cause 
damage to DNA. However, Zhang et al. reported that ATM deficiency abolished 
Ser727 phosphorylation of STAT3 [430], whereas the more recent publication 
reported that STAT3 deficiency suppressed ATM signalling [431]. The reason for this 
discrepancy is not clear although it may be related to ATM activation by hypoxia, 
which appears to differ from ATM activation by DNA damage. Nevertheless, these 
studies clearly provide evidence for an association between ATM and STAT3, which 
importantly implicates ATM in the regulation of STAT3/HIF-1a. It would be 
particularly interesting to establish whether ATM was responsible for activating 
STAT3 under hypoxia, or if indeed STAT3 mediates ATM under hypoxia. Further 
work would have to be carried out to determine ATM’s involvement in STAT3/HIF-1a 
regulation.
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6.3 AIMS
I initiated this project with the following aims:
1. To characterise m TO R C I dependent regulation of HIF-1a.
2. To examine HIF-1a regulation in the context of the disease Tuberous 
sclerosis.
3. To determine whether STAT3 is regulated by mTOR
4. To determine whether mTOR regulates STAT3 directly or via a 
downstream effector.
5. To investigate the relationship between mTOR, STAT3 and HIF-1a.
I investigated several avenues of potential m TORCI directed HIF-1a regulation and 
was able to examine the translation of HIF-1a, the stability of the HIF-1a protein and 
mRNA transcript as well as showing evidence for TSC2-mTORC1 independent 
mechanisms of HIF-1a regulation. Utilising TSC2 mutant constructs I have been able 
to demonstrate how variable HIF-1a activity may be from patient to patient in the 
context of TSC, as well identifying the TAD domain of TSC2 as a potential regulatory 
motif for HIF-1a activity. Analysis of downstream gene targets of HIF-1a revealed 
previously unreported potential differences in HIF-1a regulation. If these differences 
translate from cell line models to patients then it is possible that patients with specific 
TSC2 mutations may exhibit a more severe phenotype due to differential regulation 
of HIF-1a activity (discussed later).
Furthermore I have clearly demonstrated that mTORCI regulates STAT3, 
through direct phosphorylation at Ser727 in both in vitro and in vivo assays. I also 
observed that STAT3 transcriptional activity correlates with mTORCI activity, 
suggesting that the Ser727 phosphorylation site is key at determining downstream 
gene expression of STAT3.
Further work is required to fully clarify the relationship between mTORCI, 
STAT3 and HIF-1a. My in vivo radiolabelling experiment demonstrated that both HIF- 
1a and to a lesser extent Raptor co-purify with STAT3. From this we can hypothesise 
that mTORCI may regulate a transcriptional complex consisting of STAT3 and HIF- 
1a. Furthermore I demonstrated that expression of the dominant negative TOS 
mutant of HIF-1a can influence STAT3 transcriptional activity, suggesting an
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interdependent relationship between HIF-1a and STAT3 however the mechanisms 
governing the activity of this complex however remain unknown.
6.3.4 Significance
The significance of these findings can best be described in the context of the disease 
TSC which is characterised on a molecular level by aberrant mTORCI signalling. My 
findings explain in part how constitutive m TORCI activation in TSC patients can 
increase the levels of HIF-1a activity in cells by enhanced expression/stability of HIF- 
1a mRNA, translation of HIF-1a protein, as well as potential upregulation of HIF-1a 
activity, promoting angiogenesis, glucose transport, and erythropoeisis.
HIF-1a upregulates the expression of genes required for tumour expansion 
and there is no doubt that this significantly facilitates the growth of hamartomas 
characteristic of the TSC disease. Furthermore, I have provided evidence that HIF- 
1a is also subject to negative regulation downstream of TSC2 which is independent 
of mTORCI. I demonstrated that in cell lines deficient of TSC2, rapamycin was 
unable to normalise HIF-1a gene targets expression. This may in part contribute to 
the limited success of rapamycin observed in the ongoing clinical trials and suggests 
the requirement for combinational therapy for patients exhibiting TSC2 mutations, 
whereby a specific HIF-1a inhibitor is administered in conjunction with rapamycin to 
target both pathways. However the results of this study also indicate that targeting 
HIF-1a activity therapeutically may result in an upregulation of STAT3 transcriptional 
activity by feedback mechanisms, given that expression of the dominant TOS-mutant 
of HIF-1a caused an increase in STAT3 activity as demonstrated by the 
transcriptional reporter assay. This indicates that STAT3 plays more of a regulatory 
role over HIF-1a indicating that STAT3 may be the more appropriate therapeutic 
target.
This novel m TO RCI independent function of TSC2 towards HIF-1a may also 
partially account for the increased severity of TSC in patients who possess TSC2 
mutations as opposed to TSC1 mutations, HIF-1a mediated gene expression could 
promotes vascularisation and growth of hamartomas, increasing the likelihood of 
complications in affected organ systems.
I have also demonstrated that STAT3 is regulated at Ser727 by mTORCI 
directly, therefore elevation of STAT3 transcriptional activity will also contribute to the 
pathogenesis of the disease. Kwaitowski’s group observed an increase of STAT3
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expression in TSC deficient cells lines. Interestingly, they reported upregulation of 
STAT3 at Tyr705 caused by a suppression of IFN-y.
IFN-y is a pleiotropic cytokine which is involved in tumour suppression, 
therefore it’s suppression in the absence of TSC1/2 is likely to contribute to the 
formation of hamartomas in TSC. Kwaitowski’s group did not speculate as to the 
mechanism behind IFN-y suppression but it maybe a result of feedback mechansims 
instigated as a result of upregulated STAT3 activity (through increased Ser727 as 
mediated by m TO R C I). Alternatively it may be a previously uncharacterised 
downstream signalling effect of m TO R CI signalling.
There are extensive reports within the literature demonstrating persistent 
STAT3 upregulation in numerous human cancers and transformed cell lines [432- 
439]. This has lead to the classification of STAT3 as an oncogene [243]. STAT3 
activation is thought to contribute to the growth of tumours. STAT3 increases gene 
expression of cyclin-D1 and c-Myc, which promote cell cycle progression, as well as 
promoting the survival of tumour cells by inhibiting apoptosis through B c Ixl 
expression [432, 434].
Furthermore, STAT3 is able to promote angiogenesis in tumours through 
direct activation of VEGF as well as probable activation of HIF-1a mediated gene 
expression as seen in this study and others [209, 413, 440].
STAT3 mediated gene expression effectively functions as the ‘tumour cell 
survival kit’, facilitating cellular growth, inhibiting cellular death, whilst promoting the 
formation of blood vessels to increase nutrient supply and facilitating metastases by 
promoting cell migration and invasion. It is thought that constitutive STAT3 activation 
is required to maintain the tumour cell phenotype in certain malignancies therefore 
understanding mechanisms contributing to its regulation is of significant importance.
One example where STAT3 upregulation in cancer has been characterised is 
in the case of multiple myeloma. Multiple myeloma cells exhibit inappropriate 
elevation of IL-6 and expression of the IL-6 receptor resulting in constitutive 
activation of STAT3 through phosphorylation of Tyr705 [192, 441]. Furthermore, IL-6 
not only promotes activation of STAT3 through homodimerisation of the gp-130 
receptor, but also activates PI3 kinase and Akt signalling through receptor tyrosine 
kinase activity [442, 443], as is seen with the IL-6 related cytokine, CNTF, which was 
utilised in this study.
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Therefore, in the case of multiple myeloma, inappropriate IL-6 production 
results in upregulation of STAT3 Tyr705 phosphorylation through the JAK/STAT 
signalling pathway, but also promotes m TORCI signalling through PI3 kinase and 
Akt activation (see figure 1.5). As demonstrated in this study, mTORCI activation 
serves to increase the transcriptional activity of STAT3 by increased Ser727 
phosphorylation, further propagating the tumour phenotype. Activation of STAT3 can 
also function to promote HIF-1a activity and may augment HIF-1a mRNA levels, 
further promoting cell survival and vascularisation of malignant cells, as well as 
upregulating cell growth pathways mediated downstream of m TO R C I
This study has demonstrated how dual activation of STAT3 and pathways 
leading to m TORCI activation might function to further accentuate the tumour cell 
phenotype.
Furthermore, m TO R C I activation is also associated with suppression of p53 
mediated apoptosis [444], whilst STAT3 activation protects against apoptosis 
through increased BcIxl expression [445]. It is plausible that combined STAT3 and 
mTORCI inhibition could be sufficient to induce apoptosis in tumour cells exhibiting 
upregulation of these pathways. In support of this, both mTORCI inhibitors [446] and 
STAT3 inhibitors [447] have been demonstrated to sensitise tumour cells to DNA- 
damage induced apoptosis in separate settings. Further research is required to 
determine exactly how effective these treatments may be in combination.
It is also important to consider that IL-6 is likely to activate other cellular 
signalling pathways which may impact upon these signalling pathways. For instance, 
there are reports that IL-6 also functions to upregulate Ras-dependent ERK 
signalling [448], which also contributes to the tumour cell phenotype. Ras itself is 
also an oncogene and it has been demonstrated recently that Ser727 
phosphorylation of STAT3 is necessary for Ras-mediated oncogenic transformation. 
With Ser727 phosphorylated STAT3 localising to the mitochondria, independently of 
Tyr705 phosphorylation and its DNA binding capabilities [113]. This indicates that 
STAT3 has functions beyond that of a transcription factor which are seemingly 
governed by Ser727 phosphorylation. It is therefore likely that diseases 
demonstrating elevation of m TO RCI signalling also exhibit increased mitochondrial 
STAT3, the significance of which remains unknown.
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It may also be the case that this effect is contributing to the increased rate of 
malignancies observed in TSC patients since Ser727 phosphorylated STAT3 can 
contribute to Ras-mediated oncogenic transformation.
There is significant evidence demonstrating how STAT3 and mTORCI 
signalling can be elevated in cancer as well as the cancer-like syndromes such as 
TSC. This study has demonstrated crosstalk between the signalling pathways which 
may be functioning to aggravate the tumour cell phenotype by increasing the 
transcriptional activity of both STAT3 and HIF-1a. However, further research is 
required to determine the full implications that these over-lapping cell signalling 
pathways can evoke. Utilising cell line models not only increases our knowledge 
base of how cell signalling pathways work but also allows us to predict what happens 
when they become dysregulated in human disease. This is indispensible in the 
process of developing new and innovative therapeutic interventions to assist in the 
ongoing battle against disease.
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